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“Question everything.” - Socrates
ROCHESTER INSTITUTE OF TECHNOLOGY
Abstract
An Empirical Analysis of Predictive Machine Learning Algorithms on
High-Dimensional Microarray Cancer Data
by Jo A. Bill
This research evaluates pattern recognition techniques on a subclass of big data
where the dimensionality of the input space p is much larger than the number
of observations n. Seven gene-expression microarray cancer datasets, where the
ratio κ = n
p
is less than one, were chosen for evaluation. The statistical and
computational challenges inherent with this type of high-dimensional low sam-
ple size (HDLSS) data were explored. The capability and performance of a di-
verse set of machine learning algorithms is presented and compared. The sparsity
and collinearity of the data being employed, in conjunction with the complexity
of the algorithms studied, demanded rigorous and careful tuning of the hyper-
parameters and regularization parameters. This necessitated several extensions of
cross-validation to be investigated, with the purpose of culminating in the best
predictive performance.
For the techniques evaluated in this thesis, regularization or kernelization, and
often both, produced lower classification error rates than randomized ensemble for
all datasets used in this research. However, no one technique evaluated for clas-
sifying HDLSS microarray cancer data emerged as the universally best technique
for predicting the generalization error.1
From the empirical analysis performed in this thesis, the following fundamentals
emerged as being instrumental in consistently resulting in lower error rates when
1A predominant portion of this research was published in the Serdica Journal of Computing
(Volume 8, Number 2, 2014) as proceedings from the 2014 Flint International Statistical
Conference at Kettering University, Michigan, USA.
estimating the generalization error in this HDLSS microarray cancer data :
• Thoroughly investigate and understand the data.
• Stratify during all sampling due to the uneven classes and extreme sparsity
of this data.
• Perform 3 to 5 replicates of stratified cross-validation, implementing an adap-
tive K-fold, to determine the optimal tuning parameters.
• To estimate the generalization error in HDLSS data, replication is paramount.





respectively, to get the best generalization error estimate.
• Whenever possible, obtain an independent validation dataset.
• Seed the data for a fair and unbiased comparison among techniques.
• Define a methodology or standard set of process protocols to apply to ma-
chine learning research. This would prove very beneficial in ensuring repro-
ducibility and would enable better comparisons among techniques.
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1.1 High-Dimensional Low Sample Size Data
This thesis investigates a specific subclass of massive data where the dimensional-
ity of the input space p is often in the hundreds or thousands and the number of
observations n is normally in the tens, explicitly n≪ p. These datasets are repre-
sented here asD = {(x1, y1), (x2, y2), · · · , (xn, yn)}, where xi> ≡ (xi1, xi2, · · · , xip)
denotes the number of explanatory variables or features measured, such that each
x>i is a p-dimensional vector of the input space X , and yi represents the corre-
sponding response value, or class label, from the output space Y = {1, · · · , k}
given by design matrix
X =

x11 x12 · · · · · · · · · · · · x1j · · · x1p
...
...
. . . . . . · · · · · · · · · · · · ...
xi1 xi2 · · · · · · · · · · · · xij · · · xip
...
...
. . . . . . · · · · · · · · · · · · ...
xn1 xn2 · · · · · · · · · · · · xnj · · · xnp

Classification with this type of massive data is extremely challenging. With the
number of observations n often less than 100, the available data is already sparse
and as the number of input variables increase, the dimensionality of the input
space p grows exponentially resulting in information poverty (Fokoue, 2013). This
is often referred to in literature as the ”curse of dimensionality” (Bellman, 1961),
where the hypervolume grows exponential as a function of dimensionality.
1
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Given M ≡ linear model space where M = 2p−1 models and p is the dimensionality
of the input space. The following simple example illustrates just how quickly
exponential growth becomes unmanageable.
Figure 1.1: Exponential growth in model space.
With just two variables the model space is very reasonable at M = 22 − 1 = 3
models. When increasing to just five variables, the model space is already quite
large at 31 models. Simply doubling the variables from five to ten has the same
result as increasing the amount of models by 33 times the five variable amount
to 1023 models. By the time the amount of variables are doubled again to 20
variables, the resulting model space is over one-million models and is off the plot
in Figure (1.1).
When n is very small and the dimension of the space of variables p is extremely
large n ≪ p, the underlying statistical problem becomes ill-posed or ill-defined
(Clarke et al., 2009). Traditional statistical techniques of relying on strong model
assumptions analogous to parametric, or being distribution free as with fully non-
parametric, are inadequate and inference breaks down. This failure of traditional
statistics is due to a phenomenon known as ill-posedness. An explanation for this
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circumstance can be found in the works of Hadamard, (Hadamard, 1923) where he
states that for a problem to be well-posed it must meet the following conditions:
• A solution must exist.
• The solution must be unique.
• The solution must be stable so that the inverse mapping is continuous.
In dealing with HDLSS microarray cancer data these conditions were continually
violated, leaving traditional methods performing badly or not at all. Fortunately,
modern statistical methods are forging ahead by offering robust, machine learning
options to accommodate these previously unsolvable problems.
1.2 Machine Learning Approaches
Where traditional methods have failed on HDLSS problems, modern computer-
intensive machine learning techniques are offering new approaches by skillfully
employing complex, statistical algorithms that are proving to be quite adept at
dealing with these types of problems where κ = n
p
is < 1. This thesis compares
and contrasts the ability of computational learning techniques to perform accu-
rate prediction on microarray cancer data via supervised learning, as explained in
Chapter 3 of this thesis.
The following four approaches can be used in machine learning as techniques for
dealing with ill-posed problems.
• Regularization (Tikhonov, 1963).
Introduces a small amount of bias through the constraint while stabilizing
the variance.
• Kernelization (Vapnik, 1995).
Captures arbitrary nonlinear decision boundaries in high-dimensional space.
• Randomized Ensemble (Schapire, 1990), (Breiman, 1994),
(Breiman, 1996a), (Breiman, 2001).
A collection of models averaged out to stabilize the variance.
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• Feature Selection (Friedman, 1989), (Guo et al., 2005), (Guo et al., 2006).
Extraction of meaningful markers.
This thesis will cover the first three approaches, regularization, kernelization, and
randomized ensembles. As discussed in Chapter 2 all data used in this research
was existing data and as such, had already been statistically altered and reduced.
The previous analysis and feature selection performed on this data is noteworthy
as it was often a contributing factor to the difficulty in classification and prediction
as discussed throughout this thesis.
1.3 Gene-Expression Microarray Cancer Data
According to A Cancer Journal for Clinicians (Siegel et al., 2015), although cancer
death rates are on the decline, cancer remains a major health problem in many
parts of the world. In the United States alone nearly one of every four deaths is
due to cancer. A total of 1,658,370 new cancer cases and 589,430 cancer deaths
are projected to occur in the United States in 2015.
With the advent of gene expression microarray technology, cancer is predomi-
nantly explored and studied through datasets gathered from microarray probes.
This resulting gene-expression microarray cancer data is a prime example of high-
dimensional low sample size data.
For this research, seven existing gene expression microarray cancer datasets were
chosen, four are binary and three are multiclass.
Table 1.1: Thesis datasets investigated.
n p C κ DC Distribution of Classes
Prostate Cancer 79 500 2 0.15800 10−1 37 42
Colon Cancer 62 2000 2 0.03100 10−2 22 40
Leukemia Cancer 72 3571 2 0.02016 10−2 47 25
West Breast Cancer 49 7129 2 0.00687 10−3 24 25
Lung Cancer 197 1000 4 0.19700 10−1 139 17 21 20
Breast Cancer 97 1213 3 0.07997 10−2 11 50 36
Brain Cancer 42 5597 5 0.00750 10−3 10 10 10 4 8
DC is the dimensionality complexity and C is the number of classes.1
1These datasets are available to download through the Wallace Library at Rochester Institute
of Technology. http://scholarworks.rit.edu/spas/
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The two main goals when analyzing microarray cancer data are accurate prediction
and gene selection. The focus of this thesis is on obtaining accurate prediction of
a given disease based on a set of corresponding gene profiles. The more commonly
used techniques from the regularization, kernelization, and randomized ensembles
methods will be utilized.
1.4 Thesis Organizaion
This thesis consists of seven chapters. This introductory chapter provides a brief
explanation of high-dimensional low sample size data and the problems it poses
in classification. It then introduces possible solutions to this dilemma and gives a
brief overview of the data used in this thesis.
Chapter 2 covers more specific details about the cancer datasets used in this re-
search. The very nature of the gene-expression microarray cancer data presents
addition layers of complexity that are identified in this chapter.
Chapter 3 is dedicated to the description of data cleansing, computational pro-
cessing, and various extensions of cross-validation used to optimize the tuning
parameters with an aim toward improved prediction.
Chapter 4 presents a detailed statistical explanation of the algorithms evaluated
by this thesis, with a focus on the aspects that make them suitable for microarray
data.
Chapter 5 explains how to implement the algorithms from a computational per-
spective. An investigation of each technique’s performance and ease of use is
detailed in this chapter.
Chapter 6 presents the results from the computational experiments with an em-
phasis on the comparison of the average test error across all methods considered.
It concludes with a comparative analysis of other research utilizing these datasets
across various techniques.




Every cell in a human body, except mature red blood cells, contains a nucleus
(HumanGenomeProject, 2013) as illustrated in Figure (2.1). Inside a normal nu-
cleus are 23 pairs of chromosomes, which are long strands or sequences of De-
oxyribonucleic Acid (DNA). DNA is organized structurally into chromosomes
and is organized functionally into genes, which are essentially pieces of DNA
(GENOME.GOV, 2014). This entire set of genetic instructions found in a cell
is referred to as the genome (GENOME.GOV, 2014).
Figure 2.1: Human Cell Illustration.
1
1Image from Cancer Research UK. http://www.cancerresearchuk.org/
6
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As seen in Figure (2.2), DNA molecules are double-stranded and are composed of
two twisting paired strands often referred to as a double helix. DNA contains all
of the information needed to build and maintain any organism, a human in this
scenario.
Figure 2.2: Human DNA Illustration.
2
The DNA molecules are composed of nucleotides, each one consists of a sugar
molecule, a phosphate group, and a nitrogen-containing base. Figure (2.3) illus-
trates how each strand of the double helix is composed of four different kinds of
bases: adenine (A), thymine (T), guanine (G), and cytosine (C). Each base on
a strand will pair with its complementary base on the other strand to form ni-
trogenous base pairs. Naturally occurring nitrogenous bases are very specific; an
A always pairs with a T, and a C always with a G (NatureEducation, 2014). How
these bases are arranged results in an individual’s genetic code and the sequence
determines every protein that keeps an individual functioning.
2Image from National Human Genome Research Institute. http://www.genome.gov
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Figure 2.3: DNA Double Helix.
3
As stated previously, genes contain pieces of DNA and carry information about the
traits of an organism. In the case of a human, the genes carry information to convey
hair and eye color as well as many other traits. Genes also contain instructions to
tell the body’s cells when to grow, divide, and even when to die. Although every
cell of an individual’s body stores a complete set of genes, the activity of a gene
varies from cell to cell (SCME, 2014). Each cell has a different combination of genes
turned on and off at any given time. A cell will only express, or turn on, the genes
that are necessary for the functions of that cell (UniversityofUtah, 2015). When
a gene is turned on it is said to be expressed or working. Gene expression is the
process by which information encoded in a gene is used to direct the assembly of
a protein module by creating messenger RNA or mRNA (GENOME.GOV, 2014).
This is referred to as transcription and is part of the Central Dogma of Molecular
Biology as seen in Figure (2.4), DNA makes RNA makes proteins.
Figure 2.4: The Central Dogma of Molecular Biology.
4
3Image from Southwest Center for Microsystems Education. http://scme-nm.org
4Image from atdbio. http://www.atdbio.com
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Another very important property of DNA is that it can replicate itself. The DNA
in every cell is actually about 2 meters long and coiled very tightly to fit into a
cell (CancerResearchUK, 2014) . Therefore, the first step of replication is for the
DNA to carefully unwind itself. During the natural replication process an enzyme
called DNA Helicase breaks the hydrogen bonds between the DNA strands and
the double helix separates into two separate DNA strands. Each of the single
strands acts as a template for a new complementary strand (Brown and Brown,
2015). Through a very intricate and complicated process involving many different
enzymes, the two individual strands will replicate simultaneously with one leading
in a continual synthesizing process and one lagging and partially synthesizing in
short bursts. This replication process can take hours to complete.
Sometimes an error will occur during DNA replication. This usually happens
when an incorrect base tries to synthesize into the replicating DNA strand. DNA
actually safeguards against this by going through a type of proof reading step
where it will attempt to repair itself and fix the mispair or mismatched base pair.
However, sometimes a mispair survives becoming part of the genome and moving
on to the next round of replication. This is known as a mutation and may or
may not have a consequence on the organism. When a mutation results in a good
consequence, it provides a positive outcome by giving an organism a competitive
edge and leading to evolution by natural selection. Unfortunately, a mutation can
also have a negative consequence leading to diseases, cancer, or even death (Brown
and Brown, 2015).
Scientists have developed ways to simulate these DNA processes in the lab so
they can study the genome of many different organisms, including humans. The
analysis of genome was a very labor intensive process until the mid 1990s when
microarray technology started to become more mainstream. Prior to the Human
Genome Project of 1990-2003 scientists had believed that the human genome was
made up of 40,000 to 100,000 unique genes. As of October 2014, GENCODE
documented the number of distinct protein-coding genes at 19,814 (Harrow J,
2012). It is interesting to note that among those 19,814 genes, only about 0.1%,
or less than 20 genes, differ between any two humans (Smithsonian, 2015).
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2.2 Gene-Expression Microarray Overview
With the advent of high-throughput microarray technology it became possible for
scientists to simultaneously research a much larger number of genes than was pos-
sible with the traditional methods. Instead of looking at a few genes or even one
gene at a time, they could literally look at thousands of genes simultaneously. Es-
sentially, microarrays allow biologists to monitor genome wide expression levels of
the genes, for any given organism, in just one experiment. Microarray technology
can be thought of as breaking open a cell, isolating its genetic contents, identifying
which genes are turned on, and then generating a list of those genes for analysis
and reporting (UniversityofUtah, 2015).
One way that scientists are using this microarray technology is in the study of
cancer. Since this thesis is ultimately analyzing datasets from different cancers,
the microarray overview process is outlined in terms of a cancer experiment. The
same basic process could be used for other genome investigation and experiments
as well.
For the datasets used in this research, DNA microarrays were used. A DNA
microarray is an orderly arrangement of thousands of identified sequenced genes
printed on an impermeable solid support, usually glass, silicon chips or a nylon
membrane (GenomeResourceFacility, 2015). There are currently two types of DNA
microarrays commercially available, glass DNA microarrays with pre-fabricated
cDNA fragments on the slide, and high-density oligonucleotide microarrays some-
times referred to as chips(GenomeResourceFacility, 2015). These are illustrated
in Figure (2.5) from source (GenomeResourceFacility, 2015).
(a) Oligonucleotide (b) Glass Slide
Figure 2.5: Commercial Microarrays.
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In this figure, each grid location or circle equates to one gene. Each one of the
grid locations or circles contains multiple identical strands of DNA corresponding
to that unique gene (UniversityofUtah, 2015). The precise location and sequence
of each spot or grid square is recorded in a computer database.
It should be noted that the following process is summarized from (UniversityofU-
tah, 2015) and (GenomeResourceFacility, 2015). It is a simple example to aid in
understanding the general methodology and is not necessarily how the studies for
the files used in this thesis were executed.
Once a patient’s samples arrive at the lab, there are four main steps involved in a
typical microarray cancer experiment.
1. Sample Preparation and Labeling :
In a controlled experiment there are normally 2 samples from the patient,
1 control or healthy sample and one target or cancer sample. The goal of
microarray processing is to determine which genes are expressed or turned on,
this is accomplished by looking for messenger RNA or mRNA. Recall from
the discussion of transcription and the Central Dogma of Molecular Biology
in Figure (2.4), that mRNA is made when the cell is active or expressed.
Therefore if mRNA is detected, it means the cell was working or expressed
at the time the sample was taken. Through a series of carefully controlled
laboratory steps, the mRNA is isolated or separated from the other RNA and
DNA in the sample. It is then labeled, usually with fluorescent dye. This
process is performed for both the control and the target samples separately.
At this point the mRNA is normally converted back to the complementary
DNA because it is more stable. The mRNA to cDNA process is accomplished
using a reverse transcriptase enzyme.
2. Hybridisation :
The control and cancer samples of cDNA, usually stained green and red
respectively, are now applied together to the microarray. The probes, or
complimentary sequences on the microarray and the cDNA from the two
samples match back up in their base pairings and bind or hybridize to form
a double helix. Note that each double helix on the microarray is now labeled
with the fluorescent tags applied in the isolation and labeling step.
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3. Washing :
The array is now washed to remove any cDNA that did not hybridize on the
microarray. The microarray slide or chip is dried and placed in a laser scanner
to activate the fluorescent dyes. Another process called photolithography can
also be used instead of the laser scanner depending on the type of microarray
used.
4. Image Acquisition and Data Analysis :
Once the expressed image is generated the locations that hybridized to the
cancer sample show red and the hybridized control or healthy samples show
green. Yellow expressions mean both control and cancer samples hybridized
to the location. Recall this is an example scenario for explanation purposes,
in reality many different color combinations are used. In addition the sam-
ples, and thus the colors, may represent two or more distinct cancers as in
the two types of Leukemia illustrated in Figure (2.6).
Figure 2.6: Leukemia Cancer Microarray Expression.
5
Through the use of computers and vendor software packages, the microarray ex-
periments generate numerics which correspond to the expression of each of the
genes under the various conditions. Once the numerics are generated, statistical
methodology can be applied to them for analysis and discovery purposes (Efron
et al., 2001).


















Figure 2.7: Leukemia Cancer Microarray Input Data.
 
   Y        x.1        x.2       x.3         x.4         x.5      x.3569       x.3570     x.3571 
 1 2 -0.7883499 -0.7569130 -1.414095 -0.71802811  0.47339834  …  …   0.4688231 -0.331178875 -0.8256612 
 2 2 -1.3351630 -1.3351630 -1.335163 -1.20554205 -0.05522577  …  …   0.4610198 -0.390380406 -1.3351630 
 3 2 -1.4234988 -1.4234988 -1.389461 -0.06943838  0.91150702  …  …   0.6869878  0.355827471 -0.7082384 
 4 2 -0.9416161 -1.3627031 -1.362703 -0.95926319 -0.05264664  …  …   0.3272390 -0.874228013 -1.1499509 
 5 2 -1.3734152 -0.5271296 -1.373415 -1.19134003  0.06857248  …  …  -0.5344255 -0.325722491 -1.3734152 
 6 2 -1.1928333 -0.5886196 -1.192833 -0.67335043  0.10823422  …  …   0.5201226 -0.065572676 -0.5886196 
 7 2 -1.0888588 -1.3374205 -1.337421 -1.33742052 -0.10130485  …  …   0.9027362  0.110327970 -0.1355830 
 8 2 -1.3354139 -1.3354139 -1.335414 -0.48642704  0.24567413  …  …   1.2638028  0.009382957  0.5132999 
 9 2 -1.4243923 -0.0629569 -1.424392 -0.99882572  0.26972559  …  …   0.2763986 -0.292436935 -0.6753959 
     .     .      . 
    
       .     .      . 
    
      .     .      . 
 
64 1 -1.481628 -1.08734927 -1.4816277 -1.4816277 -0.11600433  …  …  -0.13639748 -0.38910741 -0.5692543 
65 1 -1.143158 -1.14315792 -1.1431579 -1.1431579 -0.24851057  …  …   0.65931777  0.02183197 -0.2625807 
66 1 -1.018678 -1.01867807 -1.0186781 -1.0186781  0.03940637  …  …   0.34572746 -1.01867807  1.7036124 
67 2 -1.183311 -0.51489369 -1.1833111 -0.4191722  0.88190479  …  …   0.17099146 -1.18331115 -1.1833111 
68 2 -1.069315  0.49064178 -1.3623813 -0.8376561  0.29004857  …  …   0.05038523 -0.58424586 -1.3623813 
69 2 -1.422469 -1.42246873  0.1579552  0.1210962  0.95779015  …  …   0.33394980 -0.67741512 -1.3469445 
70 2 -1.041304  0.06686525 -1.0413036 -0.6807558 -0.04015416  …  …   0.06686525 -0.51360057 -0.5027121 
71 2 -1.210655 -0.83400643 -1.2106548 -0.9202322  0.40974638  …  …  -0.03281917 -0.51892534 -1.2106548 
72 2 -1.290242 -0.16681335 -1.2902425 -1.2902425 -0.23076501  …  …   0.69514030 -0.03683578 -0.5000036  
 
An example of the leukemia cancer data as it was obtained for this thesis research. Scientists hope that by analyzing these types of gene-
expression datasets it will lead to accurate classification of tumor subtypes allowing for targeted, specific treatments with an aim to maximizing
efficacy and minimizing toxicity (Dettling and Bühlmann, 2004).
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2.3 Cancer Datasets Evaluated
As mentioned in Chapter 1, seven publicly available gene expression microarray
cancer datasets were evaluated in this thesis research, four are binary and three
are multiclass. A more detailed look at the creation and previous processing of
these datasets follows.
2.3.1 Binary Datasets
2.3.1.1 Prostate Cancer Dataset
The prostate cancer dataset used in this study was a subset of the Stephenson
2005 study (Stephenson et al., 2005). The human gene array from the original
Stephenson study contained 22,283 features which was reduced to 7,884 features.
Researcher Cao obtained the prostate dataset used in this thesis research upon
request to the Stephenson study. This prostate cancer dataset (Cao, 2009) is a
subset of 500 randomly sampled transcripts from the Stephenson study. Interest-
ingly the Stephenson reduced dataset of 7,884 features, rather than this specially
requested dataset of 500 features, was the dataset ultimately used in Cao’s subse-
quent publication (Cao et al., 2010). Consequently, there is very little information
available on the actual dataset of 500 features that was provided to me for use in
this thesis research, however from the Stephenson study the following is known.
The prostate dataset contains tissue samples from 79 patients with localized
prostate carcinoma that initially underwent radical prostatectomy alone between
1993 and 1999 (Stephenson et al., 2005). Of these 79 patients, 42 of them had
undetectable levels of prostate-specific antigen for five or more years. The corre-
sponding samples for these 42 patients were classified as non-recurrent primary
prostate tumor specimens. The remaining 37 patients had various levels of recur-
rence and the samples were classified together as recurring, making this a binary
dataset.
The following description of the microarray processing is summarized from the
Stephenson et al. study (Stephenson et al., 2005). When these samples were taken
they were snap frozen in liquid nitrogen and stored at −80 ◦C. The frozen blocks
were manually dissected for RNA target synthesis and sample labeling per institu-
tional review board protocols. The gene expression analysis was performed using
the Affymetrix U133A human gene array. For each gene of all 79 tissue samples,
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two response measurements were taken using the default settings of Affymetrix
Microarray Suite 5.0.
Multiplicative scaling was performed for the expression values on each array to
have an average expression of 500 across the central 96% of genes in the array.
The expression and fold change for each gene were then evaluated to identify
gene expression differences between recurrent and non-recurrent prostate cancer.
Additionally, after performing a log2 transformation of expression values, a 2-
sample t statistic was calculated between the non-recurrent and recurrent disease
tissue samples. The P value was corrected for a false discovery rate of 0.05. The
outcome prediction modeling was then based on logistic regression and leave-one-
out cross-validation (LOOCV).
The process described previously resulted in the prostate dataset with 7,884 fea-
tures. That dataset has been used in various publications. However for the
prostate dataset used in this thesis, containing p=500 random features, other
publications dated 2014 or previously were not found.
2.3.1.2 Colon Cancer Dataset
The colon dataset was taken from the rda R package and is from the 1999 Alon et
al. study (Alon et al., 1999). This dataset is composed of 62 sample observations
that were collected from patients in the unpublished work of two authors in the
Alon study. In this binary dataset there are 40 samples of tumor tissue and 22
samples of normal tissue. In the Alon publication (Alon et al., 1999) it implies
that the 22 normal tissue samples actually came from some of the 40 cancer pa-
tients as it states the following: “Colon adenocarcinoma specimens were collected
from patients. From some of these patients, paired normal colon tissue also was
obtained.”
Following is a summary of the colon data processing taken from the Alon et
al. study (Alon et al., 1999). For the colon cancer dataset, the samples taken
were snap-frozen in the liquid nitrogen within 20 minutes of removal. The RNA
was extracted, hybridized to oligonucleotide microarrays produced by Affymetrix
Hum6000 resulting in approximately 65,000 features. The hybridization signal
fluctuation between different features was then assessed as this fluctuation is be-
lieved to reflect variation in the hybridization kinetics of different sequences and
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the presence of background RNAs. When this hybridization signal is many times
stronger than the neighboring signal, it is considered an outlier and filtered out so
they do not interfere with the readings of the gene average intensity.
An algorithm based on deterministic-annealing was used next to organize the data
into a binary tree. Each gene k was then organized into a vector Vk, each vector or
gene was then normalized so the average intensity across the tissues was zero and
the magnitude was one. The normalization was done to emphasize the relative
variation in intensity rather than the absolute intensity. A two-way clustering
method was then applied to the gene expression dataset producing a matrix that
appeared to reveal groups of genes whose expression correlated across tissue types.
The final 2000 genes chosen for the dataset were the genes with the highest minimal
intensity across samples. In this dataset, each gene was then normalized so that
its average intensity across the samples was 0 and the standard deviation was 1.
It is important to note that a study by Li et al. (Li et al., 2001) that used this
2000 gene colon dataset believed that five of the samples were likely contaminated
and they removed them from their study. That study also noted that selecting
genes that are differentially expressed from a cluster map may be difficult and time
consuming. They also noted that important genes may not be selected (Li et al.,
2001). Simply stated, by not using a model based method for outlier detection and
feature selection, one might inadvertently remove the signal instead of the noise.
The relevance of these insights becomes apparent in the Data Standardization
section of Chapter 3.
2.3.1.3 Leukemia Cancer Dataset
The leukemia dataset came from the Golub et al. study (Golub et al., 1999) and
contains two types of acute leukemia. There are 47 samples of Acute Lymphoblas-
tic Leukemia (ALL) and 25 samples of Acute Myeloid Leukemia (AML). The 47
ALL samples can be further broken down into 38 B-cell ALL and 9 T-cell ALL
samples. In this thesis research the leukemia dataset is treated as a binary dataset
with classes of 47 and 25.
These 72 samples were actually combined from two independent datasets used by
the Golub et al. study. The first dataset was used for training and contained 38
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samples. The second dataset containing 34 samples was independently obtained
and used as a test set.
The initial 38 samples of RNA came from bone marrow aspiration of mononuclear
cells obtained at the time of diagnosis, prior to any chemotherapy. The mononu-
clear cells were collected by Ficoll sedimentation and the RNA was extracted by
Trizol or RNAqueous reagents. The initial sample of 38 contained 27 ALL sam-
ples taken from children between 1980 and 1990 that were treated by Dana-Faber
Cancer Institute (DFCI) protocols. The samples were randomly selected from the
leukemia cell bank. The 11 AML samples came from adult tissue in the Cancer
and Leukemia Group B (CALGB) leukemia bank that was obtained by the same
process (Golub et al., 1999).
The independent set of 34 samples obtained for validation were obtained from
two different sample specimens. Again the RNA from bone marrow aspiration
accounted for 24 of the samples, but the remaining 10 samples were from peripheral
blood specimens. All 34 samples were obtained at the time of leukemia diagnosis.
Of the 20 ALL samples, 17 were from DFCI Childhood ALL bank and 3 were
from St. Jude Children’s Research Hospital (SJCRH). The remaining 14 samples
in the independent set where AML samples from both adults and children. The
4 adult AML samples came from CALGB and 5 of the child samples were from
SJCRH leukemia bank and the other 5 child samples were from Children’s Cancer
Group(CCG) leukemia bank. The samples were taken in a similar process to the
original dataset except for the SJCRH samples which used hypotonic lysis instead
of Ficoll sedimentation and the RNA was prepared by aqueous extraction (Golub
et al., 1999).
The datasets combined and organized :
Table 2.1: Leukemia Data Detailed.
# Cancer Age Source Protocol
44 ALL Child DFCI Ficoll sedimentation with Trizol or
RNAqueous reagents RNA extraction (Ambion)
3 ALL Child SJCRH Hypotonic Lysis and aqueous RNA extraction (Qiagen)
15 AML Adult CALGB Ficoll sedimentation with Trizol or
RNAqueous reagents RNA extraction (Ambion)
5 AML Child CCG Ficoll sedimentation with Trizol or
RNAqueous reagents RNA extraction (Ambion)
5 AML Child SJCRH Hypotonic Lysis and aqueous RNA extraction (Qiagen)
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Once the RNA samples were extracted, they were hybridized to high-density
oligonucleotide microarrays produced by Affymetrix HU6800 containing 6,817 hu-
man gene probes. Quantitative expression levels were obtained for each gene and
the samples were subjected to quality control standards for the amount of labeled
RNA and for the quality of the scanned RNA.
With the 50 most highly correlated genes, they preprocessed the data by normal-
izing the expression levels for each gene across the samples so the mean was zero
and the standard deviation was one.
The leukemia dataset was the most easily classified of the seven datasets evaluated
in this thesis research. The Golub et al. study was a landmark, proof of concept
study to show that class discovery could happen automatically, without previous
knowledge, based only on gene expression monitoring by DNA microarrays (Golub
et al., 1999).
2.3.1.4 West Breast Cancer Dataset
The binary breast cancer dataset, referred to in this thesis research as the West
breast cancer dataset to distinguish it from the multiclass breast cancer dataset,
is from the 2001 West et al. study (West et al., 2001) using tissue samples from
the Duke Breast Cancer SPORE frozen tissue bank.
The samples used in that study were selected based on several specific criteria
(West et al., 2001) :
• The samples were primary breast tumors diagnosed as invasive ductal carci-
noma.
• The samples were either positive for the both estrogen and progesterone
receptors or negative for both the estrogen and progesterone receptors.
• The tumors were between 1.5 and 5 cm in maximal dimension.
• Each tumor underwent diagnostic axillary lymph node dissection and was
examined by hematoxylin/eosin staining. The study used only those samples
that were more than 60% tumor on a per-cell basis and had few infiltrating
lymphocytes or necrotic tissue.
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The makeup of the 49 samples from the study is documented in Table (2.2).
Table 2.2: West Breast Cancer Data.





The RNA in this study was processed differently from the others. A Lysis buffer
from the Qiagen RNeasy Mini Kit was added to the tissue and after the initial
process steps to spin and shear the genomic DNA, the total RNA was extracted
using the Qiagen RNeasy Mini Kit. Two extractions were performed following the
RNeasy protocol to ensure the proper volume of RNA and quality of the RNA. The
Affymetrix DNA microarray analysis was then performed using the HuGeneFL
GENECHIP microarray and GENECHIP Expression Analysis Algorithm (West
et al., 2001).
There were some issues with this data’s assignment of estrogen receptors (ER).
The initial classification as ER+ or ER- was done via immunohistochemistry (IHC)
at the time of diagnosis. Later the samples ER status was evaluated again using
protein immunoblotting assay. The two were then compared and five discrepancies
were found. These five samples were held out with four other random samples for
further investigation. Two other observations were rejected because they failed
the array hybridization leaving 38 samples with consistent results between IHC
and immunoblotting. The five mismatched samples were treated as uncertain ER
status and the expression predictions were explored using a statistical model (West
et al., 2001).
The statistical processing to classify the nine held-out samples involved the use
of binary regression models combined with singular value decompositions (SVDs)
and stochastic regularization using Bayesian analysis per M. West’s unpublished
work. Ultimately some of the held-out samples were clearly indicated as either
ER+ or ER-, but others were still of uncertain status when using the statistical
analysis. In addition, the statistical analysis sometimes agreed with the initial
IHC and sometimes with the immunoblotting.
The West et al. study was working more at the individual gene level and did
not appear to perform any normalization or standardization of the genes across
samples as the other studies that created the binary datasets did.
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The West et al. study found the most significant factor in overall survival to
be whether or not the breast cancer metastasized to the axillary lymph nodes.
However, obtaining these nodes for testing is a highly invasive surgery and the
decision on which nodes to select for examination introduces some bias that could
result in reported negatives that are actually positive (West et al., 2001).
The file used in this thesis research contained 24 samples labeled positive and
25 samples labeled negative with each sample containing 7129 features. This file
appears to still contain the two samples that failed the array hybridization as
well as the five held out and tested statistically due to classification discrepancies
between IHC and immunoblotting. No documentation was received with this file
to indicate whether the positive and negative classifications of the file samples
were from the original IHC or if they were altered.
The West breast cancer dataset had the highest dimensionality of the seven datasets
investigated and it was the most sparse dataset used in this research. It was also
one of the most difficult to correctly classify, likely due in part to the problems
and discrepancies in the original dataset.
2.3.2 Multiclass Datasets
2.3.2.1 Lung Cancer Dataset
The multiclass lung cancer dataset was among the easiest to classify. It had the
most samples and was the least sparse of all of the datasets evaluated in this
research. The lung dataset, like the leukemia dataset, achieved good classification
results from a number of authors on a variety of techniques. The lung dataset is
from the 2001 Bhattacharjee et al. study (Bhattacharjee et al., 2001).
The normal lung samples and a majority of the tumor samples were obtained from
two independent tumor banks, Thoracic Oncology Tumor Bank at the Brigham
and Women’s Hospital/Dana–Farber Cancer Institute. These samples had asso-
ciated clinical data. Additional tumor samples without associated clinical data
came from the Brigham/Dana–Farber Tumor Bank and the Massachusetts Gen-
eral Hospital Tumor Bank (Bhattacharjee et al., 2001).
The original file had 203 patient samples broken down in Table (2.3).
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Table 2.3: Lung Cancer Data.
# Cancer Description
139 lung adenocarcinomas samples (AD)
21 squamous cell carcinoma samples (SQ)
20 pulmonary carcinoid tumors (COID)
6 small-cell lung cancers samples (SCLC)
17 normal lung samples (NL)
When collected, the samples were snap frozen within 30 minutes of the collection.
When used the samples were homogenized in Trizol and the RNA was extracted
using RNeasy column purification kit. The total RNA extracted was then hy-
bridized to Affymetrix HGU95A v2 arrays according to the standard protocol.
These arrays contain 12,600 genes and expressed sequence tags. Expression values
for each gene were calculated by using Affymetrix GENECHIP software (Bhat-
tacharjee et al., 2001).
The data was then normalized and centered on the median. After this data prep
step, CLUSTER and TREEVIEW hierarchical clustering programs where used
for class discover on all 203 samples. Validation of the class discovery was accom-
plished by using probabilistic model-based clustering from program AUTOCLASS.
Only the 3,312 transcripts that were the most variable expressed transcripts were
used. (Bhattacharjee et al., 2001). The data used in this research was a subset of
the Bhattacharjee et al. data.
Of the 125 samples that came with associated clinical data and postoperative
surgical–pathological staging, the results are summarized in Table (2.4).




54 More than 40 pack-year smokers.
51 Less than 40 pak-year smokers.
17 Non-smoker patients.
3 Information unavailable.
76 Stage I tumors.
24 Stage II tumors.
10 Stage III tumors.
12 Putative metastatic tumors.
3 Information Unavailable
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The file used in this thesis research did not contain the 6 SCLC samples, but
contained the remaining 197 samples.
2.3.2.2 Breast Cancer Dataset
This breast cancer dataset is a multiclass dataset originating as one of the datasets
from the 2001 study and 2002 Veer et al. publication (Veer et al., 2002). A later
study by Hoshida et al. identified three subclasses for this dataset in 2007 (Hoshida
et al., 2007).
Table (2.5) provides the background detail of the original Veer et al. breast cancer
study. All 98 samples were primary invasive breast carcinoma tumors less than
5cm, from patients diagnosed between 1983-1996 with no prior malignancies. All
patients were lymph node negative and under 55 years of age at diagnosis. There
were 35 patients treated by modified radical mastectomy and the remaining 62
underwent breast-conserving treatment (Veer et al., 2002).
Table 2.5: Breast Cancer Data Detail.
# Description
34 Patients developed distant metastases within 5 years.
44 Patients were disease-free beyond the 5 year mark.
18 Patients had BRCA1 germline mutations.
2 Patients were BRCA2 carriers.
The tumor samples were snap-frozen in liquid nitrogen within one hour of surgery.
The RNA was extracted after two hybridisations using a fluorescent dye reversal
technique on Hu25K microarrays with 24,479 genes. The expressions were quan-
tified, normalized and corrected to yield optimal results. Approximately 5,000
genes were significantly regulated across the group of samples. An unsupervised
hierarchical clustering algorithm was executed on the 98 tumors across the 4,968
significant genes (Veer et al., 2002).
The Veer et al. study culminated with a three step process to classify breast
tumors into prognostic categories based on the gene expression profiles as follows
(Veer et al., 2002) :
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1. Select discriminating genes based on their correlation with the category.
2. Determine the optimal set of reporter genes using leave-one-out cross-validation.
3. Prognostic prediction based on gene expression and the optimal set of re-
porter genes.
The Hoshida et al. study further analyzed the Breast-A and Breast-B datasets
from the Veer et al. study and were able to identify and validate three subsets in
the Breast-A dataset, which is the one used in this research.
Before the clustering was executed, each column was normalized by subtracting
the column mean and dividing by the column standard deviation, more specifically
each column was standardized. The gene expression data was then converted to its
rank in each column and the clustering was performed using the rank to compute
distance. Pearson correlation and the average linkage method were used for the
hierarchical clustering (Hoshida et al., 2007). The impact of the dataset prepro-
cessing on later classification becomes apparent and is explained in Chapter 3.
The subclass labels were predetermined either by clustering or as manually as-
signed phenotypes (Hoshida et al., 2007) prior to executing the SubMap unsuper-
vised algorithm proposed in this article. In the final analysis with the SubMap
algorithm for Breast-A, sets of two candidate subclasses and sets of three candi-
date subclasses were identified. More significant associations for Breast-A were
derived from the finest granularity.
In this research, the three subclass sets were used. In addition, it should be noted
that array S54 had been removed during processing because it was determined to
be an outlier (Manual, 2014). This resulted in the dataset used here having 97
patient samples and 1213 features or variables.
2.3.2.3 Brain Cancer Dataset
The brain data used in this research was taken from the rda R package and is from
the Pomeroy et al. study (Pomeroy et al., 2002). The study was performed with
the approval of the Committee for Clinical Investigation from Boston Children’s
Hospital.
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The samples were snap frozen in liquid nitrogen and stored at −80 ◦C. The spec-
imens were analyzed with oligonucleotide microarrays that contained probes for
6,817 genes. The RNA integrity was assessed using either northern blotting or by
gel electrophoresis. RNA was hybridized overnight to HuGeneFL arrays contain-
ing 5920 known genes and 897 expressed sequence tags. Affymetrix scanners and
GENECHIP software were then used. Microarray intensity minor differences were
corrected using linear scaling. Scans that did not meet specified standards were
rejected. The gene expression data was then subjected to a variation filter and
genes showing minimal variance across the samples were excluded. The authors
normalized each column or sample, to mean zero and variance one (Pomeroy et al.,
2002).
Three datasets were generated from this study, dataset A was used in this thesis
research and is detailed in Table (2.6). The gene expression profiles of the 42
samples in dataset A served as the starting point for the Pomeroy et al. study of
central nervous system embryonal tumors.
Table 2.6: Brain Cancer Dataset A Detail.
# Age Description
10 Children Medulloblastomas.
10 Young Adults Malignant gliomas (WHO grade III and IV).
10 Children Atypical Teratoid Rhabdoid Tumor (AT/RTs).
(5 CNS and 5 renal extrarenal).
8 Children Supratentorial PNETs*.
4 Unknown Normal Cerebellums.
In the Pomeroy et al. study it should be noted that they repeated their analysis
after removing PNET sample 41 and 42 because they were pineoblastomas and
they have been including in the PNET category inconsistently across research. The
altered data is in dataset A1 from the Pomeroy study. Dataset A still contains
both pineoblastomas in the PNET category, which is class label 5.
In the Pomeroy et al. study the first thing they did was perform S-Plus principal
component analysis (PCA) on the highly varying genes for datasets A. PCA is
a technique used to reduce the dimensionality of a dataset which often contains
highly correlated features or variables, by using a transformation to convert the
observations into a reduced set of linearly uncorrelated variables that collectively
explain most of the variability in the original set (James et al., 2013). These new
variables are called principal components and are sorted in order so the components
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explaining the largest portion of the variance come first. In the Pomeroy study
they plotted the top three component dimensions as shown in Figure (2.8).
They did this to see how easily the subclasses of the datasets would separate.
This would indicate to them if the tumors could be distinguished on a molecular
level (Pomeroy et al., 2002). These three components accounted for 42.5% of the
variance in the datasest and as seen in the figure, the normal brain samples break
away easily and the other tumor classes begin to separate as well.
 






Figure 2.8: PCA of Highly Varying Genes.
6
When using the PCA technique knowledge of the individual genes is lost, but
it is a good starting point for investigating the data. In addition to PCA, the
Poneroy et al. study used GeneCluster software and self-organizing maps (SOMs)
to investigate and analyze the data.
2.3.3 Cancer Dataset Summary
As discussed in the previous section, there were some subtle differences in the
statistical methods and analysis applied to the various datasets. This informa-
tion has been summarized in Table (2.7) which consolidates pertinent information
that is unique between the seven datasets and could have a potential impact on
prediction either favorably or unfavorably.


















Table 2.7: Dataset Summary Information.
Data Study Sample Comments
Year Date
Prostate 2005 1993-1999 • Multiplicative scaling was done on each array.
• The p=500 dataset’s features were selected randomly rather than for statistical significance.
• Could not find any proceeding publications that used this specially requested file.
Colon 1999 — • Healthy samples were taken from approximately half of the cancer patients, but not all.
• Outlier detection and removal was not model based.
• Normalization was done using magnitude and emphasized relative intensity variation rather than
absolute intensity variation.
• In (Li et al., 2001), 5 samples were removed from their study as they believed the were contaminated.
Leukemia 1999 1980-1990 • Multiple tissue banks used with a good mix of samples, child and adult.
• An independent dataset was used for validation purposes.
• These two leukemias are known to be easily classified. This study was a proof-of-concept study
for DNA microarray technology.
• The study documented that one lab they used had slightly poorer performance than the others.
West Breast 2001 — • Samples came form the Duke SPORE Bank using very specific sample selection criteria.
• The RNA extraction protocol used was a slightly different method than most of the other datasets.
• Two samples did not hybridize and five had conflicting results between two laboratory test processes.
These seven samples are potentially faulty samples, but were still in the dataset used in this thesis.
Lung 2001 — • Four different tissue banks were used for samples.
• The data was normalized and centered on the median.
• AUTOCLASS validation software was used.
Breast 2007 1983-1996 • Each array column was standardized.
• After being standardized, the gene expression data was then converted to rank order.
• One outlier was removed from the dataset and was not input into this thesis either.
Brain 2002 — • Minor intensity differences were corrected using linear scaling.
• A variation filter was used to eliminate genes showing minimal variance across samples.
• Each column was then standardized following the scaling and filtering.
• PCA was run first to ensure the data would separate at a molecular level.
• The authors repeated their study, removing sample 41 and 42 to create a new dataset.
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Machine Learning Process
There are many far reaching and diverse viewpoints about the origins of Machine
Learning. For the purpose of this thesis, the definition is limited to the early 1990’s
when the intersection of Computer Science and Statistics brought new popularity
to the field of Machine Learning (SNNAdaptiveIntelligence, 2015). The synergistic
blend of these two disciplines coincided with the exponential growth of data that
began being collected and stored under the nomenclature of Big Data. Accord-
ingly, Machine Learning is a scientific discipline that explores the construction
and study of algorithms that discover knowledge and learn from specific data and
experience, based on sound statistical and computational principles (Kohavi and
Provost, 1998), (SNNAdaptiveIntelligence, 2015).
There are two main categories of machine learning problems know as supervised
learning and unsupervised learning(Hastie et al., 2001), (James et al., 2013).
• Supervised Learning: For every observation, there is a vector of features
xi, i = 1, · · · , n and its associated response, or dependent variable, yi. The
goal of supervised learning is to accurately predict the yi’s based on the
corresponding features, or predictor variables.
• Unsupervised Learning: For every observation there is a vector of features
xi, i = 1, · · · , n, but there is no associated response yi. The goal with
unsupervised learning is to identify patterns or clusters in the data and to
understand the relationship between the features or between the observa-
tions.
In this thesis, the focus is on classification using supervised learning methodology.
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3.1 Classification With Supervised Learning
The general goal of classification is to accurately assign or classify given observa-
tions, xi’s, into their correct category or class, yi, with minimal errors. This is
assessed by removing, or holding out, the class labels yi from a set of observations
and passing the corresponding feature vectors’, xi’s to a chosen algorithm to pre-
dict the class ŷi for each feature vector or observation. The predicted ŷ’s are then
compared to the corresponding held-out true y’s for each observation. For each
ŷ 6= y, a penalty or cost is incurred. This is known as the 0 - 1 loss function and




1 if Y 6= f(X)
0 if Y = f(X)
(3.1)
Given that the general goal of classification is accurate prediction, the question
then becomes, how does one achieve accurate prediction for a given dataset? The
answer is a multiple-step process that begins with using cross-validation to deter-
mine the optimal tuning parameter or parameter set, and ends with finding the
average generalization error for comparison between classifiers.
Before going more deeply into these topics, it is crucial to understand the meaning
and concepts behind bias-variance tradeoff along with the importance of the test
error and how it differs from the training error.
3.1.1 Training Error and Test Error
The training error is the error produced from fitting or training a classifier algo-
rithm on a given set of data containing both the feature vectors and their cor-
responding responses. The test error is the resulting error generated when the
trained classifier is given an out-of-sample set of feature vectors, without the re-
sponses, and is asked to classify the vectors based on what was learned from the
training set.
This process is performed by randomly partitioning a given dataset into a training
set and a test set and proceeding as outlined above. This protocol can then
be repeated a number of times by resampling the data in a process known as
replication in machine learning nomenclature. This is similar in concept to Efron’s
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bootstrap resampling technique (Efron, 1979). There are differing opinions on
what defines the best split for the partitions, in this thesis the datasets were all
partitioned into a 2
3
training set and a 1
3
test set.
Although the training error, also known as the apparent error, is sometimes pub-
lished in research, it should not be trusted. As documented by Efron (Efron, 1985),
the training error will tend to underestimate the true error because the same data
has been used twice. It has been used to fit a model and then used again to
check the accuracy of the model. The training error is not a good estimate of the
generalization error, as it does not properly account for model complexity (Hastie
et al., 2001). Figure (3.1) shows a binary and multiclass example of the training
error alongside the test error.
Figure 3.1: Training Error and Test Error.
These examples clearly illustrate the importance of model verification on out-of-
sample test data in order to get a true, unbiased estimate of the classification
generalization error. Essentially, machine learning algorithms must be able to
generalize from the training data rather than simply memorize it.
When the model is trained it is prone to overfitting as it learns the data. When a
model overfits the data it will lower the bias consequently giving a lower training
error, but this leads to a much higher amount of variance in the model in exchange.
This concept is explained more fully in the next section.
Chapter 3 Machine Learning Process 30
3.1.2 Bias-Variance Tradeoff
To better understand the concept of bias-variance tradeoff, it is important to un-
derstand the meaning of bias and variance from a statistical and machine learning
perspective. Simply, bias is the error introduced when approximating a real-life
problem (James et al., 2013). The bias of a learning algorithm is the systematic
error that the learning algorithm is expected to make when trained on a training
dataset (Dietterich and Kong, 1995). As the bias error is reduced, the model will
become more complex and the variance will then increase. Variance is the amount
function f̂ will change by if estimated using a different training dataset, given that
each training dataset will compute a different f̂ estimate (James et al., 2013). Fig-
ure (3.2) illustrates how the interaction between bias and variance determines the
training error and simultaneously effects the test error.
Figure 3.2: Bias-Variance Tradeoff.
1
As mentioned previously and demonstrated in Figure (3.2), as the training error
decreases, the model becomes more complex lowering the bias while simultaneously
increasing the variance. This happens because the model adapts itself too closely
1(Wang et al., 2008)
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to the training data (Hastie et al., 2001). Explicitly, the model starts fitting the
noise in the training data and fitting patterns that do not reappear. Once the test
sample is introduced, containing data that the algorithm has never seen before,
the test error increases quickly. This is referred to as overfitting and it results in
a proportionally higher amount of variability in response to the lower bias and
in turn causes the model to not generalize well. Conversely, when the variance is
too low, there is a very large amount of bias present in the model causing it to
underfit, which will again result in a model that does not generalize well. The
challenge then becomes finding that optimal balancing point between the bias
and variance that correspondingly provides the lowest generalization error, or test
error. This challenge is addressed by finding the optimal tuning parameters for a
given technique and data set combination that results in the lowest generalization
error. This process is covered in detail in the Cross-Validation for Optimal Tuning
section later in this chapter.
Undeniably bias-variance tradeoff, the simultaneous minimization of the two sources
of error, is one of the most important concepts in machine learning.
3.2 Data Investigation and Cleansing
Prior to evaluating different techniques for supervised classification, or even look-
ing for optimal tuning parameters, it is important to investigate the data to get a
sense of it. Start by identifying the number of observations n, the dimensionality
p, and calculating the κ ratio to determine the sparsity of the data. In addition,
it is extremely important to know not only how many class labels are represented
in the data, but what the proportions of each class are and how uneven they are.
These seemingly commonplace details, in reality, play a vital role in determining
the level of accuracy obtained in prediction, especially when dealing with HDLSS
data where κ < 1.
Data cleansing, also referred to as scrubbing the data, is a way of ensuring the
purity of the data prior to processing it. This could consist of filling in missing data;
syncing names, dates, and currencies from various sources; smoothing noise in the
data; normalizing or standardizing the data; or even running simple conversion
programs to name just a few. This type of preprocessing is extremely important
to maintaining the integrity of the data and could have a very significant impact
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on prediction. In this thesis research, which is dealing with microarray data,
preprocessing steps were limited to class label changes and transposing matrices
as described in Chapter 5, along with standardizing the data as described later in
this chapter.
3.2.1 Data Complexity
The datasets used in this thesis were detailed in Table (1.1) and are displayed
in the following figures with their respective class proportions identified. Figure
(3.3) shows the four binary datasets and Figure (3.4) shows the three multiclass
datasets.
(a) Colon Cancer (b) Prostate Cancer
(c) West Breast Cancer (d) Leukemia Cancer
Figure 3.3: Binary Data Plots.
A quick look at the proceeding binary plots shows that the West breast cancer
dataset and even the prostate cancer dataset are fairly even. The colon cancer and
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(a) Lung Cancer (b) Breast Cancer
(c) Brain Cancer
Figure 3.4: Multiclass Data Plots.
In the multiclass data plots there is a great deal more discrepancy between the
classes’ sample amounts. Although it may not seem intuitive from looking at the
plots in Figure (3.4), it is actually the brain cancer dataset which provided the
largest challenge in classification. The reason is that the class label of 4 only
has four observations, this presented a definitive challenge in maintaining class
proportions as illustrated later in the Table (3.1) example.
As mentioned previously, understanding the sparsity and proportions of the class
labels in a given dataset is a key component for accurate classification and error
prediction. Once the class proportions are identified, it is important to then dili-
gently ensure these proportions are properly maintained when performing cross
validation and replication so that the integrity of the π̂ Matrix is upheld. This is
of vital importance because the π̂ Matrix contains the prior probability estimates.
This is covered in more detail later in this chapter.
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3.2.2 Data Standardization
One of the key tasks in preprocessing data is to scale it. This could be in the
form of normalizing the data, standardizing the data, or performing some other
transformation on the data to bring the variables into proportion with one another.
One of the main advantages of scaling the data is to prevent a feature with a large
range of values from dominating a feature with a small range of values (Hsu et al.,
2003). In the case that different measurement scales are involved, scaling the data
will also transform all of the features to the same scale of measurement for a fair
comparison between them (Vapnik, 1995),(Ripley, 1996). It essentially “levels the
playing field” so all of the features or input variables are treated equally with a
consistent reference of measurement. Furthermore, scaling the data provides the
added benefit of avoiding numerical difficulties in calculations (Hsu et al., 2003).
This is especially important when dealing with kernel techniques as kernels rely
on the inner products of the features vectors, as explained in Section (4.2).
In this thesis research each gene expression array or column in a given dataset was
standardized across all samples. All seven datasets were standardized following
the same process.
Standardizing the data can result in an improved prediction rate as shown in Figure
(3.5) and reflected by the reduction in the mean misclassification rate calculated
as follows,




By standardizing the prostate data, there was a reduction in mean misclassification
rate of 11.10%, while the lung data had a very substantial reduction of 48.99%
just from standardizing the data in the preprocessing step.
A caveat must interjected at this point. As discussed in Chapter 2 the data used in
this research was existing data and had already been subjected to various smooth-
ing methodologies and feature selection processes before it was obtained for this
thesis. Sometimes if a non-model based method is used to remove outliers it can
actually suppress the signal and inadvertently incorporate the noise into the data.
This may have been the case with the Colon data whose prediction performance
worsened upon standardization of the data as seen in Figure (3.6).
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Figure 3.5: Non-Standardized and Standardized Plots.
As illustrated in the figure, when standardizing the colon data it has a ( -54.32% )
reduction in mean misclassification rate. Alternatively stated, there is over a 54%
increase in the error when standardizing the colon dataset.
Figure 3.6: Colon Non-Standard and Standardized Plot.
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Several different transforms were tried on the colon cancer dataset with each one
negatively impacting predictive performance. In the interest of completeness and
transparency, both the standardized and non-standardized versions of the colon
cancer dataset were carried forward in this research. In addition, due to the
identification of this nonconformity in the colon data, every dataset in this research
was initially tested with the standardized and non-standardized versions of the
data and, when applicable, both versions were carried forward throughout the
research. In the cases where this situation was present, it is well documented and
clearly indicated throughout the experimental results in Chapter 6.
Further, it should be noted that the regularization technique was the only one
that required standardization in this research. For the kernalization techniques,
both R packages investigated considered standardization so critical to optimal
classification that they automatically standardized the data internally within the
programming and no attempt was made to override the internal coding. The trees
and randomized ensembles techniques are coordinate-based techniques that work
by partitioning the data into regions based on given criteria as illustrated in (4.6).
Given that they are coordinate-based, there was no need for standardization.
3.3 Cross-Validation for Optimal Tuning
A crucial, and often overlooked, component to maximizing prediction results in
classification is to perform thorough and methodical cross-validation on every given
dataset and classification technique combination in order to identify the optimal
tuning parameters for each. Most commonly used packages will be programmed
with off-the-shelf defaults for the various parameters but these are not always the
best, especially given the complexity of gene-expression microarray cancer data.
Therefore, identifying the optimal hyper-parameters and tuning parameters via
cross-validation becomes vital in order to find the balancing point in the dichotomy
of bias-variance tradeoff which will result in the lowest generalization error and
concomitantly the best prediction result.
Following this principle, several extensions of cross validation were explored on
each machine learning technique for every dataset in this research. Leave-one-
out cross-validation (LOOCV) and three types of K-fold cross-validation were
evaluated. These results are detailed in Appendices A, B, and C.
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3.3.1 Leave-One-Out Cross-Validation (LOOCV)
The Leave-One-Out Cross-Validation (LOOCV) form basically performs K-fold
= n iterations on a given dataset where one observation is held out as a test case
and the remaining observations are used for training. The label of the held-out
observation is then predicted using the trained classifier and compared to the ac-
tual label, Equation (3.2). Accuracy of prediction is assessed and the process is
repeated for each observation. The mean misclassification rate for a given param-
eter or set of parameters is then assessed at the end of n iterations, Equation (3.3).
LOOCV is known to be a nearly unbiased estimator.








Given a specific parameter or parameter set, execute the following :
For i = 1 to n Loop
• Hold out the ith observation.
• Build a classifier using the remaining n− ith observations for a
specific technique.
• Give the ith held-out xi variables to the trained classifier to predict
the yi label.
• If ŷi 6= yi
◦ Total Misclassifications = Total Misclassifications + 1
End If.
End For Loop.
Mean CV error for the parameter(s) = Total Misclassification/n.
3.3.2 K-fold Cross-Validation
The following threeK-fold Cross-Validation Methods (K-fold) involve splitting the
data intoK equal, or nearly equal, folds and following a similar process as above for
cross-validation. These three K-fold methods all perform cross-validation exactly
the same and the difference lies in how the samples are split into folds. The labels
from the held fold are predicted using the trained classifier and compared to the
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actual held-out labels, Equation (3.4). When splitting or partitioning the data the
mean misclassification rate for a given parameter or set of parameters is assessed














Traditionally, when choosing the number of K folds to partition the data into
for cross-validation the industry standard has been to use 5 or 10 folds (Breiman
and Spector, 1992), (Kohavi, 1995), (Breiman, 1996b),(Clarke et al., 2009) with
K=10 being the default in most software packages. However, with this microarray
cancer data where κ < 1, the class proportions are often extremely uneven, and
there is great sparsity of data, the choice of K becomes important for optimal
prediction. In this research K=5 or smaller was found to perform the best. This
is explained in more detail in the stratified sampling section of this paper in Brain
Label Partition Splitting Example, Table (3.1).
K-fold Cross-Validation Pseudocode
For i = 1 to n Loop
• Hold out the ith fold of observations.
• ni = number of observations in the ith fold.
• Build a classifier for a given technique using the observations in the remaining
K - ith folds.
• Give the xi variables for all observations in the held-out ith fold to the
trained classifier for prediction of the yi labels.
• Average ith Misclassifications = Sum( ŷi 6= yi )/ ni.
• Total Average Misclassifications = Total Average Misclassification +
Average ith misclassifications.
End i Loop.
Mean CV error for the parameter(s) = Total Average Misclassifications / K.
As stated previously, all three cross-validation methods perform the actual cross-
validation as outlined in the K-fold Cross-Validation Pseudocode and the differ-
ence in how the methods split the observations. The three methods are outlined
in the following pages.
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Shuffle and Split (SS) is the form of cross-validation typically used by default in
existing machine learning software in both R and Matlab. In this process the
dataset is randomized and then simply split into K folds without stratification.
Each fold is held out in turn and predicted by the remaining K-1 folds for each
unique parameter or set of parameters as described previously in the K-fold Cross-
Validation Pseudocode.
SS Pseudocode
• Shuffle the observations into random order.
• Split the observations into K fold partitions.
• Given a specific parameter or parameter set, execute
 K-fold Cross-Validation Pseudocode.
Stratified Cross Validate (SCV) and Balanced Stratified Cross-Validate (BSCV)
methods differ from the SS method above in that both of these techniques use
stratification when splitting the samples into K folds. This means these two
techniques will maintain the dataset’s class proportions within each fold when the
dataset is split. This ensures that the probability of each class label occurring
in a fold is kept consistent to its probability of occurring in the original dataset,
which will in turn maintain the integrity of the π̂ Matrix. The difference in the
two methods is in how they handle uneven sample splits of classes.
The SCV form of cross-validation performs a strictly theoretical stratification
which results in folds that are slightly uneven, but it maintains pure statistical
stratification of classes. The BSCV performs a more computational stratification
when splitting the data. BSCV adheres to the statistical stratification on splits for
an even multiple of K. It will then gather any remainder from uneven class splits
and spread them evenly across all folds at the end of the process. This results in
folds of equal or almost equal sizes that are also stratified. These subtleties will
become apparent in the Brain Label Partition Splitting Example (3.1).
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SCV and BSCV Pseudocode
For j = 1 to Number of classes Loop
• For the jth class label shuffle the observations into random order for
that class.
• Split the randomized samples for the jth class label into K fold partitions.
• If SCV
 When the observations for the jth class do not split evenly across the
folds, the extra observations for the jth class are distributed one at
a time from the 1st fold, in sequence, until they are exhausted.
Else BSCV
 When the observations for the jth class do not split evenly across the
folds, the extra observations for the jth class are stored in a matrix.
End If.
• Concatenate this jth class’s K fold splits together with the previous
jth–1 class’s K fold class splits such that they accumulate together.
End j Loop.
If BSCV
• Any remaining observations from the classes that were stored in the matrix
are now shuffled randomly and then distributed one at a time from the 1st
fold, in sequence, until they are exhausted.
End If.
Given a specific parameter or set of parameters, execute
• K-fold Cross-Validation Pseudocode.
3.3.3 Stratified Sampling
The importance of stratifying the sampling when partitioning data for cross-
validation and replication was discussed previously in other sections, the following
example provides an explanation as to why stratifying the sampling is vital to
obtaining optimal prediction when classifying data.
Following is a brief example highlighting how the various cross-validation tech-
niques perform and clearly emphasizing the need for stratification in sampling,
especially when dealing with very sparse data containing uneven class sizes. For
this example the brain cancer dataset is used.
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Table 3.1: Brain Label Partition Splitting Example.
Label 1 2 3 4 5
Class Size 10 10 10 4 8
Partition Splits Partition 1 Partition 2 Partition 3 Partition 4 Partition 5
SS Results (K=5) 31114235 45552224 23153512 34213132 5153312321
SS Results (K=4) 31212212523 12212341115 1314255534 5323533534
SCV Results (K=4) 111222333455 111222333455 112233455 112233455
BSCV Results (K=4) 22515411323 41315323152 5423321513 5351212432
In the top of Table (3.1) the class distribution is shown under “Class Size”. Recall
that Label 4 only had four observations and was identified earlier in this chapter
as being an issue that would need to be addressed. Given that most of the classi-
fication packages use k=10 as a default, one can easily envision how bad 10 splits
would perform in prediction. Over half of the splits would not contain a label of
4 at all and at least 2 splits would not contain a label of 5 either. Therefore, just
taking defaults and using a k=10 fold split would be a poor choice. If k=5 was
chosen instead, which is also commonly used in data mining, the prediction would
still not be optimal.
By reviewing the top line of the table, SS with K=5, it can be observed that
Partition 3 and Partition 5 contain no class 4 labels. Additionally, Partition 2
obtained two class 4 labels and received three of the eight class 5 labels. Clearly,
these partitions do not represent the original dataset and are not well-balanced
samples. Using K=5 folds for the brain cancer dataset will cause issues in the π̂
Matrix.
By doing the initial data investigation, the unevenness of the classes would easily
be discovered. Then, given that Label 4 only contains four observations, it would
dictate that K=4 folds would be a good choice for this dataset. Moving forward
in the table using K=4 folds, the distinction between stratification and simple
randomized splitting becomes more apparent. In observing the three K-fold ex-
tensions of cross-validation represented in the last three rows, it can be seen clearly
that only the stratified sampling methods (SCV and BSCV) correctly maintain
the class proportions and represent Label 4 in each fold or partition.
The more subtle difference between SCV and BSCV can also be viewed in the table
by looking more closely at the number of observations in each partition. The SCV
front loads the first two partitions with the extra observations, whereas the BSCV
attempts to balance out the extra observations from the uneven splits throughout
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all of the partitions. In the end, SCV and BSCV both work well. There are
certain places where one will slightly outperform the other and these instances are
discussed and presented in the following section Cross-Validation Summary.
This example clearly illustrates the early works of Friedman (Friedman, 1989)
where he discusses estimation of the prior probabilities. Friedman emphasizes the
importance of maintaining the correct class proportions so that the π̂ Matrix is ac-
curately preserved. Upholding the integrity of the π̂ Matrix is a key component to
accurate classification. This is especially true in sparse datasets where κ < 1.
The following figures, (Figure (3.7), Figure (3.8), and Figure (3.9)) give empirical
evidence to support the importance of stratification in classification when dealing
with HDLSS data, especially when determining the generalization mean misclas-
sification rate.
Figure 3.7: Prostate Non-Stratified and Stratified Plot for RDA.
In each of the three plot comparisons between Non-Stratified and Stratified data,
it should be noted that the given dataset’s optimal tuning parameters were used
in processing both replicates. Additionally, 1000 replicates were run to generate
each of the boxplots and each boxplot received the exact same splits of data in
the same order, as explained in Chapter 5 by the process of “seeding”. My pur-
pose in controlling these options so strictly, was to ensure that the only difference
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between the boxplots in each of these figures was the fact that the first boxplot
was not stratified when sampling and the second boxplot was stratified. This in
turn provides credence when stating that the reduction in misclassification rate is
a result of stratification.
Figure 3.8: Brain Non-Stratified and Stratified Plot for RDA.
When looking at the leukemia cancer dataset, a big reduction in error was not
expected since the dataset is pretty easily classified with a less than 2% error for
each technique investigated. However, by looking at Figure (3.9), it is apparent the
stratification, even in an easily classified dataset, still makes a significant difference
when κ < 1.
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Figure 3.9: Leukemia Non-Stratified and Stratified Plot for RDA.
3.3.4 Cross-Validation Summary
Undeniably, the arduous process of selecting the correct hyper-parameters to op-
timize accurate classification prediction proved to be one of the most intensive
and crucial portions of this research. Recall from (Hadamard, 1923) that for a
problem to be well-posed a solution must not only exist, but it must be unique
and stable. In this research, classification with this microarray cancer data proved
to be anything but stable and returned multiple local minima when searching for
the optimal tuning parameters via cross validation. This led to the use of various
cross-validation implementations in an attempt to identify the tuning parameter
or tuning parameter set that would return the absolute minimum.
By looking through the appendices of this thesis it is quickly observable that simply
running a single cross-validate would not identify a minimum tuning parameter or
set of parameters. Occasionally just one minimum was returned, but more often
multiple parameter sets were returned with the same minimum cross-validate error.
In the case of the e1071 Support Vector Machine technique, when using the Linear
Kernel, often the entire input grid of parameters was returned as minimum.
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In an attempt to manage the multiplicity in the potential estimating functions, a
”greedy” approach was adopted. As defined by Paul Black (Black, 2005), a greedy
algorithm follows a heuristic problem-solving methodology of making the locally
optimal choice at each stage in an attempt to find the global optimum. Even
though the greedy algorithm normally does not find the optimal solution, it tends
to yield locally optimal solutions that approximate the global optimal solution.
In the spirit of the ”greedy heuristic”, the following processes was implemented
in an attempt to find the absolute minimum, or at least find a way out of the
multiplicity of the cross-validation results.
First random replications of the cross-validation jobs were performed. The ensem-
ble and kernel methods were replicated three times for the K-fold extensions. The
regularization method was replicated five times for the K-fold extensions. This
replication process provided a way of controlling some of the instability and high
variability. The replication of the K-fold cross-validations also provided an oppor-
tunity to recognize any repeating minimum tuning parameters, thus identifying
them as more plausible candidates for the true minimum.
When a replicate returned ten or fewer results, they were all sent to the next
step as possible optimum tuning parameters. When more than ten results were
returned in a given replicate, the first few results, the last few results, and some
from the middle were selected and passed on to the next step. This decision was
based on various literature where some believed taking the minimum was best and
others made a case for the maximum.
Once a reasonable group of possible optimum tuning parameters or parameter sets
was determined from all cross-validation extensions, they were then put through
a replication loop of R=500 to determine the true average test error (TE) across
replications, as defined in (6.1). These replication runs were ”seeded”, as explained
in Chapter 5, to guarantee that competing tuning parameters received the same
splits in the same order. The tuning parameter or parameter set with the minimum
test error from the seeded R=500 results was then chosen as the optimal tuning
parameter or parameter set. In the very few situations where this still resulted in
multiple minimums, a parsimonious approach was taken and the tuning parameter
or parameter set that provided the simplest model was chosen. All of these results
were well documented and are provided in Appendices A, B, and C.
Chapter 3 Machine Learning Process 46
In the end, no one cross-validation method was better than all others in all sit-
uations, it depended on the technique being investigated. With the two kernel
techniques, all four cross-validation versions did well in finding the optimal tuning
parameters with SCV performing slightly better and LOOCV sometimes failing on
the kernlab version. With RDA, the regularized technique, BCV did the best and
LOOCV only found the optimal on the multiclass datasets, but not on the binary
datasets. With the tree technique, LOOCV found the optimal on every dataset,
SCV found optimal on three, and BCV found the optimal on only one dataset.
This makes sense as the tree technique essentially performs like the LOOCV in
it’s internal algorithms. For the Random Forests technique, BCV was clearly the
best cross-validation technique finding the optimum values for five of the seven
datasets. The SCV and LOOCV each found only one optimal value for the Ran-
dom Forests technique. It should be noted that the ensemble techniques were run
later in this research and that SS cross-validate was not run on them as the earlier
research from this thesis found SS to not perform as well as SCV and BSCV (Bill
and Fokoue, 2014).
It is not surprising that the SCV and BSCV extensions were more successful in
determining the optimal tuning parameters than SS as they both perform strati-
fied sampling which is crucial to maintaining the class probabilities and thus per-
forming more accurate classification prediction. Additionally, although LOOCV
is a nearly unbiased estimator that is extensively used in data mining, when it
comes to HDLSS space it often performs sub-optimally. LOOCV often returned
30, 40, or even over 100 optimal minimum parameters compared to the K-fold
split techniques which normally returned 3-10 minimums for cross-validation on
regularization and kernel methods, the ensemble methods produced even higher
volumes of multiplicity across the board. According to Breiman (Breiman and
Spector, 1992),(Breiman, 1996b), leave-one-out cross-validation is less accurate
than leave-many-out.
It should also be noted that the LOOCV method is much more computationally in-
tensive and time consuming than the K-fold split techniques. The LOOCV option
took anywhere from 3 times up to 8 or 9 times as long to run as 3 replicates of the
K-fold splits, depending on the classification technique and dataset combination
being evaluated.
To reiterate, prior to choosing the optimal hyper-parameters and regularization
parameters for a given classification technique, the data should be scaled, unless
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done within the technique, and any transformations or other preprocessing steps
should be completed. For the actual cross-validation process, due to the high
multiplicity resulting from the potential estimating functions, it is recommended
to use replicates of either BSCV or SCV in order to consistently obtain the optimal
tuning parameters across techniques. If time and resources allow, perform both
BSCV and SCV on the given data.
The need for such careful optimization of the tuning parameters stems from the
fact that in this type of high-dimensional space, the objective function of the




Chapter 1 discussed using regularization, kernelization, and randomized ensem-
bles as approaches for dealing with the phenomenon of ill-posedness found in the
microarray cancer data. This thesis investigated Regularized Discriminant Anal-
ysis, Support Vector Machines, and Random Forests as specific techniques of the
Regularization, Kernelization, and Randomized Ensemble Methods.
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4.1 Regularization Techniques
4.1.1 Discriminant Analysis
In general, the goal of discriminant analysis is to build the best classifier function
f that assigns points to one of several classes or labels y ∈ {1, 2, · · · , k, · · · , K}
based on a set of measurements X = (x1, x2, · · · , xp) such that the classification
error is as small as possible (Friedman, 1989), (Clarke et al., 2009). This function
is constructed from a posterior distribution created via the majority rule concept
where new points, or observations, are assigned to a class k that maximizes their
probability, which equivalently minimizes their loss. Each observation is assumed
to be a member of one and only one class and an error or loss is incurred when
an observation is assigned to the incorrect class (Friedman, 1989). The 0 - 1 loss
function `(y, f(x)) defined by Equation (3.1) is the loss function generally used
for classification.
Thus, the cost function or risk functional is
R(f) = E[`(Y, f(X))] = Pr[Y 6= f(X)]. (4.1)
The optimum classifier f ∗ is the one that minimizes Equation (4.1), the rate of
misclassification (Clarke et al., 2009), and is given by
f ∗ = argmin
f
E[`(Y, f(X))] = argmin
f
Pr[Y 6= f(X)]. (4.2)
Given a multiclass setting, one of the ways to implement Equation (4.2) is to define
a discriminant function dk(x) for k ∈ 1, . . . ,K such that the predicted label of x
is given by
ŷ = f̂(x) = argmax
k∈{1,··· ,K}
{dk(x)}. (4.3)
By assigning a one unit loss to each mistake or observation incorrectly classified,
the misclassification rate for the discriminant function simply becomes a fraction
of assignments that are incorrect. The resulting optimal discriminant function is
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the posterior class membership probability given by




where pk(x) ≡ class conditional density of X in class k, meaning the probability
that the observation belongs to the kth class given the predictor values for the
observation, and πk = Pr[y = k] based on the prior class membership probability.
Since the denominator in Equation (4.4) does not depend on k, the predicting
function of Equation (4.3) simplifies to
ŷ = f̂DA(x) = argmax
k∈{1,··· ,K}
{πkpk(x)}. (4.5)
The ŷ that minimizes the risk functional in Equation (4.2), concomitantly maxi-
mizes the probability of correctly classifying the discriminant function in Equation
(4.5). Equation (4.5) chooses the optimal class label or ŷ that maximizes the pos-
terior membership probability, Pr[Y = k|x], which is known as the Bayes rule.
The Bayes rule will achieve the minimum misclassification rate among all possible
rules (Friedman, 1989). However, since conditional densities pk(x) are seldom
known, the observations in the training set are used to construct the classification
rule by estimating pk(x) for each class label k.
Finally, when the class prior probabilities are also unknown, the training data is
used once again as a random sample from the pooled population distribution. The
prior probabilities are then estimated by the fraction of each class in the pooled
training set, Equation (4.7) (Friedman, 1989). This highlights the importance of
using stratified sampling when creating training data sets in order to maintain the
integrity of the prior probability estimates π̂k.
To estimate the prior membership probabilities of each class in the pooled sample
the following equations are used.
zik =
{
1 if yi = k (observation i is in class k)
0 otherwise
(4.6)



















zikxi = xk . (4.8)
The class conditional covariance matrix is estimated using





zik(xi − µ̂k)(xi − µ̂k)T . (4.9)
concluding with the pooled or common covariance matrix given by





4.1.1.1 Linear Discriminant Analysis (LDA)
In linear discriminant analysis (LDA) the classification rule is based upon a normal
distribution with the data in each group or class following a Multivariate Gaussian
distribution with means µk and common covariance matrix Σ (Clarke et al., 2009).
As a result of the covariance matrices between the classes being relatively close
and assumed equal, such that Σ0 = Σ1 = · · · = ΣK = Σ, the decision boundary
and discriminant function are inherently linear.
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Figure 4.1: Lineary decision boundary (2-Dimensions).















−1µk + lnπk. (4.13)
Equation (4.11) can be rewritten in the familiar linear format
dk(x) = b
>
k x+ ck. (4.14)






−1µ̂k + lnπ̂k. (4.15)
The assumption that the covariance matrices are equal in this special case of dis-
criminant analysis is fundamental when dealing with sparse datasets. By making
Chapter 4 Classification Techniques 53
this assumption, only one inverse covariance matrix needs to be estimated, which
is beneficial when dealing with small sample sizes.
That said, when dealing with HDLSS data like the microarray cancer data, a
technique must also be able to handle variable sizes p several times larger than
sample size n, n ≪ p. When LDA faces this scenario of κ < 1, it suffers from
both singularity and multicollinearity, and is prone to overfitting the data. This
happens because the dimension d of the data vectors is much larger than the data
vectors available in the sample size n.
This situation was encountered repeatedly during the research for this thesis. In
fact, all seven of the microarray cancer datasets investigated in this work ob-
tained warnings of collinear variables when executed with LDA. LDA struggled
to classify the data due to the covariance matrix Σ−1 being essentially singular.
Operationally, no direct matrix inversion was actually performed by LDA in these
scenarios. Instead, an iterative process was used to perform prediction.
Although the datasets used here have already been reduced through feature selec-
tion and preprocessing, for the LDA technique to work optimally, further reduction
in variable size would be required. In this research, LDA is used solely for the pur-
pose of providing a baseline.
4.1.1.2 Quadratic Discriminant Analysis (QDA)
In the case where the covariance matrices between classes are not equal, the
quadratic discriminant analysis (QDA) technique is normally employed. The
quadratic discriminant function containing the Mahalanobis distance between x−
µk (Friedman, 1989) is given as
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k x+ ck. (4.19)
The estimator for the quadratic discriminant function, Equation (4.16), is given
by
d̂k(x̂) = ln|Σ̂k|+ (x̂− µ̂k)>Σ̂−1k (x̂− µ̂k)− 2lnπ̂k. (4.20)
However, when faced with the situation where n≪ p, the QDA technique will not
run. The sample sizes are too small to estimate more than one inverse covariance
matrix. Therefore QDA was not an option for the microarray cancer data in this
research.
4.1.1.3 Regularized Discriminant Analysis (RDA)
The failure of LDA and QDA prompts the need for regularization to stabilize
the covariance matrix Σk. In the presence of high dimensionality, the variance of
the estimator is typically very high and in the process of reducing the variance
of the estimating function, some bias is inevitably introduced. Regularization of
the estimating parameters is therefore a common protocol for introducing a small
amount of bias into the covariance matrix in exchange for the gain in stabilizing
the variance and thereby reducing generalization error.
There are several variations of regularized discriminant analysis available. In this
research the shrunken centroids regularized discriminant analysis from Guo et al.
(2005), Guo et al. (2006) was chosen.
The shrunken centroid regularized discriminant analysis, hereafter referred to as
RDA, strives to minimize the within-class scatter while maximizing the between-
class scatter in order to define the feature vectors that allow the high-dimensional
data to be projected onto a low-dimensional feature space to facilitate maximum
class separation as seen in Figure (4.2).
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Figure 4.2: Shrunken centroids for a multiclass dataset.
1
This RDA method uses regularization of the LDA method as a way to resolve the
singularity problem that occurs when the sample covariance matrix is singular and
cannot be inverted. Having a covariance matrix that is singular is an expected
impediment of dealing with n ≪ p data. The regularization hyper-parameter α
is being used in the regularization of Σ̂ to resolve singularity and stabilize the
covariance estimate.
Σ̃ = αΣ̂ + (1− α)Ip where 0 ≤ α < 1 (4.21)






−1xk + lnπ̂k (4.22)
RDA handles shrinkage slightly different than the other conventional shrinkage
methods. Rather than shrinking the centroids directly as done in the nearest
shrunken centroids method (Tibshirani et al., 2003), the shrunken centroids RDA
method (Guo et al., 2005), (Guo et al., 2006) shrinks in the following way:
Shrinkage of x∗ = Σ̃−1x, (4.23)
1Image from StackExchange CrossValidated, 2012. stats.stackexchange.com
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leading to the following formula with ∆ as the shrinkage hyper-parameter
x∗
′
= sign(x∗)(|x∗| −∆)+ where 0 ≤ ∆ ≤ 3
and (u)+ ≡ max(0, u).
(4.24)
Accordingly, the RDA function is optimized through the tuning of the two hyper-













k + lnπ̂k. (4.25)
Lastly, the estimating function for RDA is given by




4.2.1 Support Vector Machine (SVM)
Support vector machines are supervised learning methods that originated in sta-
tistical learning theory (Vapnik, 1995). When using the support vector machine
(SVM) technique for classification the goal is to use xi, the vector of explanatory
variables, to estimate the optimal decision boundary that best separates the classes
or yi labels (Vapnik, 1995), (Clarke et al., 2009). In the simple binary case seen
in Figure (4.3) where p = 2, the two classes separate linearly and the boundary
between the two classes is called the hyperplane represented by
w · x + b = 0 (4.27)
where b is equivalent to w0, a constant, and w is the vector of coefficients.
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Figure 4.3: Support Vector Machine.
In practice the optimal decision boundary is found by maximizing the margin
between the classes while simultaneously solving a quadratic optimization problem.
Basically, obtain a margin between the classes as wide as possible while jointly
minimizing the number of data points falling outside their respective discriminant
margin by applying a penalty to those points. The points that lie beyond their
margin are considered misclassified points and are represented by ξ in Figure (4.3).
The points that lie directly on their respective margin are know as support vectors
and they are the training patterns that contain all relevant information about the
classification problem (Karatzoglou et al., 2006).
Mathematically, both the quadratic optimization problem and the final decision
function, or estimating equation, depend only on dot products between the train-
ing patterns. This is important because it allows the generalization of the simple
linear case to the non-linear case (Karatzoglou et al., 2006). Opportunely, the
inner product in feature space is exactly equal to a non-linear transformation in
input space (Vapnik, 1995). This is extremely advantageous for HDLSS datasets
where attempting to identify an optimal algorithm in input space, using a stan-
dard quadratic problem solver for training, would be unmanageable and imprac-
tical. However, by projecting the vector of xi’s from input space into a higher
dimensional feature space, solving the quadratic optimization problem becomes
attainable.
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As illustrated in Figure (4.4), for each point xi in q-dimensional input space there
is an equivalent Φ(xi) in feature space, where Φ is the kernel function that implic-
itly maps the vector of xi’s into the higher dimensional space (Vapnik, 1995). This
projection, or mapping of the xi points makes it possible to find the hyperplane,
or hyperplanes with multiclass datasets, that separate the data linearly in fea-
ture space thus avoiding the much more complicated non-linear decision boundary
shown in the input space of Figure (4.4).
Figure 4.4: Mapping input space to feature space.
2
Projection of Φ is represented as
∀Φ : X → F
Figure (4.5) is a pictorial representation of the support vector machine including
the kernel function Φ.
Recall that the goal of support vector machines is to find the optimal hyperplane
w>Φ(x) + b = 0 that separates the data with the least errors while jointly max-
imizing the margin. From geometry it is known that the distance of a vector in
space can be found by dividing 1 by the norm of the vector, 1||w|| . Therefore, to
maximize the margin, maximize the length of the w vector on each side of the
hyperplane as seen in Figure (4.3) and Figure (4.5).
2Image from StackExchange Stackoverflow, 2012. stackoverflow.com
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Figure 4.5: Support Vector Machine Mapping.
3
Given the formula for the margin, namely




maximizing the margin is algebraically the same as the minimization equation





Fundamentally, the formalization for support vector machines is as follows:
When implementing C classification, which uses the Lagrange formulation for reg-












>Φ(xi) + b) ≥ 1− ξi and ξi ≥ 0, (i = 1, · · · ,m) (4.30)
where C is a constant, m is the number of training patterns or support vectors,
and Φ(xi) is the projection of xi’s into the feature space F .
3Image from Microsoft Research. http://research.microsoft.com
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When implementing ν classification, which sets the upper bound on the training
error and the lower bound for the fraction of observations that become support
vectors, solve the maximization problem for objective function
E(w, ξ, ρ) =
1
2







>Φ(xi) + b) ≥ ρ− ξi and ξi ≥ 0, (i = 1, · · · ,m) (4.32)
where ρ ≥ 0, m is the number of training patterns or support vectors, and Φ(xi)
is the projection of xi into the feature space F .





where support vectors occur when the point (xi, yi) meets the constraint and
the coefficients αi are found by solving a dual quadratic programming problem
(Karatzoglou et al., 2006).
The resulting estimating equation for SVM is given by








Unquestionably, the explicit mapping of the xi’s would be labor intensive and
problematic due to the non-linear, high dimensionality of the mapping. The true
power of the SVM algorithm comes from the kernel function’s ability to facilitate
implicitly mapping the input data points to feature space. This kernelization of
the SVM classifier enables the actual learning to take place in the feature space.
The kernel function returns the inner product between the images of two data
points in feature space (Karatzoglou et al., 2006). This results in the quadratic
programming and the final decision function depending on only the dot products
between patterns and it is what allows the generalization of the linear algorithm to
the nonlinear case (Karatzoglou et al., 2006). This is often referred to in literature
as the “kernel trick” (Scholkopf and Smola, 2002).
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Mathematically, for every mapping Φ : X → F , the kernel function K is
∃ K( ·, · ) s.t. K( xi,xj ) = 〈Φ(xi),Φ(xj)〉 = Φ(xi)>Φ(xj). (4.35)
The kernelized SVM classifier enables each x to obtain an estimated response, ŷ,
using




α̂jyj K( xj,x ) + b̂
)
. (4.36)
Each kernel K( ·, · ) defines a flexible class of base functions indexed by one or more
tuning parameters (Clarke et al., 2009). A pictorial representation of the kernel
tuning parameters can be seen in Figure (5.2). Once the optimal kernel for the data
is identified, the implicit mapping of Φ happens through tuning the kernel. Given
the critical importance of choosing the best kernel for a given dataset, multiple
kernels were explored for this research. Specifically, six kernels were investigated
in this thesis. A practical explanation of these kernels is in Chapter 5 and the
mathematical formulas for the kernels used in this thesis follow (Karatzoglou et al.,
2004).
• Linear or Vanilla Kernel
K(xi,x) = 〈xi,xj〉 = x>i xj (4.37)
• Polynomial Kernel of degree d
K(xi,xj) = (γ · 〈xi,xj〉+ τ)d = (γ x>i xj + τ)d (4.38)
where γ is the scale and is typically set to 1, τ is the offset which is typically
set to 1 or 0, and d is the degree of the polynomial.






where γ is the bandwidth and ‖xi − xj‖2 =
∑p
`=1 (xi` - xj`)
2.
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• Laplace Radial Basis Function (RBF) Kernel
K(xi,xj) = exp (−γ‖xi − xj‖) (4.40)
where γ is the bandwidth and ‖xi − xj‖ =
∑p
`=1 |xi` - xj`|.
• Hyperbolic Tangent or Sigmoid Kernel
K(xi,xj) = tanh (γ〈xi,xj〉+ τ) = tanh
(
γx>i xj + τ
)
(4.41)
where γ is the scale and τ is the offset.







−γ(xki − xkj )2
))d
(4.42)
where γ is the bandwidth, and d is the degree.
Once the optimal kernel and hyper-parameters are identified, the Gram Matrix, a
n x n matrix, can be generated as follows.
K =

K(x1,x1) K(x1,x2) · · · K(x1,xn)





K(xn,x1) K(xn,x2) · · · K(xn,xn)
 . (4.43)
A noteworthy advantage of support vector machines is the realization that with
the implementation of a valid kernel function, the algorithm can perform in any di-
mension since feature mapping is never effectively performed. The kernel is applied
directly to the data without the need to perform feature extraction (Karatzoglou
et al., 2006). This is of particular importance to HDLSS cancer data where valu-
able information could be lost due to feature extraction.
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4.3 Randomized Ensemble Techniques
4.3.1 Trees
Tree classification is the typical base learner used by randomized ensembles. For
this reason it is discussed here to provide the basis for a deeper understanding of
the randomized ensemble techniques.
Trees are a coordinate-based methodology that utilize recursive binary splitting
to partition the input space into sections, or regions, that model relationships
between the predictor variables and the class labels (Breiman et al., 1984). Trees
are beneficial because they are non-parametric and therefore require few statistical
assumptions; they can be applied to various data types; they do stepwise variable
selection and complexity reduction implicitly (SCG, 2013); and their output is
easily interpreted due to the logical nature of trees. Conversely, trees depend
heavily on the data supplied, often causing them to become unstable. Decision
tree learners are also prone to overfitting and even with pruning, they may not
generalize well to the out-of-sample test set.
A classification tree is hierarchical in nature and is typically presented in an upside
down format as seen in Figure (4.6). A tree is trained, or grown, from the root
node to the terminal nodes, often referred to as the leaves. Each terminal node will
be assigned a prediction class label that is determined by a majority vote within
that node. There are five terminal nodes shown in the diagram. Internal nodes are
the points where the predictor space is split, or partitioned, based on an attribute
value test on the predictor variables. In Figure (4.6) there are four internal nodes.
The segments connecting these nodes are referred to as the branches of the tree
(Breiman et al., 1984), (James et al., 2013).
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Figure 4.6: A Tree Plot Example.
The five leaves, or terminal nodes, in the diagram represent the five partitioned
regions of the input space. The five regions from the tree example would be written
as
• R1 = (X| x.956 < 0.2314, x.1053 <= 0.9366)
• R2 = (X| x.956 < 0.2314, x.1053 > 0.9366, x.2489 < 0.4591)
• R3 = (X| x.956 < 0.2314, x.1053 > 0.9366, x.2489 >= 0.4591)
• R4 = (X| x.956 >= 0.2314, x.2481 < 0.3157)
• R5 = (X| x.956 >= 0.2314, x.2481 >= 0.3157)
This set of splitting rules used to partition the feature space is then summarized
in a tree (James et al., 2013).
When growing or training a classification tree, the training set of observations enter
the root node where the first binary split is performed. This is the most important
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split and is the one that gleans the majority of the information responsible for
sorting out the class labels. In Figure (4.6) the root node is applying an attribute
test to predictor variable x.956, which makes predictor x.956 the most important
predictor in identifying the class labels (James et al., 2013). This split results in
two children nodes based on the test results. One of the children nodes is then
visited by each observation, depending on the outcome of the root split, and the
split process is repeated. These splits, or partitions, result from attribute rules
that are applied to the the variables in an observation. This recursive partitioning
or splitting continues one node at a time until a stopping criteria is met (Hill
and Lewicki, 2007). Splitting typically stops either when there is only one class
represented in a node, when one of the classes in the node shows a clear majority,
or when a predefined condition or threshold is met for a given node. Once splitting
stops on a given node, it becomes a terminal node and it is assigned the label of
the majority class in that node, otherwise known as the region or partition.
During the training process of a classification tree, the criterion used to determine
goodness-of-a-split is based on the resulting purity of each node. The purity of
a node is determined by the proportion of observations for the most commonly
occurring class label in the node related to total number of observations in that







I(yi = k) (4.44)
represent the proportion of class k observations in node m (Hastie et al., 2001),
(James et al., 2013). Hence the most pure node would contain only one class.




the majority class in node m.
There are three methods for measuring node impurity for a training split. The
Bayes Error or Minimum Classification Error, the Gini Index, and the Entropy
Function.
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Bayes Error is given by
E = 1− argmax
k
{p̂mk}. (4.46)
Bayes measures the misclassification rate when the majority vote is used. This
minimum error is rarely used for deciding splits when growing a tree because it
does not sufficiently reward purer nodes (Breiman et al., 1984). The following two
measures are considered better for determining the training splits.





The Gini Index is considered a measure of node purity due to the very small
values of the index when the node observations are predominantly from a single
class (Breiman et al., 1984), (James et al., 2013).
Entropy was first proposed as a measure for the goodness of a split by Quinlin in
1993 (Quinlan, 1993). Ripley later showed that the entropy reduction criterion is
equivalent to the likelihood-ratio chi-square statistic for association between the
branches and the classes (Ripley, 1996).





The Cross-Entropy Function measures deviance. It will have a value near zero
when the p̂mk
′s are all near zero or all near one. Hence, Cross-Entropy will have
a small value when the mth node is pure (James et al., 2013).
Once all of the training observations are sorted and assigned to a terminal node or
region, the large initial tree T has been grown and is ready to be pruned to identify
the best subtree of T (James et al., 2013). Pruning involves deleting a branch and
all its descendants from a tree, leaving only the branch’s root node. Pruning is how
the tree methodology deals with the concept of bias-variance tradeoff. Potentially,
a tree could be grown to the point that every node was pure with a misclassification
error of zero; however, as explained in Chapter3, this tree would not generalize
well to an out-of-sample test set.
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To narrow down the number of subtrees to be evaluated, a process is employed to
iteratively prune off the weakest link until a set of best subtrees is achieved (Hill






where t is a descendant node, |T̃ | is the number of terminal nodes in tree T , and
E(t) measures the goodness-of-fit of node t. To calculate E(t), the misclassification
rate is commonly chosen (James et al., 2013). Although the Gini Index and Cross-
Entropy Function are normally preferred for deciding on the best splits during
training, the Bayes or Classification Error is preferred when the goal is accurate
prediction of the classification label.
Although a larger subtree will typically have a lower E(T ) error value than a
smaller subtree, this is due to overfitting and results in an inflated generalization
error. To compensate for this, an added penalty based on the number of terminal
nodes |T̃ | is added to the misclassification cost. The parameter α works as a
cost-complexity measure to regularize the risk function
Eα(T ) = E(T ) + α|T̃ |, α ≥ 0. (4.50)
When a tree is large, meaning |T̃ | is large, it causes the penalty applied by α to
be heavier.
Once the best subtree T is chosen, the estimating equation for the tree is given by
ŷ = f̂TREE(x) =
|T̃ |∑
r=1
crIr(x ∈ Rr) (4.51)
where Ir(·) is the indicator function of Rr and cr is the dominant class label in
Rr. If x ∈ Rr the indicator function Ir(·) = 1 and if x /∈ Rr, Ir(·) = 0.
Given that the large variance of trees leads to instability, various methodologies
have been developed in an attempt to control this variance and stabilize the tree
technique. Most notably are bagging (Breiman, 1994), (Breiman, 1996a), boosting
(Freund and Schapire, 1996), and randomized ensembles (Breiman, 2001).
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Bagging is a methodology that uses bootstrap-resampling to average a given proce-
dure over many samples in order to reduce the variance (Breiman, 1994), (Breiman,
1996a), (Hastie et al., 2001). Boosting fits many large and small trees to reweighted
versions of the training data and then uses a weighted majority vote to classify
(Freund and Schapire, 1996). Boosting then aggregates a final classifier that is a
weighted average of all classifiers. Randomized ensembles such as random forests
aggregate a combination of tree predictors based on random, independently sam-
pled vectors with the same distribution for all trees in the forest (Breiman, 2001).
In this research, Leo Breiman’s Random Forests (2001) was chosen for exploring
the randomized ensemble methodology.
4.3.2 Random Forests
As defined by Leo Breiman (2001): “A random forest is a classifier consisting of
a collection of tree-structured classifiers {h(x,Θk), k = 1, · · ·} where the {Θk} are
independent identically distributed random vectors and each tree casts a unit vote
for the most popular class at input x”.
Random forests builds upon the concept of bagging. With bagging, or bootstrap
aggregation, the dataset is randomly sampled with replacement and many identi-
cally distributed trees are grown as a method for reducing the variance through
replication and averaging the procedure over a large number of samples. The col-
lection or committee of trees will each cast a vote for the predicted class, with the
majority class being assigned as the label or ŷ to the new x vector of input fea-
tures. Random forests improves on this by de-correlating the trees when building
the forest.
Explicitly, Leo Breiman realized that although bagging trees helped reduce the
variance through averaging, there was still a certain amount of bias in the process.
Since each tree aggregated in the bagging process is identically distributed, the
expectation of the averaged trees is the same as the expectation for an individual
tree, meaning the bias of the bagged trees is the same as that of the individual
trees (Hastie et al., 2001), (Miller and Miller, 2004). Consequently, the amount
of correlation of the pairs of bagged trees would dictate the benefits gained from
averaging. In his 2001 Random Forests paper, Leo Breiman presented a way to
further reduce variance by reducing the correlation between the trees. He proposed
de-correlating the trees by randomly limiting the number of features considered
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at each node split of every tree when the tree is grown. Following this process
reduces the correlation among the trees, which in turn reduces the variance.
The algorithmic definition following is adapted from the Elements of Statistical
Learning (Hastie et al., 2001).
Random Forest for Classification Pseudocode
• For b = 1 to B Loop
 Draw a bootstrap sample Z* of size N from the training data.
 Grow a random-forest tree Tb to the bootstrapped data :
Loop until the minimum node size nmin is reached




* Pick the best variable or split-point among the m variables.
* Split the node into two children nodes.
End Until Loop.
End For Loop.
• Output the ensemble of trees {Tb}B1 .
• Classify the new x and assign the predicted class label:
Let ŷb(x) be the class prediction of the b
th random-forest tree.
This class label is obtained via the majority vote rule, meaning its the
most frequent label throughout the B bootstrap replications.
ŷBRF (x) = majority vote{ŷb(x)}B1 .










Lastly, unlike a tree, it can be shown by A. Ya. Khintchine’s 1927 theorem,
The Strong Law of Large Numbers, that random forests are not prone to
overfitting as more trees are added. Instead, random forests will produce a limiting
value of the generalization error (Breiman, 2001).
Chapter 5
Computational Implementation
Due to the substantial computational nature of this research, most algorithms
were executed on a Intel Xeon 3.50GHz server using Ubuntu. The server has 12
cores and 32 Gb memory. R packages executed in this research were from software
version 3.1.0. Some algorithm investigation was also performed in MATLAB.
Finally, this thesis was published in LaTeX2e using Texmaker 4.4.1.
Chapter 1 of this thesis listed four approaches commonly used in machine learning
to deal with ill-posed problems like those encountered in the microarray cancer
data. Three of these approaches, Regularization, Kernelization, and Randomized
Ensembles, were investigated in this thesis and an explanation of their implemen-
tation follows.
5.1 Regularization Techniques
The LDA functionality was implemented by using function lda of the R package
MASS (Venables and Ripley, 2002). As mentioned in Chapter 4, LDA was included
as a baseline only and is not a viable option for HDLSS data where κ < 1. No
parameter tuning was performed on LDA, the labels from the training data were
passed to the function as a vector of type factor and the predictor variables from
the training dataset were passed to the function as a matrix. Although the function
did execute on all of the research datasets, it produced multiple multicollinearity
warnings as anticipated.
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The R MASS package also contains a function named qda (Venables and Ripley,
2002). As stated in Chapter 4, the QDA technique was not utilized in this re-
search. This is however a viable implementation of the mathematics for quadratic
discrimination analysis and can be used to investigate other datasets that are not
as sparse as the ones included in this thesis.
For regularized discriminant analysis the function rda from R package was used
(Guo et al., 2005), (Guo et al., 2006). This package depends on an R version ≥
2.10.
RDA was actually written for the purpose of classification on high-dimensional
data and the package contained the brain and colon cancer datasets used in this
research. Compared to other techniques RDA required more preprocessing and
more care and effort in tuning, but in the end it provided the best prediction
accuracy on many of the microarray cancer datasets.
For preprocessing, RDA required the y labels to be integers rather than factors.
Usually, y class labels are factors and most functions require the y class labels
to be type factor for classification techniques. Given this stipulation, the first
thing that must be done when using RDA is to ensure that the y class labels
are type integer. Second, RDA expects the labels to begin with 1 and continue
as consecutive integers. Therefore, in the preprocessing stage, any labels of zero
or -1 must be changed to 2 for binary datasets and to the next available integer
for multiclass datasets. Finally, RDA requires the x features to come in as a
dataset that is a numerical matrix formatted so that the columns are the sample
observations and the rows are the variables or features. To think of this in terms
of microarray expression data, the columns would be the arrays representing the
individuals’ samples and the rows would be the genes. This is the opposite of most
datasets and requires the x matrices to be transposed prior to passing them to the
rda function.
Recall that RDA is a regularization technique, and as such, it introduces a small
amount of bias to facilitate the training algorithm’s ability to generalize and accu-
rately predict out-of-sample observations. It is a commonly held conviction in the
machine learning population that every inductive learning algorithm must adopt
a measure of bias in order to generalize beyond the training data (Dietterich and
Kong, 1995).
Chapter 5 Computational Implementation 72
The bias-variance tradeoff for RDA is optimized through careful tuning of the
two hyper-parameters, α for regularization and δ for shrinkage as shown in Figure
(5.1). The optimal hyper-parameter values are the ones that jointly produce the
minimal error, thus concurrently maximizing classification performance. They are
determined from the use of cross-validation as explained in Chapter 3 of this thesis.
Figure 5.1: The RDA technique represented pictorially to show the hierarchy
leading to the two tuning hyper-parameters alpha and delta.
The regularization hyper-parameter α, can be any value between 0 and 0.99. In-
tuitively, the higher the value, the more bias is entered. The δ threshold value, or
mean shrinkage hyper-parameter, can be any value between 0 and 3. Both the α
and the δ hyper-parameters accept a vector of values or a single value.
There is also a regularization type parameter for RDA that can be either ”R” or
”S”. ”S”, which is the default and the one used in this research, applies regular-
ization to the covariance. If the regularization type is set to ”R”, regularization is
applied to the correlation.
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If the prior proportions for the classes are known, they can be entered into the
function as a numeric vector through the parameter prior. When not supplied,
the class proportions are calculated from the sample. Once again, this is why
stratification is so important when splitting the dataset into partitions.
Finally, RDA also offers a variable selection capability through the genelist pa-
rameter. If this parameter is set to “TRUE”, then an array of indices is returned
for each alpha-delta combination which indicates the pertinent genes selected by
that combination.
A detailed account of the RDA tuning is available in Appendix A. A table of the
optimal α and δ parameters for each cancer dataset is provided in Chapter 6 Table
(6.1).
5.2 Kernelization Techniques - Support Vector
Machines
Two support vector machine (SVM) packages were evaluated in this research for
their ability to correctly classify HDLSS microarray cancer data through super-
vised learning. The tuning parameters were optimized utilizing cross-validation as
explained in Chapter 3. Figure (5.2) gives a pictorial representation of the SVM
Hierarchy.
The e1071 and kernlab packages are very similar in mathematical theory, but have
slightly different technical implementations. The kernlab package depends on an R
version ≥ 2.10, while the e1071 package does not have this dependency. However,
the e1071 package does implement an interface to the libsvm C++ code (Chang
and Lin, 2001) for support vector machines.
The authors of e1071 and kernlab deemed scaling the data so important that their
software scales the input data by default. If not overridden, both packages scale
internally to zero mean and unit variance as recommended in Chapter 3 under the
section on standardization.
Additionally, in contrast to RDA, both of these packages require y to be a type
of factor for classification. If a y vector of numeric is passed to either program,
the program will perform regression instead of classification. Both packages offer
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a C and ν classification type for binary datasets with C being the default for both
when y is a factor. In this research, for e1071 the type of C − classification or
nu−classification was used for both the binary and multiclass classification. For
kernlab the type of C − svc or nu − svc was used with binary classification and
kbb−svc or spoc−svc were used with multiclass classification. Both packages offer
other classification and regression types that were not pertinent to this research.
Figure 5.2: The SVM technique is represented pictorially to show the hierar-
chy leading to tuning parameters gamma, nu, and C or cost.
The e1071 package uses tuning parameter cost for C− classification and kernlab
uses the C tuning parameter when the type is C − svc. The C or cost tuning
parameter is essentially the regularization parameter for the kernels. It controls
the penalty or cost of a constraint violation in an attempt to balance the tradeoff
between a wide margin and classification errors ξ (Meyer, 2014), as show in Figures
(4.3) and (4.5). Essentially, this is the C-constant of the regularization term in the
Lagrange formulation (Karatzoglou et al., 2004). The C formulation in the two
kernel packages is trying to control the dimensionality of the p by p matrix and
Chapter 5 Computational Implementation 75
will perform better on data that has a more discrete distribution (Clarke et al.,
2009).
The ν classification type works by controlling the error rather than the dimen-
sionality directly (Clarke et al., 2009). Both packages use the tuning parameter
nu to control the ratio of support vectors to data points (Meyer, 2014). The
nu parameter is bounded between 0 and 1 and the higher the value of nu is the
wider the margin will be (Karatzoglou et al., 2004). The ν formulation was not
as stable as the C formulation for this HDLSS microarray cancer data. During
experimentation with the ν formulation, the e1071 package was able to run, but
it was unstable. With the kernlab package, there was too much breakage with the
ν formulation and kernlab was therefore only executed with the C formulation of
classification.
Lastly, the e1071 package allows tuning of an additional hyper-parameter γ which
is used in all kernels in this research except the linear kernel. It was used in the
kernels either to tune the bandwidth or for scaling as outlined in the definitions
of the individual kernels covered in Chapter 4. The values were passed into e1071
through the gamma variable. For kernlab, γ would be updated through the vari-
able kpar which is set to “automatic” by default. Parameter kpar is a list of values
that control not only bandwidth and scale, but the sigma and other parameters
as well. Although the kpar parameter can be overridden, during experimental
research for this thesis, it remained set to ”automatic”.
Both packages offer the capability for classification of multiclass datasets. The
package e1071 documentation explains that SVMs can only solve binary classifi-
cation problems and therefore handle multiclass datasets using a one-against-one
technique that fits all of the binary subclassifiers and then finds the correct class via
a voting mechanism (Meyer, 2014). The kernlab package offers a native multiclass
classification formulation through two additional classification types, spoc-svc and
kbb-svc. Spoc-svc is based on Crammer’s and Singer’s algorithm and Kbb-svc is
based on Weston and Watkins algorithm. These additional classification types
are optimized by utilizing a chunking algorithm based on TRON QP solver which
solves a single quadratic problem involving all the classes (Karatzoglou et al.,
2004).
Each SVM package offers a standard set of kernels. In this research several ker-
nels were investigated for each package due to the vital importance of choosing
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the optimal kernel function Φ for mapping the xi vector into feature space. The
success of SVM hinges on choosing the best kernel for each dataset investigated.
Specifically, the linear, polynomial, radial basis and sigmoid kernels were investi-
gated for e1071. The vanilladot, polydot, laplacedot, anovadot, rbfdot, and the
hyperbolic tangent kernel, tanhdot were investigated for kernlab. There are other
kernels available in the kernlab package, but they did not apply to this research.
In addition, kernlab offers the capability to implement a newly developed kernel.
The linear or vanilladot kernel is the simplest of all the kernels and is typically used
with large, sparse data vectors such as those seen in text mining. The polynomial
or polydot kernel is used for classifying image data. The Gaussian Radial Base or
rbfdot kernel and the laplacedot kernel are both general purpose kernels that are
typically used when there is no prior knowledge about the data being investigated.
The sigmoid or tanhdot is mainly used as a proxy for neural networks. Finally,
anovadot was chosen to try because it works well with multidimensional regression
problems.
All of these kernels were investigated on every dataset in this research. Since there
is no theoretical proof for choosing one kernel over another, an empirical process
was utilized to choose the optimal kernel based on a comparison of prediction
error. A detailed accounting of this research and all SVM tuning is available in
Appendix B.
One final note on SVM techniques: Recall from Chapter 4 that the support vectors
carry the relevant information about the classification problem and are essentially
the training patterns that define the margin. Therefore, if deciding between two
models which are essentially the same and give the same misclassification rate,
investigate to see how many support vectors each model is using on average and
then choose the model using the smallest amount of support vectors. Choosing
the smallest amount of support vectors in this scenario will lead to the least com-
plicated and least biased model.
The final optimal kernel and tuning parameters chosen for each cancer dataset
investigated using e1071 and kernlab are provided in Chapter 6 in Table (6.2) and
Table (6.3), respectively.
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5.3 Ensemble Techniques
5.3.1 Tree (rpart)
The rpart package in R was chosen to evaluate the tree technique (Ripley et al.,
2015). The rpart package depends on R version ≥ 2.15, graphics, stats, and
grDevices. As mentioned in Chapter 4, the tree technique was included to better
understand random forests which is an ensemble of trees. Therefore, the tree
technique was not expected to perform well, but surprisingly on the West breast
cancer dataset, the rpart tree technique actually outperformed random forests as
seen in Chapter 6 Table (6.6).
As with the kernelization methods, the rpart function requires y to be a type of fac-
tor when performing classification. For classification, the method variable should
also be set to “class”. When performing classification with rpart, the rpart.control
option was used to pass a list of arguments to the rpart algorithm which were used
to control the details of the algorithm. Specifically, cp and minsplit were passed
for tuning the algorithm in this research.
The tuning parameter cp is the complexity parameter. If a potential split will not
decrease the lack-of-fit by a factor of the cp value, it is not performed. It can be
thought of as pruning off splits that are obviously not worthwhile. The minsplit
tuning parameter controls the minimum number of observations that must exist
in a given node in order for a split to be attempted.
Since the tree functionality grows the largest tree and then prunes it, it is not
surprising that there was a substantially larger amount of multiplicity in this
technique compared to the others. When multiple results were returned with
the same minimum misclassification rate and the same cp value but had different
minsplit values, the optimum was chosen as the one with the largest minsplit.
Alternatively stated, the model that required the largest amount of observations
in the node in order to split it was essentially the least complex model. As such,
the parameter set containing the largest minsplit value was chosen as the optimal
tuning parameter set when all else was equal among those returned.
The detailed results from tuning the rpart technique are available in Appendix C.
The optimal tuning parameters chosen for each cancer dataset are provided in
Chapter 6 Table (6.4).
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5.3.2 Random Forests
The package randomForest in R was chosen as the ensemble methodology to evalu-
ate the microarray cancer datasets (Breiman and Cutler, 2015). The randomForest
package depends on R version ≥ 2.5 and stats. The algorithm in the R package is
based on the original Fortran code from Breiman and Cutler and it has the capac-
ity to perform both supervised and unsupervised learning. In this thesis research,
only supervised learning was employed.
When performing supervised learning with the random forests technique, the vec-
tor of y class labels must be a type of factor when performing classification. For
this research, ntree and nodesize were the tuning parameters chosen for optimiza-
tion. The ntree variable controls the number of trees to grow in the forest. This
number needs to be set large enough that each observation, or input row, gets pre-
dicted a few times. The nodesize conveys the minimum size of the terminal nodes
or the smallest number of observations found in the leaf. The nodesize default
value for classification is 1. The larger this number is, the smaller the individual
trees in the forest will grow.
Recall from Chapter 4, that since the random forests algorithm converges, overfit-
ting is not a concern as it is with its base learner trees.
Appendix C contains a detailed account of the ensemble tuning investigation. A
table of the optimal ntree and nodesize tuning parameters for each cancer dataset
is provided in Chapter 6 Table (6.5).
5.4 Random Generator Seeding
Throughout the previous chapters there was information about the use of “seeding”
when comparing generalization errors. The following is an explanation of how
seeding works.
The randomized sampling referred to in data mining and machine learning is
actually performed by a number generator, or rather an algorithm that executes
to produce “random” or seemingly random numbers. The randomness results from
the entry point into the number generator algorithm. Once the generator is called,
since it is an algorithm, it will produce a set series or pattern of numbers. If a
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function enters at the exact same entry point again, then it will receive the same
series or pattern of numbers.
Number Generator Example  
 
(Replicate of 3) 
  
 
Random splits sent to Technique A Random splits sent to Technique B 
 
$idx1 (Training indices split 1) 
 [1]  5  3 10  4  6  1  8 11 15 20 17 16 12 18 29 24 25  
        22 27 21 28 31 34 32 38 37 41 40 42 
 
$idx2 (Test indices split 1) 
 [1]  2  7  9 13 14 19 23 26 30 33 35 36 39 
 
$idx1 (Training indices split 2) 
 [1]  2  6  8  5  9  4  7 11 12 14 19 16 15 17 27 25 23  
        30 21 28 29 34 31 33 41 35 36 42 40 
 
$idx2 (Test indices split 2) 
 [1]  1  3 10 13 18 20 22 24 26 32 37 38 39 
 
$idx1 (Training indices split 3) 
 [1]  9  7  8  6  4 10  1 12 13 18 16 20 19 11 29 30 28  
         25 24 27 22 34 32 31 37 42 39 35 38 
 
$idx2 (Test indices split 3) 
 [1]  2  3  5 14 15 17 21 23 26 33 36 40 41 
 
$idx1 (Training indices split 1) 
 [1]  7  2  1  4  6  8  3 13 15 18 19 14 17 16 28 22 29  
        30 25 23 27 31 34 32 42 40 41 39 37 
 
$idx2 (Test indices split 1) 
 [1]  5  9 10 11 12 20 21 24 26 33 35 36 38 
 
$idx1 (Training indices split 2) 
 [1]  5  2  4  1  7  8  3 18 11 13 14 20 12 16 27 26 30  
        28 29 24 21 31 32 34 35 38 36 39 41 
 
$idx2 (Test indices split 2) 
 [1]  6  9 10 15 17 19 22 23 25 33 37 40 42 
 
$idx1 (Training indices split 3) 
 [1] 10  5  7  9  6  1  2 18 17 13 15 11 20 19 26 29 30  
        21 22 25 23 34 32 33 37 40 35 39 38 
 
$idx2 (Test indices split 3) 
 [1]  3  4  8 12 14 16 24 27 28 31 36 41 42 
 
Seeded splits sent to Technique A 
set.seed(123) 
Seeded splits sent to Technique B 
set.seed(123) 
 
$idx1 (Training indices split 1) 
 [1]  4  9 10  8  2  7  1 19 16 11 14 17 18 12 30 25 27  
        21 26 29 22 31 34 33 35 38 42 37 39 
 
$idx2 (Test indices split 1) 
 [1]  3  5  6 13 15 20 23 24 28 32 36 40 41 
 
$idx1 (Training indices split 2) 
 [1]  9  8  6 10  2  4  3 11 20 17 13 16 12 19 21 26 29  
        30 23 28 22 34 33 32 40 36 37 38 39 
 
$idx2 (Test indices split 2) 
 [1]  1  5  7 14 15 18 24 25 27 31 35 41 42 
 
$idx1 (Training indices split 3) 
 [1]  7  4  6  3  1  2 10 11 18 15 12 14 19 17 23 27 28  
        30 22 29 26 32 33 31 37 35 36 40 39 
 
$idx2 (Test indices split 3) 
 [1]  5  8  9 13 16 20 21 24 25 34 38 41 42 
 
 
$idx1 (Training indices split 1) 
 [1]  4  9 10  8  2  7  1 19 16 11 14 17 18 12 30 25 27  
        21  26 29 22 31 34 33 35 38 42 37 39 
 
$idx2 (Test indices split 1) 
 [1]  3  5  6 13 15 20 23 24 28 32 36 40 41 
 
$idx1 (Training indices split 2) 
 [1]  9  8  6 10  2  4  3 11 20 17 13 16 12 19 21 26 29  
        30 23 28 22 34 33 32 40 36 37 38 39 
 
$idx2 (Test indices split 2) 
 [1]  1  5  7 14 15 18 24 25 27 31 35 41 42 
 
$idx1 (Training indices split 3) 
 [1]  7  4  6  3  1  2 10 11 18 15 12 14 19 17 23 27 28  
        30 22 29 26 32 33 31 37 35 36 40 39 
 
$idx2 (Test indices split 3) 
 [1]  5  8  9 13 16 20 21 24 25 34 38 41 42 
 
Figure 5.3: Random Number Generator With and Without Seeding.
By using a set.seed(<integer>) command in R once before the very first split, one
can control the entry point into the number generator and thus ensure the exact
same splits in the same order. This is not something one would do in the normal
course of testing functions; however, it is a means to fairly assess comparisons
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between two competing functions or techniques once the respective models are
chosen. It ensures that the competing techniques are getting the exact same data
splits in the exact same order with the goal being a fair and unbiased comparison.
To be a truly equitable comparison, they should also perform the same number
of replicates as discussed in more detail in Chapter 6. Figure (5.3) illustrates this
process in an example. The numbers that are generated are actually the indices
to the observations in a given dataset.
Another benefit of using the set.seed(<integer>) with the generalization error is




6.1 Optimal Tuning Parameters
The following tables contain the culmination of an intensive cross-validation analy-
sis to obtain the optimal tuning parameters for each predictive technique across all
seven datasets. The detail from this analysis is provided in Appendices A, B, and C.
6.1.1 Regularization Tuning
Table (6.1) presents the optimal hyper-parameters for the regularization technique,
Regularized Discriminant Analysis (RDA). Recall from Chapter 4 that the δ hyper-
parameter is used to control the shrinkage of the means. The α hyper-parameter
is the regularization term that introduces a small amount of bias in order to help
stabilize the covariance matrix and address the singularity problem.
Given that the RDA technique’s algorithm utilizes the δ parameter to shrink
the centers, it is interesting to note that the δ parameter is actually a zero for
three of the datasets; leukemia, lung, and breast(NS). Essentially, for these three
datasets, the tuning parameter responsible for shrinking the centers is not being
implemented. All three of these datasets also use an α regularization parameter
of only 0.05.
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Table 6.1: RDA Optimal Hyper-Parameters.
#Classes α δ
Prostate Cancer 2 0.30 0.20
Colon Cancer(NS) 2 0.10 0.15
Colon Cancer(S) 0.05 0.20
Leukemia Cancer 2 0.05 0
West Breast Cancer 2 0 0.55
Lung Cancer 4 0.05 0
Breast Cancer(NS) 3 0.05 0
Breast Cancer(S) 0 0.10
Brain Cancer(NS) 5 0.15 0.10
Brain Cancer(S) 0.05 0.55
When looking at the actual RDA average test error (TE) for these three datasets
in Table (6.6), it can be seen that the leukemia and lung datasets have an average
TE of less than 3%, and the breast dataset’s average TE is less than 8% whether
standardized or not. These three datasets happened to obtain the lowest average
test errors for the RDA technique, and two of these three datasets actually had
more accurate prediction from another technique. It could be that when a dataset
is relatively easy to classify or separate, then the corresponding penalization ap-
plied on the parameter space by the RDA regularization and shrinkage algorithms
may turn out to be unnecessary to get an accurate estimate of the generalization
error.
Recall in Chapter 2 that there were three datasets that underwent some non-
model based processing. Those three datasets were colon, breast, and brain. Note
in Table (6.1) that those three datasets resisted standardization during cross-
validation necessitating both standatdized and non-standardized parameters being
reported in the table for completeness. In reviewing Appendix A, it can be seen
that for these three datasets, cross-validation results favored the non-standardized
data.
It is noteworthy however to observe in Table (6.1) the effect that standardizing
the data has on the α regularization parameter. In all three of these datasets
that resisted standardization it can be observed that the non-standardized version
requires a larger regularization parameter than the standardized version. This
would be expected, but it underscores the importance of scaling the data prior to
performing classification.
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6.1.2 Kernelization Tuning
6.1.2.1 SVM (e1071)
Two support vector machines (SVM) were evaluated in this research for the kernel-
ization methodology. Table (6.2) contains the optimal tuning parameters for the
e1071 SVM functionality and Table (6.3) contains the optimal tuning parameters
for the kernlab SVM functionality.
The author of package e1071 emphasizes the importance of choosing the correct
kernel parameters for the data and recommends an extensive grid search on a
range of parameter values before the results are to be trusted (Meyer, 2014).
Accordingly, simply executing this code off-the-shelf and accepting all defaults
would not provide optimal results.
Table 6.2: SVM (e1071) Optimal Tuning Parameters.
#Classes Classification Kernel γ Cost/ν
Prostate Cancer 2 nu-classification radial gamma=0.002 nu=0.5
Colon Cancer 2 C-classification sigmoid gamma=0.0005 cost=1
Leukemia Cancer 2 nu-classification linear nu=0.5
West Breast Cancer 2 C-classification sigmoid gamma=0.0001402721 cost=2
Lung Cancer 4 nu-classification sigmoid gamma=0.001 nu=0.125
Breast Cancer 3 nu-classification linear nu=0.0625
Brain Cancer 5 C-classification sigmoid gamma=0.0001786671 cost=2
It can be seen in Table (6.2) that there is no one best classification type or kernel
for all datasets. The cost and ν values also vary among the datasets. The γ value is
the only uniformly consistent tuning parameter with all datasets using the default
value of 1
p
, where p is the dimensionality or number of features in the dataset.
Of the packages evaluated in this research, e1071 was the simplest to tune because
the stability of the results coupled with lower levels of multiplicity in the output
results made obtaining the optimal hyper-parameter and tuning parameters a far
easier process across all datasets.
Reflected in Table (6.2) are the final optimal tuning parameters chosen for each
dataset. These are the kernels and other tuning parameters from each dataset
that provided the lowest average test error over 500 replicates executed for each
of the multiple minimums returned from intensive cross-validation. To see the full
analysis and evaluation of all four kernels under both classification types, please
refer to Appendix B.1.
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6.1.2.2 SVM (kernlab)
For the kernlab package the tuning results are very consistent and standard across
the datasets. The C−svc classification type that uses regularization to control the
dimensionality is chosen for all binary datasets. Remembering that the “C ′′ value
is the regularizing parameter for the kernels and controls the penalty of a constraint
violation, it can be seen that the “C” values for the binary datasets are relatively
small. The simple linear kernel (vanilladot) is chosen almost exclusively for all
datasets in this study. Interestingly, the linear kernel does not use the γ parameter.
Recall that this tuning parameter was part of the kpar list of parameters and was
not tuned for this package; as instructed, kpar was set to “automatic”.
Table 6.3: SVM (kernlab) Optimal Tuning Parameters.
#Classes Classification Kernel C / ν
Prostate Cancer 2 C-svc vanilladot C=0.0008302176
Colon Cancer 2 C-svc vanilladot C=0.0006579332
Leukemia Cancer 2 C-svc vanilladot C=0.0001629751
West Breast Cancer 2 C-svc vanilladot C=0.0002595024
Lung Cancer 4 kbb-svc anovadot
Breast Cancer 3 spoc-svc vanilladot
Brain Cancer 5 kbb-svc vanilladot
Once again, Table (6.3) provides only the final optimal tuning parameters. To see
the full cross-validation analysis on all six kernels across the classification types,
please refer to Appendix B.2.
6.1.2.3 Kernelization Summary
Evaluating the predictive results between just the two SVM kernel methods studied
in this research, it can be observed that the e1071 had the lowest average test error
on 4 of 7 datasets. The remaining 3 datasets had lower average test errors with
the kernlab SVM technique, as seen in Table (6.6). However, it was the kernlab
version of SVM that ultimately gave the best prediction rates or lowest average
test error on the two datasets that outperformed RDA.
Chapter 6 Research Results 85
6.1.3 Ensemble Tuning
6.1.3.1 Tree (rpart)
Even though the tree technique was presented as the foundation to the random-
ized ensemble technique random forests, the same amount of effort was put forth
in tuning the parameters as with all other techniques evaluated in this thesis.
The full cross-validation analysis for the grid of values investigated is provided in
Appendix C.1. The optimal results for each dataset are given in Table (6.4).
Table 6.4: Tree (rpart) Optimal Tuning Parameters.
#Classes CP Minsplit
Prostate Cancer 2 0.04 6
Colon Cancer 2 0.04 8
Leukemia Cancer 2 0.10 7
West Breast Cancer 2 0.25 10
Lung Cancer 4 0.03 4
Breast Cancer 3 0.15 10
Brain Cancer 5 0.01 4
6.1.3.2 Random Forests
Table (6.5) lists the optimal parameters for the random forests technique. It is
interesting to look at each dataset and see the wide range of numbers chosen as
the optimal number of trees for a given forest. The answer may lie in the works of
Segal. Segal stated that although random forests are not supposed to overfit, when
used on some noisy datasets it tends to overfit (Segal, 2004). Segal did continue on
to state that overfitting in classification problems is influenced by the loss function
used and that overfitting is less of an issue with the 0-1 loss function which is what
is used in this thesis. Siegal also focused more on random forest regression as he
believed that random forest classification can perform poorly when the classes are
not balanced.
It is shown in Table (1.1) that the datasets evaluated in this thesis often contained
unbalanced classes. Also, recall from Table (2.7) that many of the datasets used
in this thesis may have inadvertently suppressed the signal and incorporated noise
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during the early processing steps of the data in the original studies. This may ac-
count for some of the results seen in Table (6.5). Segal recommends tuning against
a grid of tree numbers and obtaining additional gains by regulating the tree size
via the size of the nodes or the number of splits. This is the process that was
implemented in the cross-validation investigation performed in this thesis. The
detailed cross-validation analysis facilitating the choice of values in the table as
optimal is listed in Appendix C.2.
Table 6.5: Random Forests Optimal Tuning Parameters.
#Classes Ntree Nodesize
Prostate Cancer 2 320 9
Colon Cancer 2 280 14
Leukemia Cancer 2 1000 9
West Breast Cancer 2 395 11
Lung Cancer 4 435 12
Breast Cancer 3 110 10
Brain Cancer 5 380 2
6.1.3.3 Ensemble Summary
As mentioned preciously, trees are known to be very unstable and the random
forests technique grows many trees as a means of addressing the instability and
reducing variance, thus accomplishing better predictive performance. Given this
premise one would expect the random forests technique to have much lower test
errors than the trees across all datasets. As seen in Table (6.6) this is normally
the case, except for the West breast cancer dataset. With the West breast cancer
dataset the tree technique yielded a significantly lower test error than random
forests. Once again, remember in Table (2.7) that the West breast cancer data
was possibly contaminated with noise due to the two samples that did not hybridize
along with the five samples that gave different labels depending on the protocol
testing performed. This may be the reason for the tree technique outperforming
random forests in this dataset, given the research of Segal (Segal, 2004).
Chapter 6 Research Results 87
6.2 Average Test Error
The final evaluation to determine how well the techniques performed on gene-
expression microarray cancer data is based on the mean or average test error (TE)
across many replications. This is often referred to in machine learning nomen-
clature as the generalization error and is estimated using Equation (6.1), where


























is the jth observation from the test set at the rth random replication
of the split of the data (Clarke et al., 2009).
Note that the AVTE contains the familiar 0-1 loss function discussed in Section


















Ultimately the end goal of any supervised learning classification technique is to
minimize the error over the whole population, which is essentially minimizing
Equation (6.1).





test dataset were used to obtain an estimate of the generalization er-
ror. The pseudocode to estimate the generalization error is given in Test Error
Replication Pseudocode.
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Test Error Replication Pseudocode
R = 1000
For r = 1 to R Loop





• Build the model with the chosen technique and optimal tuning parameters
using the 2
3
partition as training data.




• Store the rth error in matrix Merrr.
End Loop




The decision to use 1000 replicates for this research was determined through an
empirical process explained in Section (6.3).
6.3 Optimal Replication
Performing replication is believed to help stabilize unstable procedures because
the averaged predictors are a more stable sequence with lower predictive loss and
less biased predictive estimates (Breiman, 1996b).
While there are many publications discussing cross-validation replication, random
forests replication, and even test error replication for κ > 1 (large n and small p),
there is very little information about replication with HDLSS datasets.
Therefore, empirical testing was performed on two datasets using two techniques
to determine some guidelines for the ideal number of replications. One binary
dataset and one multiclass dataset were chosen. RDA and SVM were run on both
and the output was evaluated for patterns.
• The binary dataset chosen was the prostate dataset as it was the least sparse
of the binary datasets. The brain dataset was chosen for multiclass as it had
the most class labels and was the most sparse of the mutliclass datasets.
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• Random replicates of R ∈ {10, 50, 100, 200, 500, 1000} were used for each
technique and dataset combination. Each replicate amount was executed in
10 random runs; 10 replicates run 10 times, 50 replicates run 10 times, · · · ,
1000 replicates run 10 times. All replicates were completely random and no
seeding was performed.
• The optimal tuning parameters, as determined by the extensive cross-validation
analysis and documented in Tables (6.1), (6.2), and (6.3), were used for all
replicates in each scenario.
• Boxplots were generated and documented along with the median, mean, and
standard deviation for the 10 runs of each replicate size for each dataset and
technique combination.
The results for the binary prostate dataset analysis are given in Figures (6.1) for
RDA and (6.2) for SVM. Prostate gave a lower error in cross-validation for the




                     R10         R50          R100         R200          R500        R1000 
 
Medians:  29.43%             27.80%               28.62%             28.15%             28.32%             28.11% 
Means:      28.73%             27.88%                  28.58%               28.32%             28.28%               28.14% 
SD:               1.80%               0.68%                  0.69%                0.48%                0.38%               0.23% 
 
Figure 6.1: RDA Replication Results For Prostate Cancer.
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                        R10            R50             R100            R200               R500                R1000 
 
Medians:    28.46%              30.04%                29.90%                      29.68%                29.62%               29.65% 
Means:         29.27%              30.08%              29.76%               29.80%                  29.62%                    29.65% 
SD:                  2.73%                0.36%                0.72%                0.61%                 0.21%              0.24% 
Figure 6.2: KSVM Replication Results For Prostate Cancer.
As documented in Table (2.7), the prostate dataset may have lost some of the
signal when the variables were randomly selected instead of selected based on
statistical significance. However, as the replicates increase, the variance decreases
and the process tries to converge to the generalization error estimate for both
RDA and KSVM. For the RDA technique in Figure (6.1) the standard deviation
and mean are still slowly decreasing at replicates of 500 and 1000. For KSVM in
Figure (6.2), the standard deviation and the mean start to increase again between
replicates of 500 amd 1000. It is also interesting that the top whisker is barely
visible above the upper quartile in the KSVM plot for 1000 replicates. Overall,
the errors are slightly lower with the RDA technique for the prostate dataset
generalization example.
The results for the multiclass brain dataset replication analysis are given in Figures
(6.3) and (6.4). In this example the e1071 version of SVM is used with the optimal
parameters for the brain dataset.
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                      R10         R50                 R100       R200        R500     R1000  
Medians:  15.77%             16.38%              16.77%               16.82%             16.85%             16.87% 
Means:      15.92%             16.60%            16.76%               16.73%              16.76%             16.84% 
SD:                2.40%               0.77%               1.00%                 0.54%               0.36%               0.16%    
Figure 6.3: RDA Replication Results For Brain Cancer.
                          R10             R50             R100             R200                R500              R1000 
 
Medians:      16.92%             16.46%                 17.77%                      16.94%                 16.98%               17.14% 
Means:            17.84%               16.52%              17.70%                17.08%                  16.99%                 17.16% 
SD:                   3.61%                1.23%                0.62%                 0.91%                 0.25%                0.17%      
Figure 6.4: SVM Replication Results For Brain Cancer.
The brain dataset with the RDA technique in Figure (6.3) illustrates perfectly why
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averaged test errors with higher replicates are to be trusted more than a lower repli-
cate or cross-validation for predicting the generalization error. Leo Breiman’s ci-
tation from the beginning of this section bears repeating: Replication will stabilize
unstable procedures because the averaged predictors are a more stable sequence
with lower predictive loss and less biased predictive estimates (Breiman, 1996b).
This is seen easily in the boxplots as the variability continually decreases and the
extreme fluctuations in the error rates diminishes. This is a perfect example of
Leo Breiman’s work.
As with the prostate data and kernlab boxplots, the brain data and e1071 boxplots
tend to fluctuate more than their RDA boxplot versions. Unlike the prostate data,
the standard deviation on the brain data does not fluctuate as much, except for
the boxplot of the 200 replicate tests. These 10 runs had some outliers that
really caused the standard deviation to shoot up, illustrating again the need for a
higher number of replicates when dealing with this type of HDLSS data in order
to facilitate obtaining a reliable generalization error estimate.
From reviewing the four boxplot figures and the corresponding standard deviation
values it should be apparent that a generalization error estimate from a replicate
of 500 or 1000 should be trusted much more than an estimate from cross-validation
or very low replicates, given the same technique and the same data. While cross-
validation results and the results from using a smaller number of replicates may
give a lower value for the generalization error estimate, it is most likely due to the
entry point into the data and splits of the data evaluated by the algorithm and
should not be trusted as a true estimate of the generalization error.
For illustration purposes, assume a researcher reports an averaged test error of
12.00% as the estimated generalization error for the brain data when using the
RDA technique. This researcher also documents that it is from a CV=10 or a
replicate of R=10 or R=20. Once that model or algorithm is put against an
independent validation dataset, it will most likely struggle and report a much
higher error. This can be seen by looking at the red, R10 boxplot in Figure (6.3)
and realizing an estimate of 12.00% is actually in the lower whisker. Staying at this
figure and looking at the R500 or R1000 blue boxplots, if an estimate of 16.50%
was given as the averaged test error from another researcher performing R=500
replicates on the brain data with RDA, this is actually a more accurate and true
estimate of the generalization error. Even though it is 4.5% higher than the first
researcher’s estimate, it is much closer to the true error and when that algorithm
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is run against an independent validation test set it should provide a validation
error very close to its test error estimate, given that similar protocols and data
collection processes are followed in obtaining that dataset.
As the field of machine learning continues to evolve and researchers continue
to compare and contrast the latest algorithms, this becomes a very important
concept to understand and practice. This point will be covered further in the
Summary and Conclusions Section of this thesis.
Given the previous hypothetical scenario, a review of Appendix B, and the empir-
ical evidence in Figures (6.1), (6.2), (6.3), and (6.4), a value of R=1000 replicates
was chosen as the standard for reporting all average test errors in this thesis re-
search.
6.4 Performance Results
One of my goals in this research was for it to be completely transparent, re-
producible, and unbiased with the desire that others may be able to build upon
it or learn from it and find better solutions. To this purpose, I have provided
the tuning parameters that I found to be optimal for each technique in Ta-
bles (6.1), (6.2), (6.3), (6.4), and (6.5). I also provided the detailed analysis in
Appendices A,B, and C that enabled me to determine which of the multiple kernels
to use and which of the numerous tuning parameters where optimal. I discussed the
need for replication in the previous section, Average Generalization Error and ex-
plained why I chose R=1000 replicates as the number of replicates to estimate the
generalization error. Finally, recalling the explanation of seeding from Chapter 5,
I seeded the random number generator with set.seed(1398398) for each and every
technique across all seven datasets tested to ensure each technique was given the
exact same data splits in the same order.
6.4.1 Average Generalization Error Comparison
In Table (6.6) is the final comparative performance analysis of the classification
algorithms evaluated in this research. The algorithms were evaluated on all seven
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HDLSS microarray cancer datasets discussed in Chapter 2. The Test Error Repli-
cation Pseudocode summarizes the comparison procedure used with each tech-
nique. The final evaluation is based on the mean or average test error across
all replications as given in Equation (6.1), with the standard deviation shown in
parenthesis below the average test error.
The regularization technique RDA clearly outperformed the kernels and random
forests on the prostate, West breast, and lung cancer datasets. However, on the
leukemia and breast cancer datasets, the kernels outperformed RDA and random
forests. The brain cancer dataset could be equally classified by either regulariza-
tion (RDA) or kernelization (SVM-e1071) as the difference between their average
errors was insignificant. For the colon cancer dataset, it depends on whether the
colon data is standardized or not. If the data is used without standardization,
RDA has a lower error than the kernels. However, if the colon cancer data is
standardized, then kernelization is better with e1071 (SVM) providing the lowest
average test error. Recall that the SVM kernels standardize by default within the
coding, therefore, comparing SVM to the standardized version of RDA is probably
a fairer comparison and one where SVM provides the lowest error and hence the
better performance.
The one consistency in Table (6.6) is that the ensemble technique random forests
did not outperform RDA and SVM on any dataset. Random forests actually
performed worse than the baseline LDA in four of the seven datasets. Random
forests did the best on the leukemia data where it performed better than RDA and
the baseline LDA, but not as well as SVM. Recall from Chapter 2 that leukemia
is the easiest dataset to classify and it provided the cleanest, least noisy data to
work with. It is possible that a boosting ensemble algorithm may have done well
or a mixture of ensembles, but they were not evaluated in this research.
No one universally best algorithm or technique for dealing with HDLSS microarray












Table 6.6: Classification Technique Comparison of Average Test Error.
#Classes n p κ = n
p
LDA RDA RDA SVM SVM Tree RF
NS S (e1071) (kernlab)
Prostate Cancer 2 79 500 0.15800 29.36 28.39 30.20 29.90 41.95 32.90
(7.65) (7.46) (7.88) (7.25) (8.53) (8.57)
Colon Cancer 2 62 2000 0.03100 13.96 11.05 13.14 11.77 11.85 27.52 13.66
(6.49) (6.04) (6.42) (6.23) (6.40) (9.45) (6.08)
Leukemia Cancer 2 72 3571 0.02016 3.43 1.99 1.47 1.45 14.02 1.88
(3.61) (2.40) (2.13) (2.10) (5.68) (2.44)
West Breast Cancer 2 49 7129 0.00687 38.90 19.99 35.99 37.31 29.84 39.97
(11.03) (9.08) (10.77) (10.37) (14.67) (11.67)
Lung Cancer 4 197 1000 0.19700 3.93 2.88 3.11 3.62 12.38 4.40
(2.05) (1.70) (1.77) (1.86) (4.57) (2.10)
Breast Cancer 3 97 1213 0.07997 9.22 7.15 7.55 6.43 5.96 17.72 12.13
(4.29) (3.71) (3.94) (3.83) (4.73) (7.50) (3.90)
Brain Cancer 5 42 5597 0.00750 31.18 16.74 16.71 16.73 17.07 50.77 24.13
(9.84) (8.29) (8.10) (8.14) (8.71) (12.25) (8.29)
Results from R=1000 Replicates with Seed(1398398).
............... The average classification error and standard deviation are given in the table as percentages.
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Figures (6.5) and (6.6) provide a visual representation of the error results. The
dataset results have been separated into a binary and a multiclass plot. Please
note in both plots that only the lower RDA error is used, which is NS for colon
and breast and standard S for brain.
Figure 6.5: Classification Comparison of Average Test Error for Binary.
In Figure (6.5), the binary results from RDA stand out as doing better on the
datasets that are potentially contaminated with bad samples or possibly had their
signal suppressed. Recall from Table (2.7) that the West breast cancer dataset
had two samples that did not hybridize and five with conflicting classifications.
In Figure (6.5) for the West breast cancer dataset, RDA clearly outperformed the
others. For the prostate cancer dataset, where the features were chosen randomly
instead of by a model as documented in Table (2.7), RDA is the only technique to
outperform the baseline LDA. RDA’s success in these scenarios may result from
the algorithms ability to shrink the mean through its δ parameter. From Table
(6.1), the δ is set to 0.55 for the West breast cancer dataset with a regularization
α of zero, and the δ is 0.20 with an α of 0.30 for the prostate dataset. Notice also
that the shrinkage parameter is set quite high for the two colon datasets as well,
and it is zero for leukemia where the kernels outperformed RDA.
In reviewing the multiclass plot in Figure (6.6), we see visually how RDA and the
kernels perform fairly similar across the datasets. With the lung and breast cancer
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multiclass datasets that are more easily classified, again the δ shrinkage parameter
for RDA is zero. For the more complicated brain cancer dataset, δ is again 0.55.
With the brain cancer dataset the kernel techniques do equally as well. Recall
from Chapter 2 that through PCA analysis the authors believed they would be
able to distinguish the labels on a molecular level and PCA showed the classes
separating more easily.
Figure 6.6: Classification Comparison of Average Test Error for Multiclass.
In summary, by separating these datasets into binary and multiclass and looking at
them visually through the plots, we can see more clearly that the RDA and kernel
techniques are very close in the multiclass datasets with the biggest difference
coming from the breast cancer dataset where the kernel outperformed RDA. With
the binary datasets there was more of a difference with RDA outperforming the
kernels on prostate and West breast cancer.
6.4.2 Execution Time Comparison
Table (6.7) contains the timing results for the techniques compared in Table (6.6).
In this table both the non-standardized and the standardized times are shown.













Table 6.7: Classification Technique Comparison of Execution Times.
#Classes n p κ = n
p
LDA RDA RDA SVM SVM Tree RF
NS S (e1071) (kernlab)
Prostate Cancer 2 79 500 0.15800 58.9 29.2 186.8 161.9 143.5 178.5
Colon Cancer 2 62 2000 0.03100 509.6 85.5 79.5 958.6 872.9 818.7 445.9
Leukemia Cancer 2 72 3571 0.02016 1551.2 155.5 2365.9 2301.6 2001.5 2669.6
West Breast Cancer 2 49 7129 0.00687 3463.4 238.5 7276.1 7120.3 6564.5 1690.4
Lung Cancer 4 197 1000 0.19700 448.8 124.3 485.0 4615.3 506.3 1083.7
Breast Cancer 3 97 1213 0.07997 298.2 69.2 67.6 536.0 498.5 427.5 230.1
Brain Cancer 5 42 5597 0.00750 2353.3 199.5 213.0 4726.3 4587.3 4412.9 1468.0
Results shown in user CPU seconds.
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From comparing the execution time in Table (6.7), RDA was clearly faster on every
single data set. For the binary datasets RDA is anywhere from 51
2
times to over 30
times faster than kernels. On the multiclass datasets RDA ran from approximately
4 times to over 22 times faster than kernels. Random forests ran from the middle
to the high end in both binary and multiclass. To distinguish between the two
kernels, the SVM-kernlab was faster than SVM-e1071 on all binary datasets and
two multiclass datasets. The kernlab was much slower than e1071 on the lung
dataset however.
Looking at plots (6.7) and (6.8) provides a better understanding of the differ-
ences in execution time. RDA performs very well and is minimally affected by
changes in dimension or number of classes. The kernels do not handle the change
in dimensionality as well. The CPU time for kernels increases steadily with the
dimensionality in the binary datasets and increases more drastically in the multi-
class datasets where the classes and the dimensionality are both increased. The
SVM (kernlab) appears to be affected by the number of classes even more than
the dimensionality. It has long execution times for lung cancer with 4 classes and
brain cancer with 5 classes, but the execution time drops down for breast can-
cer with only 3 classes. Once again, the random forests technique falls between
RDA and the kernels. Random forests does handle the change in dimensionality
much better than the kernels, but random forests is also affected by the number
of classes.
Figure 6.7: Classification Comparison of CPU User Time for Binary.
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Figure 6.8: Classification Comparison of CPU User Time for Multiclass.
6.4.3 Percent Reduction from Baseline Comparison
In Chapter 4 when LDA was introduced it was stated that LDA was not a viable
option for HDLSS datasets, but it was being included as a baseline for comparison.
In Table (6.8) LDA is now being used to calculate the percent reduction in error
(or gain in error) by the techniques being evaluated.
Table 6.8: Percent Reduction in Average Test Error.
#Classes κ = np LDA-RDA* LDA-SVM LDA-SVM LDA-Tree LDA-RF
(e1071) (kernlab)
Prostate Cancer 2 0.158 3.30 (-2.86) (-1.84) (-42.88) (-12.06)
Colon Cancer(NS)* 2 0.031 20.85 15.69 15.11 (-97.13) 2.15
Leukemia Cancer 2 0.020 41.98 57.14 57.73 (-308.75) 45.19
West Breast Cancer 2 0.007 48.61 7.48 4.09 23.29 (-2.75)
Lung Cancer 3 0.197 26.72 20.87 7.89 (-215.01) (-11.96)
Breast Cancer(NS)* 4 0.080 22.45 30.26 35.36 (-92.19) (-31.56)
Brain Cancer(S)* 5 0.008 46.41 46.34 45.25 (-62.83) 22.61
* Note: Only the best performing datasets between the RDA NS and RDA S are shown here.
As noted previously, the two kernals performed worse than the baseline on the
prostate data. The trees and random forests were overall very poor performers on
HDLSS microarray cancer data.
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Following in Figures (6.9) and (6.10) is a visual representation of Table (6.8). For
the RDA technique, only the best performer between NS and S was displayed.
In addition, the tree technique has been omitted from the plots as it was only
evaluated as a base learner for random forests and the numbers were so largely
negative, as seen in Table (6.8), that it distorted the graph.
Figure 6.9: Percent Reduction of Average Test Error for Binary.
Figure 6.10: Percent Reduction of Average Test Error for Multiclass.
The plots present a more effective representation of the difficulty the random
forests technique had trying to correctly classify the microarray cancer data in
this research.
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6.5 Analogous Research
Table (6.9) shows the average test errors from Table (6.6) alongside research from
other publications using various machine learning techniques on some of the same
datasets. Only the corresponding authors are listed in the table, but the studies
are cited at the end of the table. Following the table, in the interest of full
transparency and authenticity, there is a brief description of how each study was
performed to aid in comparing with the results from this thesis.
It is important to note that many of these comparative test errors were generated
using a reduced number of features that were believed to be the significant features
for a given cancer dataset. Based on the Bias-Variance Tradeoff principle discussed
in Chapter 3, this should result in lower variance in their models and hence a better
prediction rate if the correct features were found and the integrity of the signal
was maintained.
Most of the studies found dealt with the data at an individual gene level and
often did not publish class prediction. In addition, many of the studies that did
do prediction only used one execution of cross-validation. There were only four
studies found that performed the type of replication that was described in the Test
Error Replication Pseudocode, and those are included in the table. There were
another three studies that performed replication of the cross-validation process.
This would provide similar results to those given in Appendices A, B, and C of this
thesis. For completeness, those three studies were also included in the table, but
the test errors from them should not be trusted as estimates for the generalization
error.
As mentioned previously, not every dataset used in this thesis was used by the
other studies. Where those studies did not use the dataset there will be a blank
space. Where the study used the dataset, but did not report an error for it,
there will be an NA. Finally as previously mentioned, for some of the datasets no
corresponding work could be found to reference.
Table (6.9) is ordered with the most reliable predictors of generalized test error
coming first and then by performance order second.
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Following is the citation for each research publication in the table along with a
brief explanation of how the research was implemented for comparison purposes.
• Bill, J:
From this thesis research, An Empirical Analysis of Predictive Machine
Learning Algorithms on High-Dimensional Microarray Cancer Data, six tech-
niques were evaluated across seven gene expression microarray cancer datasets.
The techniques were LDA, RDA, SVM(e1071), SVM(kernlab), Trees, and
RF. LDA was evaluated as a baseline for this thesis and is not shown in
Table (6.9). Except where denoted otherwise, the data was standardized
for each gene array across samples in a preprocessing step. All techniques
were tuned first on each dataset and then executed using the optimal tuning





test set. The averaged test error from these replicates appears in Table
(6.9). The entry point into the random number generator for each technique
on every dataset was seeded at 1398398 to ensure equitable, unbiased testing
among the algorithms.
• Li, H:
In the (Li et al., 2005) publication, they introduced Generalized Linear Dis-
criminant Analysis (GLDA) as a general, direct, and complete solution to
optimize Fisher’s criterion. This study also evaluated Penalized Discrimi-
nant Analysis (PDA), Direct Linear Discriminant Analysis (DLDA), SVM,
RF, and K Nearest Neighbor (kNN). This study obtained some of their data
(including colon, leukemia, and brain) from the Dettling et. al study listed
in the next item. Therefore the preprocessing for the data is listed in the
”Dettling, M” item below. Li et al. published the average classification er-
ror for 200 runs with partitions of 2
3
for training and 1
3
test. There was no
mention of tuning or seeding.
• Dettling, M:
In the (Dettling, 2004) publication, they introduced the concept of BagBoost,
a combination of bagging and boosting. This study also evaluated DLDA,
SVM, RF, Boosting, kNN and Prediction Analysis Microarrays (PAM). The
gene expression profiles were base-10 log-transformed and then standardized.
They published the average classification error or misclassification rate for
50 runs with partitions of 2
3
for training and 1
3
test. The authors reported
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that tuning was performed on SVM (radial base kernel with default cost
of 1) and kNN (1- nearest neighbor rule and euclidean distance). However,
the remaining techniques were run with defaults. There was no mention of
seeding.
• Elshrif M:
From the (Elshrif and Fokoue, 2015) arXiv archive paper, this research in-
troduced an adaptive random subspace learning algorithm (RSSL) for pre-
diction. It is an ensemble random subspace learning method presented in
the paper in various scenarios. For purposes of this thesis, only the pre-
sentation for the binary classification task is evaluated. When performing
binary classification the authors used GLM as the base learner with a F-
statistic weighting scheme. The GLM and RF techniques were also used and
evaluated in this paper. There was no mention of standardization or nor-
malization in the paper. The tuning is inherent in the RSSL methodology.
The paper documented using 100 replicates for the synthetic data and the
assumption was made that 100 replicates were also used on the real cancer
data, although it was not specifically stated. The proportions for the 100
splits was not documented. No mention was made of tuning or seeding.
• Gündüz N:
From the (Gündüz and Fokoue, 2015) arXiv archive paper, this research fo-
cused on prediction using existing robust techniques Projection Pursuit (PP)
and Robust Soft Independent Modeling of Class Analogies (SIMCA). They
also evaluated Diagonal Discriminant Analysis (DDA) and RF. The authors
documented four variants of the PP algorithm in their paper, however, in
Table (6.9), only the PP-sest was carried forward as it performed the best
on all of the datasets common to this thesis.
To briefly explain, Projection Pursuit is basically a method of projecting
data into a lower-dimensional space in an attempt to identify the structure
in a multivariate dataset (Rousseeuw and Leroy, 2005). SIMCA attempts to
find local models for possible groups and then predict a class membership
for a new observation. It is a supervised method, running separate Principal
Component Analysis (PCA) for each class. Robust SIMCA is essentially
based on robust estimation of the PCA spaces (Varmuza and Filzmoser,
2009).
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Note that in Table (6.9) there are two rows for each technique under the
colon dataset, one black and one gray. It was not definitively stated in
the (Gündüz and Fokoue, 2015) paper, but it appears that the raw colon
data (equivalent to the non-standardized in this thesis) is colon-1 in their
paper and the black lines in Table (6.9). The gray lines in Table (6.9)
are colon-2 from the (Gündüz and Fokoue, 2015) paper. For colon-2 the
authors performed a log-transformation and then individually centered each
row using its median. It is not documented in their paper whether the row
was the gene expression or the sample. No other mention was made by the
authors for how the remaining datasets were preprocessed, or if they were
preprocessed. Their average test error was obtained from 200 replications.
The partition split for the replicates was not documented. There was no
mention of tuning or seeding.
One final note: For the prostate and brain data, only the apparent error
rate or training error were available from this paper. The authors stated
that the prostate and brain test errors were not available because some of
the methods were unable to run the datasets. The apparent or training
errors are indicated in Table (6.9) by a double dagger, ‡. Please recall that
the training error is known to underestimate the test error, as seen in Figure
(3.1). Their training errors were identified and used in Table (6.9) because
the Gündüz et al. 2015, paper along with the Elshrif et al. 2015 paper
above, were the only papers that have become available that use the same
prostate dataset that was used in this thesis research.
• Moon H:
In the (Moon et al., 2006) publication, they introduced Classification by En-
sembles from Random Partitions (CERP). As its name implies, this is an
ensemble learner and it has been specifically designed for high-dimensional
datasets. Other techniques evaluated in this publication are RF, Boost-
ing, SVM, DLDA, Shrunken Centroid (SC), Classification and Regression of
Trees (CART), and two other single-tree algorithms (QUEST and CRUISE).
It stated the datasets were normalized, but it did not document how. There
was no mention of tuning. This publication reported the accuracy of the
techniques over 20 replicates of 10-fold cross-validation. The accuracy val-
ues were subtracted from one to produce the average test error given in Table
(6.9). There was no mention of seeding.
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• Guo Y:
In the (Guo et al., 2005) publication, they introduced the RDA technique
evaluated in this thesis research. The RDA technique was explained in Chap-
ter 4 and Chapter 5. The authors reported on several versions of RDA using
both hard and soft thresholds. In the publication they also evaluated PAM
and SVM. There was no mention of scaling or standardization. They tuned
the RDA techniques through the α and δ hyper-parameters, but no mention
was made of tuning PAM or SVM. For the average test errors the colon and
brain data were partitioned into training sets of 2
3
and test sets of 1
3
, the
leukemia data was partitioned in half for equal partitions of training and
test. It did not document how many replications were executed. There was
no mention of seeding.
• Libralon G:
In the (Libralon et al., 2009) publication, they evaluate the use of distance-
based pre-processing techniques for noise detection in gene-expression mi-
croarray data. The techniques evaluated were noise detection filters Edited
Nearest Neighbor (ENN), Repeated ENN (RENN), and all based on kNN
(AllkNN). The SVM, C4.5, and RIPPER techniques were evaluated against
the data by themselves and then with each distance-based pre-processing
method. The C4.5 algorithm uses a greedy approach to progressively grow
a decision tree. RIPPER produces a set of rules from the dataset. There
was no mention of standardizing or normalizing the data. There was some
tuning with the k parameter. One execution of 10-fold cross-validation was
implemented for the test error. There was no mention of seeding.
In reviewing Table (6.9), it appears that the estimated generalization errors given
in this thesis for the seven datasets evaluated are equivalent, and in most cases
lower than other published works. Based on the discussions from the Optimal
Replication section of this chapter, the test errors given in this thesis, which were
averaged over 1000 replicates, should be more accurate and closer to the true gen-
eralization error than those averaged by cross-validation or over a smaller number
of replicates.
In the interest of comparison of techniques, the lowest errors found for each dataset
are in bold in Table (6.9). In the situations were the errors were separated by tenths
or hundredths of a point, all numbers are in bold. Following is a brief discussion
of the results of each dataset.
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• Prostate Cancer Data:
As discussed throughout this thesis, this dataset was created as a special
request by another author and the features contained within it may not be
the optimal features to predict the disease. This dataset was not widely used
and only two recent studies were located that could be used to compare with
the results from this thesis. Looking at results available, the RDA technique
as implemented in this thesis, outperforms all other techniques across all
authors.
• Colon Cancer Data:
This dataset is a little more complicated to evaluate. The RDA technique,
as implemented in this thesis, is the lowest if the data is not standardized.
However, if the colon data is standardized, then the SVM(e1071) technique,
as implemented in this thesis, will outperform RDA.
• Leukemia Cancer Data:
Recalling that this dataset is easily classified there are several low errors.
Only those errors under 2% will be addressed here. Basically, every technique
that was tuned and evaluated in this thesis except for Trees(rpart) came in at
under 2%. Of these, the lowest error came from the two SVM kernelization
techniques that were both 1.5% (rounded). The other results that were under
2% were from Moon et al. at 1.4% with CERP and Guo et al. at 0.00% with
SVM. The Guo study found the same technique as this thesis to be optimal.
It should be noted that for that file they did a 50/50 split of the data instead




. Also, for both Moon and Guo, they averaged over cross-
validations or very low replicates and therefore the errors from this thesis
would be more representative of the true generalization error.
• West Breast Cancer Data:
Unfortunately, no other studies or papers using this dataset were found.
However, among the techniques evaluated in this thesis, RDA was the best
performer by a substantial margin.
• Lung Cancer Data:
For the lung data, the discriminant methods obtained the lowest average
test errors in classification. The RDA technique, as implemented in this
thesis, obtained a 2.88% average test error over 1000 replicates, and the
DDA evaluated by Gündüz et al. obtained a 2.69 % average test error over
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200 replicates. Recall from the Optimal Replication section that an error
from 1000 replicates should be viewed as a more accurate estimate of the
true error than an error from a 200 replicates. Additionally, by comparing
the RDA technique to the DDA technique across the other datasets, it can
be seen that RDA is performing substantially better than DDA overall.
• Breast Cancer Data:
Again, other studies or papers that used this dataset for prediction alone were
not found. Of the methods evaluated in this thesis, kernelization performed
the best with SVM(kernlab) or KSVM producing the lowest error.
• Brain Cancer Data:
In this thesis, regularization and kernelization both performed equally on the
brain cancer data, with regularization slightly outperforming kernelization.
The RDA technique tuned and evaluated in this thesis and the GLDA dis-
criminant proposed by Li et al. were the top performers. RDA had an error
of 16.71% and GLDA had an error of 16.60%. As mentioned with the lung
data, an estimate from a replicate of 1000 should be considered closer to the
true generalization error than an estimate from a replicate of 200. Also, by
looking across the other datasets, RDA is outperforming GLDA.
From the expanded comparison in Table (6.9), there is still no universal method for
classifying microarray cancer data. The kernelization and regularization methods
performed the best. The randomized ensembles, other subspace learners, tree
techniques, kNN, and the robust noise reduction methods were unable to match
the performance of regularization and kernelization. Of all of those compared here,
RDA from Guo et al., SVM(e1071) and SVM(kernlab), as implemented by this
theses, performed the best across all datasets collectively.
On a final note, although this was not an option for the thesis research, whenever
possible it is advantageous to obtain an independent set of data, often referred to
as a validation dataset. This validation dataset is used to verify the final chosen
classification algorithms or models. This will be data that the algorithm has never




In this thesis, I provided an overview on gene-expression microarray cancer data
and described in detail the seven datasets evaluated in this research, while iden-
tifying any potential problems with the preexisting datasets. I then evaluated
and presented the findings from various classification algorithms and explained
the importance of thoroughly tuning the algorithms. The research was completed
by presenting the final results from the thesis with the analogous research of other
authors. I hereby conclude the results of my research in the following summary.
7.1 Machine Learning With Microarray Data
7.1.1 HDLSS Data Issues
Given the fact that the microarray data evaluated in this thesis is high-dimensional
low sample size data makes it difficult to work with. As illustrated and docu-
mented throughout this thesis, the microarray cancer data repeatedly violated
most of Hadamard’s conditions for a well-posed solution. The appendices thor-
oughly recorded how the cancer data often returned multiple solutions with the
same minimum error, and the instability of these solutions was clearly illustrated.
This made it extremely difficult to find the absolute minimum, or that one optimal
solution. In the end, I implemented a type of ”greedy heuristic” approach to cross-
validation processing in the belief that if I did not find the global optimal solution,
I would at least yield a locally optimal solution that would approximate the global
optimal solution.
112
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7.1.2 Gene-Expression Data Issues
Adding to this already complex situation is the fact that these datasets are ex-
pression datasets and expression datasets are only meaningful when they are in-
terpreted in the context of the experiment (Winstead, 2001). A certain level of
expertise is needed to analyze and interpret this kind of data. Most of the gene
expression measures are obtained from the changes in the gene expression rather
than an objective unit measure of the gene expression. This of course allows in
a certain amount of subjective analysis and potential bias. Finally, this is hu-
man genetic data; resulting in an extremely high level of collinearity between the
features of any given dataset, often with very minimal differences.
In addition to the data challenges, there is the equipment measurement variance to
consider, as well as differences between laboratories processing the data. Reflecting
back on this thesis study alone and the data used in it, there were hybridization
failures, inconsistent labeling of the samples between two different testing methods,
and differences in the quality of samples between different labs, just to name a few
of the issues.
7.1.3 Need for Standards
Understanding the need for standards and protocols, a group of scientists from gov-
ernment, academia, and industry with expertise in microarrays and bioinformatics
formed a self-directed grass-roots movement in 1999 to propose some voluntary
standards. Originally started as the Microarray Gene Expression Database group
(MGED) (Winstead, 2001), the group is now known as the Functional Genomics
Data (FGED) Society, and their mission now has a broader genomic focus for
standards.
7.2 Best Classifiers With Microarray Data
Given the complex nature of this gene-expression microarray cancer data, classi-
fication efforts were challenging and demanding. The following processes resulted
in the best classification results:
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• Repeated stratified cross-validation, implementing an adaptiveK-fold, yielded
the optimal tuning parameters for the various techniques.
• Regularization and kernelization were the best methods for classifying these
datasets and out performed the ensemble method, random forests. However,
there was no one universally best classification method.
• The RDA technique that offers tuning parameters for regularization and
mean shrinkage outperforms other regularization techniques presented by
the analogous authors.
• SVM (e1071) and SVM (kernlab) both did a good job classifying the gene-
expression microarray cancer data. Neither one was consistently a better
performer than the other. What was most important with the kernelization
methods was ensuring the right kernel had been chosen and that the proper
tuning for the tuning parameters had been performed. Not every dataset had
the same optimal kernel. For SVM (kernlab) or KSVM, the best kernel was
predominantly vanilladot, although one dataset tuned best with anovadot.
For SVM(e1071), the best kernels were linear, sigmoid, and radial, with
sigmoid being optimal most often.
7.3 Process Standards in Machine Learning
7.3.1 Making Research Reproducible
In recent years there has been much debate in the statistical community, as well
as the medical community, as to whether or not studies and experiments should
be reproducible and replicable. Most recently, Roger Peng wrote an article in
Significance magazine asking for standards and protocols. He stated that “in
investigations where computation plays a large part in deriving the findings, re-
producibility is important because it is essentially the only thing an investigator
can gaurantee about a study” (Peng, 2015).
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7.3.2 Some Simple Steps
A defined methodology or standard set of process protocols applied to machine
learning research would be very beneficial and contribute to the goal of repro-
ducibility, while having the added benefit of better comparisons among techniques
and algorithms. Simply publishing some of the details, such as the tuning parame-
ters, the number of replicates performed, and the partition proportions, along with
implementing and documenting the seed for the final averaged test error would go
a long way toward reproducibility.
At the beginning of this thesis, the following question was posed:
Given that the general goal of classification is accurate prediction, the question
then becomes, how does one achieve accurate prediction for a given dataset?
The answer is a multiple-step process that begins with using cross-validation to
determine the optimal tuning parameter or parameter set, and ends with finding
the average generalization error for comparisons among classifiers.
Specifically, that multiple-step process is:
• Thoroughly investigate and understand the data.
• Stratify during all sampling due to the uneven classes and extreme sparsity
of this data.
• Perform 3 to 5 replicates of stratified cross-validation, implementing an adap-
tive K-fold, to determine the optimal tuning parameters.
• To estimate the generalization error in HDLSS data, replication is paramount.





respectively, to get the best generalization error estimate.
• Whenever possible, obtain an independent validation dataset.
• Seed the data for a fair and unbiased comparison among techniques.
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7.3.3 Closing Thoughts
Throughout this thesis I explained methodically the steps and processes taken,
gave multiple examples, provided all optimal tuning parameters along with the
detail in obtaining them, and provided empirical evidence to support this multiple-
step process listed above.
In the final analysis, the results from this multiple-step process were compared to
the results of many other authors and the results from the thesis were found to be
at least equivalent, and most often better than the analogous results, even when
using the same technique.
In an effort to make this research reproducible, I have been completely transparent
and provided
• All optimal tuning parameters chosen for each technique evaluated.
• The pseudocode used for tuning and testing.
• The proportions for the data partitions.
• The number of replicates performed to obtain the averaged test errors.
• The seed used as the entry point into the random number generator during
the replication process.
As the final step, I am submitting all datasets used in this research along with
my thesis to RIT Scholar Works at the Rochester Institute of Technology, making




1All cross-validate errors (CVE) were the minimum values returned from a random execution of cross-validation


























































































































































































































































































































































































































































































1All cross-validate errors (CVE) were the minimum values returned from a random execution of cross-validation





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































         kernlab ksvm C-svc 
         C-svc  vanilladot 
         
           LOOCV - Detail (# 1 ) 
                 Parm           CVE            TE 





           SS - 3 Reps - Detail 
         #1 (# 1 ) 
  
#2 (#  2 ) 
  
#3 (#  69 ) 
            Parm             CVE           TE 
 
            Parm           CVE           TE 
 
             Parm              CVE           TE 
0.01353048 24.17% 30.20% 
 
0.01353048 29.00% 30.20% 
 
0.0004132012 28.92% 30.17% 
    
0.01707353 29.00% 30.45% 
 
0.0005214008 28.92% 29.81% 
        
0.0006579332 28.92% 29.65% 
         
… 
 
        
29.15053 28.92% 30.38 
        
36.78380 28.92% 30.38 
         
… 
 
        
62802.91 28.92% 30.38 
        
79248.29 28.92% 30.38 
        
100000.00 28.92% 30.38 
           BCV - 3 Reps - Detail 
         #1 (# 1) 
  
#2 (#  2) 
  
#3 (# 1) 
            Parm             CVE            TE 
 
           Parm             CVE            TE 
 
             Parm              CVE            TE 
0.008497534 27.75% 30.07% 
 
0.0004132012 29.08% 30.17% 
 
0.01072267 24.42% 29.75% 
    
0.0021049041 29.08% 30.35% 



















Prostate: C-svc vanilladot Continued 
      
           SCV - 3 Reps - Detail 
         #1 (# 6) 
  
#2 (# 1) 
  
#3 (#  3) 
    Parm                      CVE            TE 
 
   Parm                      CVE           TE 
 
             Parm              CVE            TE 
0.0003274549 28.78% 30.93% 
 
0.01707353 27.76% 30.45% 
 
0.0008302176 27.61% 29.35% 
0.0004132012 28.78% 30.17% 
     
0.0010476158 27.61% 29.36% 
0.0005214008 28.78% 29.81% 
     
0.0013219411 27.61% 29.50% 
0.0006579332 28.78% 29.65% 
        0.0008302176 28.78% 29.35% 
        0.0010476158 28.78% 29.36% 



















Prostate Cancer  
         kernlab ksvm C-svc 
         C-svc polydot 
         
           LOOCV - Detail (# 1 ) 
                    Parm           CVE          TE 
        0.01072267 24.05% 29.75% 
        
           SS - 3 Reps - Detail 
         #1 (#  67) 
  
#2 (#  72 ) 
  
#3 (#  1 ) 
             Parm           CVE         TE 
 
            Parm              CVE         TE 
 
          Parm            CVE          TE 
0.02154435 23.83% 30.41% 
 
0.0008302176 27.92% 29.35% 
 
0.01072267 27.83% 29.75% 
0.02718588 23.83% 30.37% 
 
0.0010476158 27.92% 29.36% 
    0.03430469 23.83% 30.38% 
 
0.0013219411 27.92% 29.50% 
    
 
… 
   
… 
     36.78380 23.83% 30.38% 
 
23.10130 27.92% 30.38% 
    46.41589 23.83% 30.38% 
 
29.15053 27.92% 30.38% 
    
 
… 
   
… 
     62802.91 23.83% 30.38% 
 
62802.91 27.92% 30.38% 
    79248.29 23.83% 30.38% 
 
79248.29 27.92% 30.38% 
    100000.00 23.83% 30.38% 
 
100000.00 27.92% 30.38% 



















Prostate: C-svc polydot Continued 
       
           BCV - 3 Reps - Detail 
         #1 (# 5) 
  
#2 (# 3) 
  
#3 (# 2) 
             Parm           CVE          TE 
 
            Parm              CVE          TE 
 
          Parm            CVE           TE 
0.0006579332 29.00% 29.65% 
 
0.0005214008 27.67% 29.81% 
 
0.0006579332 29.17% 29.65% 
0.0008302176 29.00% 29.35% 
 
0.0006579332 27.67% 29.65% 
 
0.0008302176 29.17% 29.35% 
0.0010476158 29.00% 29.36% 
 
0.0016681005 27.67% 29.88% 
    0.0013219411 29.00% 29.50% 
     
  
  0.0170735265 29.00% 30.45% 
        
           SCV - 3 Reps - Detail 
         #1 (# 2) 
  
#2 (# 2) 
  
#3 (#  1) 
             Parm           CVE          TE 
 
            Parm              CVE          TE 
 
          Parm            CVE           TE 
0.006734151 25.41% 30.13% 
 
0.0010476160 27.29% 29.36% 
 
0.0013219410 29.57% 29.50% 
0.008497534 25.41% 30.07% 
 
0.0013219410 27.29% 29.50% 



















Prostate Cancer  
         kernlab ksvm C-svc 
        C-svc rbfdot 
         
           LOOCV - Detail (# 1 ) 
            Parm                        CVE            
TE 
        236.4489 27.85% 30.98% 
        
           SS - 3 Reps - Detail 
        #1 (# 2 ) 
               Parm         CVE          TE 
 
#2 (#  12 ) 
  
#3 (#  2 ) 
 1.78865 30.42% 31.70% 
 
           Parm          CVE           TE 
 
  Parm                       CVE            TE 
2.25702 30.42% 30.80% 
 
4.534879 26.58% 30.77% 
 
3.593814 26.58% 30.29% 
    
29.150531 26.58% 30.98% 
 
24770.763560 26.58% 30.98% 
    
36.783798 26.58% 30.98% 
    
     
… 
     
    
599.4843 26.58% 30.98% 
    
    
954.5485 26.58% 30.98% 
    
     
… 
     
    
24770.7636 26.58% 30.98% 
    
    
79248.2900 26.58% 30.98% 
    
    
100000.0000 26.58% 30.98% 
    



















Prostate: C-svc rbfdot Continued 
      
           BCV - 3 Reps - Detail 
        #1 (# 1) 
  
#2 (#  5) 
  
#3 (#  2) 
       Parm         CVE           TE 
 
           Parm          CVE           TE 
 
           Parm          CVE           TE 
3.593814 26.50% 30.29% 
 
11.497570 20.67% 30.98% 
 
31257.16 22.75% 30.98% 
    
117.681200 20.67% 30.98% 
 
79248.29 22.75% 30.98% 
    
376.493580 20.67% 30.98% 
    
    
1519.911080 20.67% 30.98% 
    
    
3053.855510 20.67% 30.98% 
    
           SCV - 3 Reps - Detail 
        #1 (# 2) 
  
#2 (# 3) 
  
#3 (#  2) 
       Parm         CVE           TE 
 
           Parm          CVE           TE 
 
           Parm          CVE           TE 
599.4843 28.94% 30.98% 
 
376.4936 23.92% 30.98% 
 
2.848036 28.78% 30.20% 
9770.1 28.94% 30.98% 
 
3853.5286 23.92% 30.98% 
 
3.593814 28.78% 30.29% 
    
24770.7636 23.92% 30.98% 
    



















Prostate Cancer  
         kernlab ksvm C-svc 
        C-svc laplacedot 
         
           LOOCV - Detail (# 1 ) 
            Parm                        CVE            
TE 
        29.15053 30.38% 31.37% 
        
           SS - 3 Reps - Detail 
         #1 (#  1) 
  
#2 (#  32 ) 
  
#3 (#  33 ) 
       Parm          CVE          TE 
 
                Parm         CVE            TE 
 
        Parm          CVE         TE 
29.15053 32.83% 31.73% 
 
73.90722 31.75% 30.78% 
 
58.57021 29.00% 30.62% 
    
93.26033 31.75% 30.79% 
 
73.90722 29.00% 30.78% 
    
117.68120 31.75% 30.78% 
 
93.26033 29.00% 30.79% 
     
… 
   
… 
 
    
2420.128 31.75% 30.78% 
 
1917.910 29.00% 30.78% 
    
3053.856 31.75% 30.78% 
 
2420.128 29.00% 30.78% 
     
… 
   
… 
 
    
62802.91 31.75% 30.78% 
 
62802.91 29.00% 30.78% 
    
79248.29 31.75% 30.78% 
 
79248.29 29.00% 30.78% 
    
100000.00 31.75% 30.78% 
 




















Prostate: C-svc laplacedot Continued 
      
           BCV - 3 Reps - Detail 
        #1 (# 1) 
  
#2 (#  1) 
  
#3 (# 1) 
       Parm          CVE           TE 
 
                Parm         CVE            TE 
 
        Parm          CVE          TE 
0.005337 32.92% 46.15% 
 
0.0006579332 34.50% 46.15% 
 
0.0067342 26.50% 46.15% 
           SCV - 3 Reps - Detail 
        #1 (#  3) 
  
#2 (# 34) 
  
#3 (# 1 ) 
       Parm          CVE           TE 
 
                Parm         CVE            TE 
 
        Parm          CVE          TE 
3.593814 31.61% 34.33% 
 
46.41589 29.10% 30.58% 
 
36.7838 28.08% 30.69% 
4.534879 31.61% 33.40% 
 
58.57021 29.10% 30.62% 
    7.220809 31.61% 33.02% 
 
73.90722 29.10% 30.78% 
    
     
… 
     
    
1917.91 29.10% 30.78% 
    
    
2420.128 29.10% 30.78% 
    
     
… 
     
    
62802.91 29.10% 30.78% 
    
    
79248.29 29.10% 30.78% 
    
    
100000 29.10% 30.78% 



















Prostate Cancer  
         kernlab ksvm C-svc 
         C-svc anovadot 
         
           LOOCV - Detail (# 2 ) 
                   Parm             CVE           TE 
        0.0053366990 30.38% 33.75% 
        0.006734151 30.38% 32.08% 
        
           SS - 3 Reps - Detail 
         #1 (#  1) 
  
#2 (#   69) 
  
#3 (#  1 ) 
            Parm             CVE          TE 
 
           Parm            CVE          TE 
 
        Parm              CVE           TE 
0.006734151 27.75% 32.08% 
 
0.01353048 27.92% 32.85% 
 
0.008497534 35.50% 31.78% 
    
0.01707353 27.92% 32.98% 
    
    
0.02154435 27.92% 33.00% 
    
     
… 
     
    
29.15053 27.92% 33.00% 
    
    
36.78380 27.92% 33.00% 
    
     
… 
     
    
62802.91 27.92% 33.00% 
    
    
79248.29 27.92% 33.00% 
    
    
100000.00 27.92% 33.00% 



















Prostate: C-svc anovadot Continued 
      
           BCV - 3 Reps - Detail 
         anovadot 
   
  
     #1 (# 1) 
  
#2 (#  1) 
  
#3 (# 1) 
            Parm             CVE           TE 
 
           Parm            CVE           TE 
 
        Parm              CVE           TE 
0.005336699 32.92% 33.75% 
 
0.0006579332 34.50% 35.93% 
 
0.006734151 26.50% 32.08% 
           SCV - 3 Reps - Detail 
         #1 (# 1) 
  
#2 (# 1) 
  
#3 (# 1) 
            Parm             CVE           TE 
 
           Parm            CVE           TE 
 
        Parm              CVE           TE 
0.01353048 34.12% 32.85% 
 
0.008497534 26.59% 31.78% 
 




















Prostate Cancer  
         kernlab ksvm C-svc 
         C-svc tanhdot 
         
           LOOCV - Detail (# 1 ) 
                   Parm          CVE            TE 
        5.722368 29.11% 41.48% 
        
           SS - 3 Reps - Detail 
         #1 (#  5) 
  
#2 (#  1 ) 
  
#3 (#  1 ) 
   Parm                   CVE            TE 
 
         Parm            CVE          TE 
 
       Parm         CVE          TE 
0.06892612 36.58% 37.49% 
 
0.3511192 33.00% 35.56% 
 
0.2782559 40.50% 35.45% 
0.08697490 36.58% 36.39% 
        0.10974988 36.58% 35.88% 
        0.13848864 36.58% 35.38% 
        0.17475284 36.58% 35.14% 



















Prostate: C-svc tanhdot Continued 
       
            BCV - 3 Reps - Detail 
          #1 (# 1) 
  
#2 (#  8) 
  
#3 (#  1 ) 
    Parm                   CVE            TE 
 
         Parm            CVE           TE 
 
       Parm         CVE           TE 
 1.123324 30.33% 40.61% 
 
0.04328761 34.25% 41.45% 
 
0.1384886 33.08% 35.38% 
 
    
0.05462277 34.25% 39.29% 
     
    
0.06892612 34.25% 37.49% 
     
    
0.08697490 34.25% 36.39% 
     
    
0.10974988 34.25% 35.88% 
     
    
0.13848864 34.25% 35.38% 
     
    
0.17475284 34.25% 35.14% 
     
    
0.22051307 34.25% 35.08% 
     
            SCV - 3 Reps - Detail 
          #1 (# 2) 
  
#2 (# 4) 
  
#3 (#  1) 
    Parm                   CVE            TE 
 
         Parm            CVE           TE 
 
       Parm         CVE           TE 
 0.1747528 33.80% 35.13% 
 
0.06892612 34.82% 37.49% 
 
0.4430621 35.45% 35.92% 
 0.2205131 33.80% 35.08% 
 
0.0869749 34.82% 36.39% 
     
    
0.10974988 34.82% 35.88% 
     
    
0.13848864 34.82% 35.38% 
     



















Colon Cancer  
          kernlab ksvm  
         C-svc  vanilladot 
         
           LOOCV - Detail 
 
(# 10 ) 
                    Parm             CVE            TE 
        0.0002056512 12.90% 16.36% 
        0.0002595024 12.90% 13.40% 
        0.0003274549 12.90% 12.65% 
        0.0004132012 12.90% 12.29% 
        0.0005214008 12.90% 12.05% 
        0.0006579332 12.90% 11.91% 
        0.0008302176 12.90% 11.99% 
        0.0010476158 12.90% 12.48% 
        0.0013219411 12.90% 13.32% 
        0.0016681005 12.90% 14.46% 
        
           SS - 3 Reps - Detail 
        #1 (# 2 ) 
  
#2 (#  7 ) 
  
#3 (#  7 ) 
             Parm              CVE           TE 
 
            Parm              CVE          TE 
 
             Parm              CVE            TE 
0.0008302176 9.62% 11.99% 
 
0.0002595024 13.08% 13.40% 
 
0.0003274549 11.41% 12.65% 
0.0010476158 9.62% 12.48% 
 
0.0003274549 13.08% 12.65% 
 
0.0004132012 11.41% 12.29% 
    
0.0004132012 13.08% 12.29% 
 
0.0005214008 11.41% 12.05% 
    
0.0005214008 13.08% 12.05% 
 
0.0006579332 11.41% 11.91% 
    
0.0006579332 13.08% 11.91% 
 
0.0008302176 11.41% 11.99% 
    
0.0008302176 13.08% 11.99% 
 
0.0010476158 11.41% 12.48% 
    
0.0010476158 13.08% 12.48% 
 




















Colon: C-svc   vanilladot Continued 
      
           BCV - 3 Reps - Detail 
        #1 (#  4) 
  
#2 (# 7 ) 
  
#3 (#  2) 
             Parm              CVE            TE 
 
            Parm              CVE           TE 
 
    Parm                     CVE           TE 
0.0004132012 11.15% 12.29% 
 
0.0002595024 9.74% 13.40% 
 
0.0008302176 9.87% 11.99% 
0.0005214008 11.15% 12.05% 
 
0.0003274549 9.74% 12.65% 
 
0.0010476158 9.87% 12.48% 
0.0006579332 11.15% 11.91% 
 
0.0004132012 9.74% 12.29% 
    0.0008302176 11.15% 11.99% 
 
0.0005214008 9.74% 12.05% 
    
    
0.0006579332 9.74% 11.91% 
    
    
0.0008302176 9.74% 11.99% 
    
    
0.0010476158 9.74% 12.48% 
    
           SCV - 3 Reps - Detail 
        #1 (# 8) 
  
#2 (# 7) 
  
#3 (#  5) 
             Parm              CVE            TE 
 
            Parm              CVE           TE 
 
    Parm                     CVE           TE 
0.0002595024 9.62% 13.40% 
 
0.0002595024 11.41% 13.40% 
 
0.0003274549 9.87% 12.65% 
0.0003274549 9.62% 12.65% 
 
0.0004132012 11.41% 12.29% 
 
0.0004132012 9.87% 12.29% 
0.0004132012 9.62% 12.29% 
 
0.0005214008 11.41% 12.05% 
 
0.0005214008 9.87% 12.05% 
0.0005214008 9.62% 12.05% 
 
0.0006579332 11.41% 11.91% 
 
0.0006579332 9.87% 11.91% 
0.0006579332 9.62% 11.91% 
 
0.0008302176 11.41% 11.99% 
 
0.0008302176 9.87% 11.99% 
0.0008302176 9.62% 11.99% 
 
0.0010476158 11.41% 12.48% 
    0.0010476158 9.62% 12.48% 
 
0.0013219411 11.41% 13.23% 
    0.0013219411 9.62% 13.23% 



















Colon Cancer  
      
 
kernlab ksvm  
         C-svc   polydot 
         
           LOOCV - Detail (# 10 ) 
                 Parm                 CVE           TE 





0.0002595024 12.90% 13.40% 
        0.0003274549 12.90% 12.65% 
        0.0004132012 12.90% 12.29% 
        0.0005214008 12.90% 12.05% 
        0.0006579332 12.90% 11.91% 
        0.0008302176 12.90% 11.99% 
        0.0010476158 12.90% 12.48% 
        0.0013219411 12.90% 13.32% 
        0.0016681005 12.90% 14.46% 
        
           SS - 3 Reps - Detail 
  
 
     #1 (# 1 ) 
  
#2 (#  4 ) 
  
#3 (#  1 ) 
          Parm                 CVE           TE 
 
            Parm              CVE           TE 
 
           Parm             CVE           TE 
0.0010476160 11.41% 12.48% 
 
0.0005214008 12.82% 12.05% 
 
0.0002595024 13.08% 13.04% 
    
0.0006579332 12.82% 11.91% 
    
    
0.0008302176 12.82% 11.99% 
    
    
0.0010476158 12.82% 12.48% 



















Colon: C-svc   polydot Continued 
                 BCV - 3 Reps - Detail 
  
  
     #1 (# 10) 
  
#2 (# 6) 
  
#3 (#4 ) 
          Parm                 CVE          TE 
 
            Parm              CVE          TE 
 
           Parm             CVE          TE 
0.0002056512 12.95% 16.36% 
 
0.0003274549 12.56% 12.65% 
 
0.0002595024 11.54% 13.40% 
0.0003274549 12.95% 12.65% 
 
0.0004132012 12.56% 12.29% 
 
0.0003274549 11.54% 12.65% 
0.0004132012 12.95% 12.29% 
 
0.0005214008 12.56% 12.05% 
 
0.0008302176 11.54% 11.99% 
0.0005214008 12.95% 12.05% 
 
0.0006579332 12.56% 11.91% 
 
0.0010476158 11.54% 12.48% 
0.0006579332 12.95% 11.91% 
 
0.0008302176 12.56% 11.99% 
    0.0008302176 12.95% 11.99% 
 
0.0010476158 12.56% 12.48% 
    0.0010476158 12.95% 12.48% 
        0.0013219411 12.95% 13.32% 
        0.0016681005 12.95% 14.46% 
        0.0021049041 12.95% 15.77% 
        
           SCV - 3 Reps - Detail 
  
  
     #1 (# 1) 
  
#2 (# 9 ) 
  
#3 (#  3) 
          Parm                 CVE           TE 
 
            Parm              CVE           TE 
 
           Parm             CVE           TE 
0.000205651 11.15% 16.36% 
 
0.0002056512 11.41% 16.36% 
 
0.0010476160 11.28% 12.48% 
    
0.0002595024 11.41% 13.40% 
 
0.0013219410 11.28% 13.32% 
    
0.0003274549 11.41% 12.65% 
 
0.0016681010 11.28% 14.46% 
    
0.0004132012 11.41% 12.29% 
    
    
0.0005214008 11.41% 12.05% 
    
    
0.0006579332 11.41% 11.91% 
    
    
0.0008302176 11.41% 11.99% 
    
    
0.0010476158 11.41% 12.48% 
    
    
0.0013219411 11.41% 13.32% 



















Colon Cancer  
         kernlab ksvm C-svc 
         C-svc  rbfdot 
         
           LOOCV - Detail (# 1 ) 
                 Parm           CVE            TE 
        0.89021500 11.29% 18.58% 
        
           SS - 3 Reps - Detail 
  
  
    #1 (# 2 ) 
  
#2 (#  5 ) 
  
#3 (#  2 ) 
          Parm           CVE            TE 
 
       Parm         CVE          TE 
 
       Parm         CVE           TE 
1.123324 14.74% 14.53% 
 
1.123324 12.95% 14.53% 
 
1.123324 11.28% 14.53% 
1.417474 14.74% 14.01% 
 
1.417474 12.95% 14.01% 
 
1.417474 11.28% 14.01% 
    
1.788650 12.95% 13.93% 
    
    
2.257020 12.95% 14.48% 
    
    
2.848036 12.95% 15.41% 
    
           BCV - 3 Reps - Detail 
  
  
    #1 (#  1) 
  
#2 (#  3) 
  
#3 (#  1) 
          Parm           CVE            TE 
 
       Parm         CVE         TE 
 
       Parm         CVE          TE 
0.8902151 11.15% 18.58% 
 
0.8902151 11.41% 18.58% 
 
1.123324 11.28% 14.53% 
    
1.123324 11.41% 14.53% 
    
    
1.4174742 11.41% 14.01% 



















Colon: C-svc   rbfdot Continued 
      
           SCV - 3 Reps - Detail 
  
  
    #1 (# 5) 
  
#2 (# 5) 
  
#3 (#  1) 
          Parm           CVE            TE 
 
       Parm         CVE          TE 
 
       Parm         CVE           TE 
0.89021510 12.56% 18.58% 
 
1.1233240 12.94% 14.53% 
 
1.1233240 14.49% 14.53% 
1.12332400 12.56% 14.53% 
 
1.4174740 12.94% 14.01% 
    1.41747420 12.56% 14.01% 
 
1.7886500 12.94% 13.93% 
    1.78864950 12.56% 13.93% 
 
2.2570200 12.94% 14.48% 
    2.25701970 12.56% 14.48% 
 
2.8480360 12.94% 15.41% 



















Colon Cancer  
         kernlab ksvm C-svc 
        C-svc  laplacedot 
         
           LOOCV - Detail (# 1 ) 
                Parm        CVE           TE 
        36.7838 12.90% 18.37% 
        
           SS - 3 Reps - Detail 
  
  
     #1 (# 3 ) 
  
#2 (#  34 ) 
  
#3 (#  1 ) 
         Parm        CVE           TE 
 
             Parm           CVE           TE 
 
        Parm           CVE            TE 
36.7838 14.49% 18.37% 
 
46.41589 13.21% 14.57% 
 
36.7838 12.95% 18.37% 
46.41589 14.49% 14.57% 
 
58.57021 13.21% 13.85% 
    58.57021 14.49% 13.85% 
 
73.90722 13.21% 13.91% 
    
     
… 
     
    
1917.91 13.21% 15.18% 
    
    
2420.128 13.21% 15.18% 
    
     
… 
     
    
62802.91442 13.21% 15.18% 
    
    
79248.28984 13.21% 15.18% 
    
    
100000.00 13.21% 15.18% 



















Colon: C-svc   laplacedot Continued 
      
           BCV - 3 Reps - Detail 
 
  
     #1 (#  1 ) 
  
#2 (#  1 ) 
  
#3 (# 3 ) 
 
        Parm        CVE           TE 
 
             Parm           CVE           
TE 
 
        Parm           CVE            TE 
46.41589 11.15% 14.57% 
 
46.41589 9.48% 14.57% 
 
46.41589 14.10% 14.57% 
        
58.57021 14.10% 13.85% 
        
73.90722 14.10% 13.91% 
           SCV - 3 Reps - Detail 
 
  
     #1 (# 3) 
  
#2 (# 1) 
  
#3 (#  34) 
 
        Parm        CVE           TE 
 
             Parm           CVE           
TE 
 
        Parm           CVE            TE 
46.41589 12.95% 14.57% 
 
36.7838 11.03% 18.37% 
 
46.41589 14.49% 14.57% 
58.57021 12.95% 13.85% 
     
58.57021 14.49% 13.85% 
73.90722 12.95% 13.91% 
     
73.90722 14.49% 13.91% 
         
… 
 
        
1519.911 14.49% 15.18% 
        
1917.910 14.49% 15.18% 
         
… 
 
        
62802.91 14.49% 15.18% 
        
79248.29 14.49% 15.18% 
        






















          kernlab ksvm C-svc 
         C-svc  anovadot 
         
           LOOCV - Detail 
 
(# 1 ) 
               Parm               CVE            TE 
        0.0005214008 11.29% 28.20% 
                   SS - 3 Reps - Detail 
  
  
     #1 (# 2 ) 
  
#2 (#  4 ) 
  
#3 (# 3  ) 
        Parm               CVE           TE 
 
            Parm            CVE         TE 
 
            Parm            CVE         TE 
0.0008302176 12.95% 14.57% 
 
0.0008302176 12.95% 14.57% 
 
0.0008302176 11.28% 14.57% 
0.0010476158 12.95% 14.41% 
 
0.0010476158 12.95% 14.41% 
 
0.0010476158 11.28% 14.41% 
    
0.0013219411 12.95% 15.02% 
 
0.0013219411 11.28% 15.02% 
    
0.0016681005 12.95% 16.25% 
         BCV - 3 Reps - Detail 
  
  
     #1 (#  1 ) 
  
#2 (#  2 ) 
  
#3 (#  1 ) 
        Parm               CVE            TE 
 
            Parm            CVE          TE 
 
            Parm            CVE          TE 
0.0006579332 12.95% 17.28% 
 
0.0006579332 12.95% 17.28% 
 
0.0006579332 12.82% 17.28% 
    
0.0008302176 12.95% 14.57% 
               SCV - 3 Reps - Detail 
  
  
     #1 (# 3 ) 
  
#2 (# 1 ) 
  
#3 (# 4 ) 
        Parm               CVE            TE 
 
            Parm            CVE          TE 
 
            Parm            CVE          TE 
0.0006579332 12.82% 17.28% 
 
0.0006579332 14.62% 17.28% 
 
0.0006579332 14.36% 17.28% 
0.0008302176 12.82% 14.57% 
     
0.0008302176 14.36% 14.57% 
0.0010476158 12.82% 14.41% 
     
0.0010476158 14.36% 14.41% 
        




















Colon Cancer  
         kernlab ksvm C-svc 
         C-svc  tanhdot 
         
           LOOCV - Detail (# 3 ) 
                  Parm           CVE             TE 
        0.1097499 20.97% 23.62% 
        148.4968262 20.97% 30.35% 
        475.0810162 20.97% 30.31% 
        
           SS - 3 Reps - Detail 
  
  
     #1 (#  1 ) 
  
#2 (#  1 ) 
  
#3 (#   1) 
 
          Parm           CVE             TE 
 
         Parm           CVE           TE 
 
         Parm           CVE              
TE 
0.1384886 21.03% 22.62% 
 
0.1097499 19.49% 23.62% 
 
0.1747528 22.56% 23.31% 
           BCV - 3 Reps - Detail 
  
  
     #1 (# 1 ) 
  
#2 (#  1) 
  
#3 (# 1 ) 
 
          Parm           CVE             TE 
 
         Parm           CVE           TE 
 
         Parm           CVE              
TE 
0.3511192 19.10% 26.59% 
 
0.559081 21.28% 28.17% 
 
0.1384886 22.44% 22.62% 
           SCV - 3 Reps - Detail 
  
  
      #1 (# 1) 
  
#2 (# 1) 
  
#3 (#  2) 
 
          Parm           CVE             TE 
 
         Parm           CVE           TE 
 
         Parm           CVE              
TE 
0.1747528 20.90% 23.31% 
 
0.2782559 20.90% 25.69% 
 
0.1097499 20.90% 23.62% 
        




















Leukemia Cancer  
         kernlab ksvm C-svc 
         C-svc vanilladot 
         
           LOOCV - Detail (# 91 ) 
                   Parm            CVE         TE 
        0.0000811131 1.39% 8.32% 
        0.0001023531 1.39% 2.78% 
        0.0001291550 1.39% 1.66% 
        
 
… 
         2.257020 1.39% 1.80% 
        2.848036 1.39% 1.80% 
        
 
… 
         62802.91 1.39% 1.80% 
        79248.29 1.39% 1.80% 
        100000.00 1.39% 1.80% 
        
           SS - 3 Reps - Detail 
  
 
     #1 (# 89 ) 
  
#2 (# 89  ) 
  
#3 (#  6 ) 
            Parm            CVE         TE 
 
           Parm             CVE         TE 
 
          Parm             CVE         TE 
0.0001291550 1.33% 1.66% 
 
0.0001291550 1.43% 1.66% 
 
0.0001023531 1.43% 2.78% 
0.0001629751 1.33% 1.50% 
 
0.0001629751 1.43% 1.50% 
 
0.0001291550 1.43% 1.66% 
0.0002056512 1.33% 1.52% 
 
0.0002056512 1.43% 1.52% 
 
0.0001629751 1.43% 1.50% 
 
… 
   
… 
  
0.0002056512 1.43% 1.52% 
2.848036 1.33% 1.80% 
 
2.848036 1.43% 1.80% 
 
0.0002595024 1.43% 1.61% 
3.593814 1.33% 1.80% 
 
3.593814 1.43% 1.80% 
 
0.0003274549 1.43% 1.64% 
 
… 
   
… 
     62802.91 1.33% 1.80% 
 
62802.91 1.43% 1.80% 
    79248.29 1.33% 1.80% 
 
79248.29 1.43% 1.80% 
    100000.00 1.33% 1.80% 
 
100000.00 1.43% 1.80% 



















Leukemia:  C-svc   vanilladot Continued 
      
           BCV - 3 Reps - Detail 
  
 
     #1 (# 4 ) 
  
#2 (#  6) 
  
#3 (#  3) 
            Parm            CVE         TE 
 
           Parm             CVE         TE 
 
          Parm             CVE         TE 
0.0001023531 1.33% 2.78% 
 
0.0000811131 1.33% 8.32% 
 
0.0001291550 1.43% 1.66% 
0.0001291550 1.33% 1.66% 
 
0.0001023531 1.33% 2.78% 
 
0.0001629751 1.43% 1.50% 
0.0001629751 1.33% 1.50% 
 
0.0001291550 1.33% 1.66% 
 
0.0002056512 1.43% 1.52% 
0.0002056512 1.33% 1.52% 
 
0.0001629751 1.33% 1.50% 
    
    
0.0002056512 1.33% 1.52% 
    
    
0.0002595024 1.33% 1.61% 
    
           SCV - 3 Reps - Detail 
  
  
     #1 (# 90) 
  
#2 (# 6) 
  
#3 (#  90) 
            Parm            CVE         TE 
 
           Parm             CVE         TE 
 
          Parm             CVE         TE 
0.0001023531 1.43% 2.78% 
 
0.0001023531 1.43% 2.78% 
 
0.0001023531 1.33% 2.78% 
0.0001291550 1.43% 1.66% 
 
0.0001291550 1.43% 1.66% 
 
0.0001291550 1.33% 1.66% 
0.0001629751 1.43% 1.50% 
 
0.0001629751 1.43% 1.50% 
 




0.0002056512 1.43% 1.52% 
  
… 
 2.8480360 1.43% 1.80% 
 
0.0002595024 1.43% 1.61% 
 
2.8480360 1.33% 1.80% 
3.5938140 1.43% 1.80% 
 
0.0003274549 1.43% 1.64% 
 
3.5938140 1.33% 1.80% 
 
… 
       
… 
 62802.91 1.43% 1.80% 
     
62802.91 1.33% 1.80% 
79248.29 1.43% 1.80% 
     
79248.29 1.33% 1.80% 
100000 1.43% 1.80% 
     




















Leukemia Cancer  
         kernlab ksvm C-svc 
         C-svc  polydot 
         
           LOOCV - Detail (# 91 ) 
                 Parm               CVE        TE 





0.0001023531 1.39% 2.78% 
        0.0001291550 1.39% 1.66% 
        
 
… 
         2.257020 1.39% 1.80% 
        2.848036 1.39% 1.80% 
        
 
… 
         62802.91 1.39% 1.80% 
        79248.29 1.39% 1.80% 
        100000.00 1.39% 1.80% 
        
           SS - 3 Reps - Detail 
  
  
     #1 (#  90) 
  
#2 (#  4 ) 
  
#3 (#  90 ) 
          Parm             CVE           TE 
 
        Parm              CVE         TE 
 
         Parm             CVE         TE 
0.0001023531 1.43% 2.78% 
 
0.0001629751 1.33% 1.50% 
 
0.0001023531 1.33% 2.78% 
0.0001291550 1.43% 1.66% 
 
0.0002056512 1.33% 1.52% 
 
0.0001291550 1.33% 1.66% 
0.0001629751 1.43% 1.50% 
 
0.0002595024 1.33% 1.61% 
 




0.0003274549 1.33% 1.64% 
  
… 
 2.848036 1.43% 1.80% 
     
2.848036 1.33% 1.80% 
3.593814 1.43% 1.80% 
     
3.593814 1.33% 1.80% 
 
… 
       
… 
 62802.91 1.43% 1.80% 
     
62802.91 1.33% 1.80% 
79248.29 1.43% 1.80% 
     
79248.29 1.33% 1.80% 
100000.00 1.43% 1.80% 
     




















Leukemia:  C-svc   polydot Continued 
      
           BCV - 3 Reps - Detail 
  
 
     #1 (# 91) 
  
#2 (#  6) 
  
#3 (# 3) 
             Parm            CVE       TE 
 
           Parm           CVE       TE 
 
           Parm            CVE      TE 
0.0000811131 1.43% 8.32% 
 
0.0000811131 1.33% 8.32% 
 
0.0001291550 1.33% 1.66% 
0.0001023531 1.43% 2.78% 
 
0.0001023531 1.33% 2.78% 
 
0.0001629751 1.33% 1.50% 
0.0001291550 1.43% 1.66% 
 
0.0001291550 1.33% 1.66% 
 




0.0001629751 1.33% 1.50% 
    2.257020 1.43% 1.80% 
 
0.0002050651 1.33% 1.52% 
    2.848036 1.43% 1.80% 
 
0.0002595024 1.33% 1.61% 
    
 
… 
         62802.91 1.43% 1.80% 
        79248.29 1.43% 1.80% 
        100000.00 1.43% 1.80% 
        
           SCV - 3 Reps - Detail 
  
  
     #1 (# 90) 
  
#2 (# 89) 
  
#3 (# 5 ) 
             Parm            CVE       TE 
 
           Parm           CVE       TE 
 
           Parm            CVE      TE 
0.0001023531 1.43% 2.78% 
 
0.0001291550 1.43% 1.66% 
 
0.0001023531 1.33% 2.78% 
0.0001291550 1.43% 1.66% 
 
0.0001629751 1.43% 1.50% 
 
0.0001291550 1.33% 1.66% 
0.0001629751 1.43% 1.50% 
 
0.0002056512 1.43% 1.52% 
 
0.0001629751 1.33% 1.50% 
 … 
   
… 
  
0.0002056512 1.33% 1.52% 
2.84803600 1.43% 1.80% 
 
2.84803600 1.43% 1.80% 
 
0.0002595024 1.33% 1.61% 
3.59381400 1.43% 1.80% 
 
3.59381400 1.43% 1.80% 
    
 
… 
   
… 
     62802.91 1.43% 1.80% 
 
62802.91 1.43% 1.80% 
    79248.29 1.43% 1.80% 
 
79248.29 1.43% 1.80% 
    100000 1.43% 1.80% 
 
100000 1.43% 1.80% 



















Leukemia Cancer  
         kernlab ksvm C-svc 
         C-svc rbfdot 
          
           LOOCV - Detail 
 
(# 52 ) 
                     Parm           CVE           TE 
        0.70548020 1.39% 7.91% 
        0.89021510 1.39% 3.08% 
        1.12332400 1.39% 1.95% 
        
 
… 
         187.38170 1.39% 1.69% 
        236.44890 1.39% 1.69% 
        
 
… 
         62802.91 1.39% 1.69% 
        79248.29 1.39% 1.69% 
        100000.00 1.39% 1.69% 
        
           SS - 3 Reps - Detail 
  
  
     #1 (#  48 ) 
  
#2 (#   50) 
  
#3 (#  51 ) 
               Parm          CVE           TE 
 
      Parm          CVE         TE 
 
      Parm         CVE          TE 
1.788650 1.43% 1.69% 
 
1.123324 1.33% 1.95% 
 
0.8902151 1.33% 3.08% 
2.257020 1.43% 1.69% 
 
1.417474 1.33% 1.72% 
 
1.1233240 1.33% 1.95% 
2.848036 1.43% 1.69% 
 
1.788650 1.33% 1.69% 
 
1.4174742 1.33% 1.72% 
 
… 
   
… 
   
… 
 376.4936 1.33% 1.69% 
 
298.3647 1.33% 1.69% 
 
236.4489 1.33% 1.69% 
475.0810 1.33% 1.69% 
 
376.4936 1.33% 1.69% 
 
298.3647 1.33% 1.69% 
 
… 
   
… 
   
… 
 62802.91 1.43% 1.69% 
 
62802.91 1.33% 1.69% 
 
62802.91 1.33% 1.69% 
79248.29 1.43% 1.69% 
 
79248.29 1.33% 1.69% 
 
79248.29 1.33% 1.69% 
100000.00 1.43% 1.69% 
 
100000.00 1.33% 1.69% 
 




















Leukemia:  C-svc   rbfdot Continued 
      
           BCV - 3 Reps - Detail 
  
 
     #1 (#  51) 
  
#2 (#  50) 
  
#3 (#  51) 
                Parm            CVE          TE 
 
         Parm          CVE        TE 
 
         Parm           CVE        TE 
0.89021510 1.33% 3.08% 
 
1.12332400 1.33% 1.95% 
 
0.89021510 1.43% 3.08% 
1.12332400 1.33% 1.95% 
 
1.41747400 1.33% 1.72% 
 
1.12332400 1.43% 1.95% 
1.41747400 1.33% 1.72% 
 
1.78865000 1.33% 1.69% 
 
1.41747420 1.43% 1.72% 
 
… 
   
… 
   
… 
 236.44890000 1.33% 1.69% 
 
298.36470 1.33% 1.69% 
 
236.44890 1.33% 1.69% 
298.36470000 1.33% 1.69% 
 
376.49360 1.33% 1.69% 
 
298.36470 1.33% 1.69% 
 
… 
   
… 
   
… 
 62802.91 1.33% 1.69% 
 
62802.91 1.33% 1.69% 
 
62802.91 1.33% 1.69% 
79248.29 1.33% 1.69% 
 
79248.29 1.33% 1.69% 
 
79248.29 1.33% 1.69% 
100000.00 1.33% 1.69% 
 
100000.00 1.33% 1.69% 
 
100000.00 1.33% 1.69% 
           SCV - 3 Reps - Detail 
  
  
    #1 (# 51) 
  
#2 (# 51) 
  
#3 (#  51) 
                Parm            CVE          TE 
 
         Parm          CVE         TE 
 
         Parm           CVE         TE 
0.8902151 1.43% 3.08% 
 
0.8902151 1.43% 3.08% 
 
0.8902151 1.43% 3.08% 
1.123324 1.43% 1.95% 
 
1.123324 1.43% 1.95% 
 
1.123324 1.43% 1.95% 
1.4174742 1.43% 1.72% 
 
1.4174742 1.43% 1.72% 
 
1.4174742 1.43% 1.72% 
 
… 
   
… 
   
… 
 236.4489 1.43% 1.69% 
 
236.4489 1.43% 1.69% 
 
236.4489 1.43% 1.69% 
298.3647 1.43% 1.69% 
 
298.3647 1.43% 1.69% 
 
298.3647 1.43% 1.69% 
 
… 
   
… 
   
… 
 62802.91 1.43% 1.69% 
 
62802.91 1.43% 1.69% 
 
62802.91 1.43% 1.69% 
79248.29 1.43% 1.69% 
 
79248.29 1.43% 1.69% 
 
79248.29 1.43% 1.69% 
100000 1.43% 1.69% 
 
100000 1.43% 1.69% 
 




















Leukemia Cancer  
         kernlab ksvm C-svc 
         C-svc laplacedot 
         
           LOOCV - Detail (# 34 ) 
                     Parm         CVE          TE 
        46.415890 1.39% 3.65% 
        58.570210 1.39% 1.89% 
        73.907220 1.39% 1.62% 




        1519.911080 1.39% 1.63% 
        1917.910260 1.39% 1.63% 




        62802.914420 1.39% 1.63% 
        79248.289840 1.39% 1.63% 
        100000.00 1.39% 1.63% 
        
           SS - 3 Reps - Detail 
  
  
     #1 (# 33 ) 
  
#2 (#  33 ) 
  
#3 (#   34) 
              Parm         CVE          TE 
 
       Parm            CVE         TE 
 
      Parm              CVE        TE 
58.57021 1.33% 1.89% 
 
58.57021 1.33% 1.89% 
 
46.41589 1.33% 3.65% 
73.90722 1.33% 1.62% 
 
73.90722 1.33% 1.62% 
 
58.57021 1.33% 1.89% 
93.26033 1.33% 1.62% 
 
93.26033 1.33% 1.62% 
 
73.90722 1.33% 1.62% 
 
… 
   
… 
   
… 
 1917.910 1.33% 1.63% 
 
1917.910 1.33% 1.63% 
 
1917.910 1.33% 1.63% 
2420.128 1.33% 1.63% 
 
2420.128 1.33% 1.63% 
 
2420.128 1.33% 1.63% 
 
… 
   
… 
   
… 
 62802.91 1.33% 1.63% 
 
62802.91 1.33% 1.63% 
 
62802.91 1.33% 1.63% 
79248.29 1.33% 1.63% 
 
79248.29 1.33% 1.63% 
 
79248.29 1.33% 1.63% 
100000.00 1.33% 1.63% 
 
100000.00 1.33% 1.63% 
 




















Leukemia:  C-svc  laplacedot Continued 
      
           BCV - 3 Reps - Detail 
  
 
     #1 (# 34) 
  
#2 (# 34 ) 
  
#3 (# 33 ) 
         Parm         CVE            TE 
 
       Parm          CVE           TE 
 
     Parm           CVE           TE 
46.415890 1.43% 3.65% 
 
46.415890 1.43% 3.65% 
 
58.570210 1.43% 1.89% 
58.570210 1.43% 1.89% 
 
58.570210 1.43% 1.89% 
 
73.907220 1.43% 1.62% 
73.907220 1.43% 1.62% 
 
73.907220 1.43% 1.62% 
 
93.260330 1.43% 1.62% 
 
… 
   
… 
   
… 
 1519.9110 1.43% 1.63% 
 
1519.9110 1.43% 1.63% 
 
1917.9100 1.43% 1.63% 
1917.9100 1.43% 1.63% 
 
1917.9100 1.43% 1.63% 
 
2420.128 1.43% 1.63% 
 
… 
   
… 
   
… 
 62802.91 1.43% 1.63% 
 
62802.91 1.43% 1.63% 
 
62802.91 1.43% 1.63% 
79248.29 1.43% 1.63% 
 
79248.29 1.43% 1.63% 
 
79248.29 1.43% 1.63% 
100000.00 1.43% 1.63% 
 
100000.00 1.43% 1.63% 
 
100000.00 1.43% 1.63% 
           SCV - 3 Reps - Detail 
  
  
     #1 (# 34) 
  
#2 (# 33) 
  
#3 (#  32) 
         Parm         CVE           TE 
 
        Parm          CVE           TE 
 
       Parm         CVE           TE 
46.41589 1.43% 3.65% 
 
58.57021 1.43% 1.89% 
 
73.90722 1.43% 1.62% 
58.57021 1.43% 1.89% 
 
73.90722 1.43% 1.62% 
 
93.26033 1.43% 1.62% 
73.90722 1.43% 1.62% 
 
93.26033 1.43% 1.62% 
 
117.6812 1.43% 1.62% 
 
… 
   
… 
   
… 
 1917.91 1.43% 1.63% 
 
1917.91 1.43% 1.63% 
 
2420.128 1.43% 1.63% 
2420.128 1.43% 1.63% 
 
2420.128 1.43% 1.63% 
 
3053.856 1.43% 1.63% 
 
… 
   
… 
   
… 
 62802.91 1.43% 1.63% 
 
62802.91 1.43% 1.63% 
 
62802.91 1.43% 1.63% 
79248.29 1.43% 1.63% 
 
79248.29 1.43% 1.63% 
 
79248.29 1.43% 1.63% 
100000 1.43% 1.63% 
 
100000 1.43% 1.63% 
 




















Leukemia Cancer  
         kernlab ksvm C-svc 
         C-svc anovadot 
         
           LOOCV - Detail 
 
(# 85 ) 
                  Parm             CVE         TE 
        0.0003274549 1.39% 4.49% 
        0.0004132012 1.39% 2.70% 
        0.0005214008 1.39% 2.10% 




        4.5348790 1.39% 1.96% 
        5.7223680 1.39% 1.96% 




        62802.91 1.39% 1.96% 
        79248.29 1.39% 1.96% 
        100000.00 1.39% 1.96% 
        
           SS - 3 Reps - Detail 
  
  
     #1 (#  84) 
  
#2 (# 83 ) 
  
#3 (#  82) 
           Parm             CVE         TE 
 
         Parm             CVE         TE 
 
        Parm               CVE         TE 
0.0004132012 1.33% 2.70% 
 
0.0005214008 1.33% 2.10% 
 
0.0006579332 1.43% 1.97% 
0.0005214008 1.33% 2.10% 
 
0.0006579332 1.33% 1.97% 
 
0.0008302176 1.43% 1.96% 
0.0006579332 1.33% 1.97% 
 
0.0008302176 1.33% 1.96% 
 
0.0010476158 1.43% 1.96% 
 
… 
   
… 
   
… 
 5.722368 1.33% 1.96% 
 
5.722368 1.33% 1.96% 
 
7.220809 1.33% 1.96% 
7.220809 1.33% 1.96% 
 
7.220809 1.33% 1.96% 
 
9.111628 1.33% 1.96% 
 
… 
   
… 
   
… 
 62802.91 1.33% 1.96% 
 
62802.91 1.33% 1.96% 
 
62802.91 1.43% 1.96% 
79248.29 1.33% 1.96% 
 
79248.29 1.33% 1.96% 
 
79248.29 1.43% 1.96% 
100000.00 1.33% 1.96% 
 
100000.00 1.33% 1.96% 
 




















Leukemia:  C-svc anovadot Continued 
      
           BCV - 3 Reps - Detail 
  
 
     #1 (# 82) 
 
  #2 (# 85 ) 
  
#3 (# 83 ) 
            Parm             CVE          TE 
 
            Parm            CVE         TE 
 
          Parm             CVE           TE 
0.0006579332 1.33% 1.97% 
 
0.0003274549 1.33% 4.49% 
 
0.0005214008 1.33% 2.10% 
0.0008302176 1.33% 1.96% 
 
0.0004132012 1.33% 2.70% 
 
0.0006579332 1.33% 1.97% 
0.0010476160 1.33% 1.96% 
 
0.0005215008 1.33% 2.10% 
 
0.0008302176 1.33% 1.96% 
 
… 
   
… 
   
… 
 7.2208090 1.33% 1.96% 
 
4.5348790 1.33% 1.96% 
 
4.5348790 1.33% 1.96% 
9.1116280 1.33% 1.96% 
 
5.7223680 1.33% 1.96% 
 
5.7223680 1.33% 1.96% 
 
… 
   
… 
   
… 
 62802.91 1.33% 1.96% 
 
62802.91 1.33% 1.96% 
 
62802.91 1.33% 1.96% 
79248.29 1.33% 1.96% 
 
79248.29 1.33% 1.96% 
 
79248.29 1.33% 1.96% 
100000.00 1.33% 1.96% 
 
100000.00 1.33% 1.96% 
 
100000.00 1.33% 1.96% 
           SCV - 3 Reps - Detail 
  
  
     #1 (# 84) 
  
#2 (# 84) 
  
#3 (#  84) 
             Parm             CVE        TE 
 
            Parm            CVE        TE 
 
         Parm              CVE         TE 
0.0004132012 1.33% 2.70% 
 
0.0004132012 1.43% 2.70% 
 
0.0004132012 1.33% 2.70% 
0.0005214008 1.33% 2.10% 
 
0.0005214008 1.43% 2.10% 
 
0.0005214008 1.33% 2.10% 
0.0006579332 1.33% 1.97% 
 
0.0006579332 1.43% 1.97% 
 
0.0006579332 1.33% 1.97% 
 
… 
   
… 
   
… 
 5.7223680 1.33% 1.96% 
 
5.7223680 1.43% 1.96% 
 
5.7223680 1.33% 1.96% 
7.2208090 1.33% 1.96% 
 
7.2208090 1.43% 1.96% 
 
7.2208090 1.33% 1.96% 
 
… 
   
… 
   
… 
 62802.91 1.33% 1.96% 
 
62802.91 1.43% 1.96% 
 
62802.91 1.33% 1.96% 
79248.29 1.33% 1.96% 
 
79248.29 1.43% 1.96% 
 
79248.29 1.33% 1.96% 
100000 1.33% 1.96% 
 
100000 1.43% 1.96% 
 




















Leukemia Cancer  
         kernlab ksvm C-svc 
         C-svc tanhdot 
         
           LOOCV - Detail ( #1 ) 
                 Parm            CVE            TE 
        0.8902151 1.39% 12.24% 
        
           SS - 3 Reps - Detail 
  
  
     #1 (#  1 ) 
  
#2 (#  1 ) 
  
#3 (#   1) 
          Parm            CVE             TE 
 
          Parm            CVE          TE 
 
         Parm             CVE            TE 
0.1097499 8.29% 8.30% 
 
0.0869749 6.95% 8.29% 
 
0.0869749 5.43% 8.29% 
           BCV - 3 Reps - Detail 
  
  
     #1 (#  1 ) 
  
#2 (#   2) 
  
#3 (#   2) 
          Parm            CVE              TE 
 
          Parm            CVE           TE 
 
         Parm             CVE            TE 
0.10974990 2.86% 8.30% 
 
0.06892612 6.86% 8.08% 
 
0.08697490 6.76% 8.29% 
    
0.08697490 6.86% 8.29% 
 
0.13848860 6.76% 8.91% 
           SCV - 3 Reps - Detail 
  
  
     #1 (# 1) 
  
#2 (# 2) 
  
#3 (#  1) 
          Parm            CVE              TE 
 
          Parm            CVE           TE 
 
         Parm             CVE            TE 
0.05462277 4.10% 9.22% 
 
0.05462277 5.52% 9.22% 
 
0.05462277 9.52% 9.22% 
    
0.06892612 5.52% 8.08% 



















West Breast Cancer  
         kernlab ksvm C-svc 
         C-svc vanilladot 
         
           LOOCV - 
Detail 
 
(# 85 ) 
            Parm             CVE            TE 
        0.0002056512 36.73% 37.74% 
        0.0002595024 36.73% 36.68% 
        0.0005214008 36.73% 37.61% 
         …          4.534879 36.73% 38.15% 
        5.722368 36.73% 38.15% 
         …          62802.91 36.73% 38.15% 
        79248.29 36.73% 38.15% 
        100000.00 36.73% 38.15% 
        
           SS - 3 Reps - Detail 
  
  
     #1 (#  3) 
  
#2 (#  82 ) 
  
#3 (#  1 ) 
    Parm                    CVE          TE 
 
   Parm                     CVE           TE 
 
   Parm                     CVE           TE 
0.0002056512 42.67% 37.74% 
 
0.0006579332 42.67% 38.04% 
 
0.0004132012 36.22% 37.26% 
0.0002595024 42.67% 36.68% 
 
0.0008302176 42.67% 38.15% 
    0.0003274549 42.67% 36.74% 
 
0.0010476158 42.67% 38.15% 
    
     
… 
     
    
7.220809 42.67% 38.15% 
    
    
9.111628 42.67% 38.15% 
    
     
… 
     
    
62802.91 42.67% 38.15% 
    
    
79248.29 42.67% 38.15% 
    
    
100000.00 42.67% 38.15% 



















West Breast :  C-svc   vanilladot Continued 
      
           BCV - 3 Reps - Detail 
  
  
     #1 (#  2) 
  
#2 (#  2) 
  
#3 (#  1) 
    Parm                     CVE           TE 
 
   Parm                      CVE             TE 
 
   Parm                     CVE             TE 
0.0001023531 35.11% 44.21% 
 
0.0002056512 32.89% 37.74% 
 
0.0002595024 30.89% 36.68% 
0.0001291550 35.11% 41.44% 
 
0.0002595024 32.89% 36.68% 
    
           SCV - 3 Reps - Detail 
  
  
     #1 (#  1) 
  
#2 (#  86) 
  
#3 (#  84) 
    Parm                      CVE           TE 
 
   Parm                      CVE           TE 
 
   Parm                      CVE           TE 
0.0000403702 42.89% 49.56% 
 
0.0002056512 34.44% 37.74% 
 
0.0004132012 30.67% 37.26% 
    
0.0002595024 34.44% 36.68% 
 
0.0005214008 30.67% 37.61% 
    
0.0003274549 34.44% 36.74% 
 
0.0006579332 30.67% 38.04% 
     
… 
   
… 
 
    
4.5348790 34.44% 38.15% 
 
5.7223680 30.67% 38.15% 
    
5.7223680 34.44% 38.15% 
 
7.2208090 30.67% 38.15% 
     
… 
   
… 
 
    
62802.91 34.44% 38.15% 
 
62802.91 30.67% 38.15% 
    
79248.29 34.44% 38.15% 
 
79248.29 30.67% 38.15% 
    
100000 34.44% 38.15% 
 




















West Breast Cancer  
         kernlab ksvm C-svc 
         C-svc polydot 
         
           LOOCV - Detail (# 85 ) 
            Parm             CVE            TE 
        0.0002056512 36.73% 37.74% 
        0.0002595024 36.73% 36.68% 
        0.0005214008 36.73% 37.61% 




        4.534879 36.73% 38.15% 
        5.722368 36.73% 38.15% 




        62802.91 36.73% 38.15% 
        79248.29 36.73% 38.15% 
        100000.00 36.73% 38.15% 
        
           SS - 3 Reps - Detail 
  
  
     #1 (# 1 ) 
  
#2 (#  1 ) 
  
#3 (#  2 ) 
    Parm                    CVE          TE 
 
   Parm                     CVE          TE 
 
   Parm                     CVE           TE 
0.0005214008 36.89% 37.61% 
 
0.0002595024 34.89% 36.68% 
 
0.0004132012 30.44% 37.26% 
        




















West Breast :  C-svc   polydot Continued 
      
           BCV - 3 Reps - Detail 
  
  
     #1 (# 2) 
  
#2 (# 3) 
  
#3 (#  1) 
    Parm                     CVE           TE 
 
   Parm                      CVE             TE 
 
   Parm                     CVE             TE 
0.0002595024 36.89% 36.68% 
 
0.0002595024 28.44% 36.68% 
 
0.0003274549 32.67% 36.74% 
0.0003274549 36.89% 36.74% 
 
0.0003274549 28.44% 36.74% 
    
    
0.0004132012 28.44% 37.26% 
    
           SCV - 3 Reps - Detail 
  
  
     #1 (#  1) 
  
#2 (# 2) 
  
#3 (#  1) 
    Parm                      CVE          TE 
 
   Parm                      CVE           TE 
 
   Parm                      CVE          TE 
0.0003274549 26.44% 36.74% 
 
0.0003274549 28.44% 36.74% 
 
0.0002595024 34.44% 36.68% 
    
0.0004132012 28.44% 37.26% 
    
           



















West Breast Cancer  
         kernlab ksvm C-svc 
         C-svc rbfdot 
          
           LOOCV - Detail (#  4 ) 
            Parm              CVE            TE 
        1.417474 38.77% 39.62% 
        1.78865 38.77% 38.70% 
        2.25702 38.77% 38.38% 
        2.84803600 38.77% 38.46% 
        
           SS - 3 Reps - Detail 
  
  
     #1 (# 11 ) 
  
#2 (#  35 ) 
  
#3 (#   4) 
 
   Parm                    CVE          TE 
 
   Parm                     CVE           
TE 
 
   Parm                     CVE           TE 
2.848036 40.67% 38.46% 
 
2.848036 38.67% 38.46% 
 
1.78865 34.67% 38.70% 
4.534879 40.67% 39.00% 
 
4.534879 38.67% 39.00% 
 
18.30738 34.67% 39.01% 
29.150531 40.67% 39.01% 
 
5.722368 38.67% 39.01% 
 
148.49683 34.67% 39.01% 
 
… 
   
… 
  
7742.63683 34.67% 39.01% 
73.907220 40.67% 39.01% 
 
475.0810 38.67% 
     148.496826 40.67% 39.01% 
 
599.4843 38.67% 
     
 
… 
   
… 
     9770.099573 40.67% 39.01% 
 
62802.91 38.67% 39.01% 
    39442.060594 40.67% 39.01% 
 
79248.29 38.67% 39.01% 
    49770.235643 40.67% 39.01% 
 
100000.00 38.67% 39.01% 



















West Breast :  C-svc   rbfdot Continued 
      
           BCV - 3 Reps - Detail 
  
  
    #1 (#  3) 
  
#2 (#  12) 
  
#3 (#  1 ) 
 
   Parm                     CVE           TE 
 
   Parm                      CVE            
TE 
 
   Parm                     CVE             TE 
5.722368 32.67% 39.01% 
 
11.49757 32.67% 39.01% 
 
1.78865 42.67% 38.70% 
46.415888 32.67% 39.01% 
 
58.57021 32.67% 39.01% 
    7742.636827 32.67% 39.01% 
 
187.38174 32.67% 39.01% 
    
     
 …  
     
    
756.46333 32.67% 39.01% 
    
    
1204.50354 32.67% 39.01% 
    
     
 …  
     
    
15556.7614 32.67% 39.01% 
    
    
39442.0606 32.67% 39.01% 
    
    
49770.2356 32.67% 39.01% 
    
           SCV - 3 Reps - Detail 
  
  
    #1 (#  2) 
  
#2 (#  1) 
  
#3 (#  16) 
 
   Parm                      CVE           TE 
 
   Parm                      CVE          
TE 
 
   Parm                      CVE           TE 
1.78865 38.67% 38.70% 
 
1.417474 32.89% 39.62% 
 
5.722368 36.67% 39.01% 
2.25702 38.67% 38.38% 
     
14.508288 36.67% 39.01% 
        
29.150531 36.67% 39.01% 
         
… 
 
        
376.4936 36.67% 39.01% 
        
475.0810 36.67% 39.01% 
         
… 
 
        
24770.763560 36.67% 39.01% 
        
31257.158497 36.67% 39.01% 
        




















West Breast Cancer  
        kernlab ksvm C-svc 
         C-svc laplacedot 
         
           LOOCV - Detail (# 2 ) 
            Parm            CVE            TE 
        117.6812 36.73% 38.62% 
        148.4968 36.73% 37.35% 
        
           SS - 3 Reps - Detail 
  
  
     #1 (#   1) 
  
#2 (#  28 ) 
  
#3 (#   1) 
 
   Parm                    CVE          TE 
 
   Parm                     CVE           TE 
 
   Parm                     CVE           
TE 
117.6812 34.67% 38.62% 
 
187.3817 44.44% 37.25% 
 
187.3817 39.56% 37.25% 
    
236.4489 44.44% 37.31% 
    
    
298.3647 44.44% 37.31% 
    
     
… 
     
    
3853.529 44.44% 37.31% 
    
    
4862.602 44.44% 37.31% 
    
     
… 
     
    
62802.91 44.44% 37.31% 
    
    
79248.29 44.44% 37.31% 
    
    
100000.00 44.44% 37.31% 



















West Breast :  C-svc   laplacedot Continued 
      
           BCV - 3 Reps - Detail 
  
  
     #1 (#  30) 
  
#2 (#  28 ) 
  
#3 (#  1) 
    Parm                     CVE           TE 
 
   Parm                      CVE             TE 
 
   Parm            CVE             TE 
58.570210 44.89% 48.62% 
 
187.38170 32.67% 37.25% 
 
73.90722 42.89% 46.14% 
148.496830 44.89% 37.35% 
 
236.44890 32.67% 37.31% 
 
   
187.381700 44.89% 37.25% 
 
298.36470 32.67% 37.31% 
 
   
 
 …  
 
  






2420.128260 44.89% 37.31% 
 
3053.85550 32.67% 37.31% 
 
   
3053.855510 44.89% 37.31% 
 
3853.52860 32.67% 37.31% 
 
   
 
 …  
 
  






62802.91 44.89% 37.31% 
 





79248.29 44.89% 37.31% 
 
79248.23980 32.67% 37.31% 
 
   
100000.00 44.89% 37.31% 
 




           SCV - 3 Reps - Detail 
  
  
     #1 (#  1) 
  
#2 (#  1) 
  
#3 (#  29) 
    Parm                      CVE           TE 
 
   Parm                      CVE           TE 
 
   Parm            CVE              TE 
93.26033 40.67% 42.29% 
 
93.26033 34.67% 42.29% 
 
117.6812 32.44% 38.62% 
        
187.3817 32.44% 37.25% 
        
236.4489 32.44% 37.31% 
         
… 
 
        
3053.856 32.44% 37.31% 
        
3853.529 32.44% 37.31% 
         
… 
 
        
62802.91 32.44% 37.31% 
        
79248.29 32.44% 37.31% 
        




















West Breast Cancer  
         kernlab ksvm C-svc 
         C-svc anovadot 
         
           LOOCV - Detail (# 1 ) 
            Parm                       CVE               TE 
        0.0004132012 36.73% 39.55% 
        
           SS - 3 Reps - Detail 
  
  
     #1 (# 84 ) 
  
#2 (#   1) 
  
#3 (#   1) 
    Parm                    CVE         TE 
 
   Parm                     CVE           TE 
 
   Parm                     CVE           TE 
0.0004132012 42.89% 39.55% 
 
0.0005214008 40.67% 39.29% 
 
0.0005214008 51.33% 39.29% 
0.0005214008 42.89% 39.29% 
        0.0006579332 42.89% 39.32% 
        
 
… 
         5.722368 42.89% 39.36% 
        7.220809 42.89% 39.36% 
        
 
… 
         62802.91 42.89% 39.36% 
        79248.29 42.89% 39.36% 
        100000.00 42.89% 39.36% 



















West Breast :  C-svc   anovadot Continued 
      
           BCV - 3 Reps - Detail 
  
  
     #1 (#  1) 
  
#2 (# 81 ) 
  
#3 (#  1) 
           Parm                CVE           TE 
 
          Parm                  CVE             TE 
 
       Parm                 CVE                TE 
0.0004132012 44.89% 39.55% 
 
0.0008302176 43.11% 39.36% 
 
0.0005214008 32.67% 39.29 
    
0.0010476158 43.11% 39.36% 
    
    
0.0013219411 43.11% 39.36% 
    
     
… 
     
    
7.22080900 43.11% 39.36% 
    
    
9.11162800 43.11% 39.36% 
    
     
… 
     
    
62802.91 43.11% 39.36% 
    
    
79248.29 43.11% 39.36% 
    
    
100000.00 43.11% 39.36% 
               SCV - 3 Reps - Detail 
  
  
     #1 (#  1) 
  
#2 (#  82) 
  
#3 (#  83) 
         Parm                  CVE          TE 
 
           Parm                 CVE            TE 
 
        Parm                CVE              TE 
0.0003274549 32.89% 41.59% 
 
0.0006579332 38.67% 39.32% 
 
0.0005214008 33.11% 39.29% 
    
0.0008302176 38.67% 39.36% 
 
0.0006579332 33.11% 39.32% 
    
0.0010476158 38.67% 39.36% 
 
0.0008302176 33.11% 39.36% 
     
… 
   
… 
 
    
7.2208090 38.67% 39.36% 
 
5.7223680 38.67% 39.36% 
    
9.1116280 38.67% 39.36% 
 
7.2208090 38.67% 39.36% 
     
… 
   
… 
 
    
62802.91 38.67% 39.36% 
 
62802.91 33.11% 39.36% 
    
79248.29 38.67% 39.36% 
 
79248.29 33.11% 39.36% 
    
100000 38.67% 39.36% 
 




















West Breast Cancer  
        kernlab ksvm C-svc 
        C-svc tanhdot 
         
           LOOCV - Detail (# 1 ) 
            Parm             CVE            TE 
        31257.16 26.53% 43.46% 
        
           SS - 3 Reps - Detail 
  
  
     #1 (# 17 ) 
  
#2 (#   2) 
  
#3 (#   1) 
      Parm           CVE          TE 
 
       Parm             CVE              TE 
 
   Parm            CVE             TE 
2420.128 30.67% 43.28% 
 
0.1747528 39.11% 40.83% 
 
0.278256 34.67% 41.15% 
3053.856 30.67% 43.40% 
 
0.2205131 39.11% 40.85% 
    3853.529 30.67% 43.31% 
        
 
… 
         12328.47 30.67% 43.44% 
        15556.76 30.67% 43.40% 
        
 
… 
         62802.91 30.67% 43.39% 
        79248.29 30.67% 43.49% 
        100000.00 30.67% 43.39% 



















West Breast :  C-svc   tanhdot Continued 
      
           BCV - 3 Reps - Detail 
  
  
     #1 (#  1) 
  
#2 (#  2 ) 
  
#3 (#  1) 
    Parm              CVE           TE 
 
       Parm              CVE             TE 
 
   Parm            CVE              TE 
0.3511192 32.44% 41.75% 
 
0.06892612 38.67% 44.73% 
 
0.10975 33.11% 41.25% 
    
0.08697490 38.67% 42.01% 
    
           SCV - 3 Reps - Detail 
  
  
     #1 (#  1) 
  
#2 (#  1) 
  
#3 (#  1) 
       Parm           CVE           TE 
 
         Parm            CVE               TE 
 
    Parm            CVE             TE 
0.1747528 28.67% 40.83% 
 
0.3511192 29.33% 41.75% 
 




















Lung Cancer Multiclass 
    
Breast Cancer Multiclass 
   
             Classifier Kernel TE  # 1 TE  # 2 TE  # 3 Avg TE 
 
Classifier Kernel TE  # 1 TE  # 2 TE  # 3 Avg TE 
spoc-svc vanilladot 5.08% 5.29% 5.24% 5.20% 
 
spoc-svc vanilladot 5.79% 5.98% 6.01% 5.93% 
spoc-svc polydot 4.78% 4.89% 4.96% 4.88% 
 
spoc-svc polydot 5.90% 6.11% 5.96% 5.99% 
spoc-svc anovadot 4.05% 3.95% 4.25% 4.08% 
 
spoc-svc anovadot 14.57% 12.81% 11.69% 13.02% 
spoc-svc laplacedot 30.30% 30.30% 30.30% 30.30% 
 
spoc-svc laplacedot 61.39% 62.32% 62.41% 62.04% 
spoc-svc rbfdot 3.78% 3.86% 4.02% 3.89% 
 
spoc-svc rbfdot 12.09% 10.38% 11.59% 11.35% 
spoc-svc tanhdot 49.85% 50.22% 50.19% 50.09% 
 
spoc-svc tanhdot 24.35% 24.16% 23.93% 24.15% 
             kbb-svc polydot 4.83% 4.85% 4.92% 4.87% 
 
kbb-svc polydot 6.70% 6.40% 6.70% 6.60% 
kbb-svc vanilladot 4.88% 4.99% 5.02% 4.96% 
 
kbb-svc vanilladot 6.50% 7.16% 6.92% 6.86% 
kbb-svc anovadot 3.64% 3.48% 3.60% 3.57% 
 
kbb-svc anovadot 72.51% 74.52% 74.58% 73.87% 
kbb-svc laplacedot 30.39% 30.02% 30.15% 30.19% 
 
kbb-svc laplacedot 72.91% 73.33% 73.85% 73.36% 
kbb-svc rbfdot 4.12% 4.09% 4.09% 4.10% 
 
kbb-svc rbfdot 89.22% 89.56% 89.51% 89.43% 
kbb-svc tanhdot  ---   ---   ---   ---  
 
kbb-svc tanhdot 17.91% 20.79% 20.16% 19.62% 
             500 Random replicates per iteration 
   
500 Random replicates per iteration 
  
             
             Lung Cancer Multiclass 
    
Breast Cancer Multiclass 
   
             
Classifier Kernel 
TE 
    
Classifier Kernel 
TE 
   spoc-svc rbfdot 3.90% 
    
spoc-svc polydot 6.35% 
   kbb-svc anovadot 3.64% 
    
spoc-svc vanilladot 6.36% 
   
             Final TE  Seeded with  500 Replicates  
   
Final TE  Seeded with  500 Replicates  




















Brain Cancer Multiclass 
   
      Classifier Kernel TE  # 1 TE  # 2 TE  # 3 Avg TE 
spoc-svc vanilladot 16.83% 16.78% 17.40% 17.00% 
spoc-svc polydot 16.37% 16.57% 17.18% 16.71% 
spoc-svc anovadot 20.11% 19.89% 20.54% 20.18% 
spoc-svc laplacedot 69.63% 70.54% 71.06% 70.41% 
spoc-svc rbfdot 19.45% 18.22% 18.58% 18.75% 
spoc-svc tanhdot 55.46% 55.34% 54.85% 55.22% 
      kbb-svc polydot 17.95% 17.09% 17.31% 17.45% 
kbb-svc vanilladot 17.49% 17.60% 17.18% 17.42% 
kbb-svc anovadot 34.00% 34.55% 33.60% 34.05% 
kbb-svc laplacedot 76.92% 76.92% 76.92% 76.92% 
kbb-svc rbfdot 46.12% 45.91% 45.42% 45.82% 
kbb-svc tanhdot  ---   ---   ---   ---  
      500 Random replicates per iteration 
  
      
      Brain Cancer Multiclass 
   
      Classifier Kernel TE 
   spoc-svc polydot 17.22% 
   spoc-svc vanilladot 17.26% 
   
      Final TE  Seeded with  500 Replicates  
  
       * Vanilladot chosen for parsimony as the difference is insignificant 
 
Appendix C
Randomized Ensemble Cross-Validation Results
1
1All cross-validate errors (CVE) were the minimum values returned from a random execution of cross-validation

















































Tree Prostate  Cancer 
           
              LOOCV (# 16)                         
CP minsplit CVE TE 
          0.01 5 36.71% 42.40% 
          0.01 6 36.71% 42.38% 
          0.02 5 36.71% 42.40% 
          0.02 6 36.71% 42.38% 
          0.03 1 36.71% 42.89% 
          0.03 2 36.71% 42.89% 
          0.03 3 36.71% 42.89% 
          0.03 4 36.71% 42.91% 
          0.03 5 36.71% 42.40% 
          0.03 6 36.71% 42.38% 
 
 
        0.04 1 36.71% 42.32% 
          0.04 2 36.71% 42.32% 
          0.04 3 36.71% 42.32% 
          0.04 4 36.71% 42.32% 
          0.04 5 36.71% 42.32% 
          0.04 6 36.71% 42.32% 
          
























Tree Prostate  Cancer Continued
BCV 
#1 (# 2) #2 (# 2) #3 (# 3)
CP minsplit CVE TE CP minsplit CVE TE CP minsplit CVE TE
0.01 1 0.00% 42.89% 0.01 1 0.00% 42.89% 0.01 1 0.00% 42.89%
0.01 2 0.00% 42.89% 0.01 2 0.00% 42.89% 0.01 2 0.00% 42.89%
0.01 3 0.00% 42.89%
SCV 
#1 (# 8) #2 (# 6) #3 (# 3)
CP minsplit CVE TE CP minsplit CVE TE CP minsplit CVE TE
0.01 1 0.00% 42.89% 0.01 1 0.00% 42.89% 0.01 1 0.00% 42.89%
0.01 2 0.00% 42.89% 0.01 2 0.00% 42.89% 0.01 2 0.00% 42.89%
0.01 3 0.00% 42.89% 0.01 3 0.00% 42.89% 0.01 3 0.00% 42.89%
0.01 4 0.00% 42.91% 0.02 1 0.00% 42.89%
0.02 1 0.00% 42.89% 0.02 2 0.00% 42.89%
0.02 2 0.00% 42.89% 0.02 3 0.00% 42.89%
0.02 3 0.00% 42.89%
























Tree Colon  Cancer 
                          LOOCV (# 12)                         
CP minsplit CVE TE 
          0.01 8 11.29% 27.31% 
          0.01 9 11.29% 27.32% 
          0.01 10 11.29% 27.32% 
          0.02 8 11.29% 27.31% 
          0.02 9 11.29% 27.32% 
          0.02 10 11.29% 27.32% 
          0.03 8 11.29% 27.31% 
          0.03 9 11.29% 27.32% 
          0.03 10 11.29% 27.32% 
          0.04 8 11.29% 27.31% 
          0.04 9 11.29% 27.32% 
          0.04 10 11.29% 27.32% 
          
              BCV                            
#1 (# 16) 
   
#2 (# 16) 
   
#3 (# 4) 
  CP minsplit CVE TE 
 
CP minsplit CVE TE 
 
CP minsplit CVE TE 
  0.01              1 0.00% 28.00% 
 
0.01 1 0.00% 28.00% 
 
0.01 1 0.00% 28.00% 
0.01 2 0.00% 28.00% 
 
0.01 2 0.00% 28.00% 
 
0.01 2 0.00% 28.00% 
0.01 3 0.00% 28.00% 
 
0.01 3 0.00% 28.00% 
 
0.02 1 0.00% 28.00% 
0.01 4 0.00% 28.00% 
 
0.01 4 0.00% 28.00% 
 
0.02 2 0.00% 28.00% 
0.02 1 0.00% 28.00% 
 
0.02 1 0.00% 28.00% 
     0.02 2 0.00% 28.00% 
 
0.02 2 0.00% 28.00% 
     0.02 3 0.00% 28.00% 
 
0.02 3 0.00% 28.00% 
     0.02 4 0.00% 28.00% 
 
0.02 4 0.00% 28.00% 
     0.03 1 0.00% 28.00% 
 
0.03 1 0.00% 28.00% 
     0.03 2 0.00% 28.00% 
 
0.03 2 0.00% 28.00% 
     0.03 3 0.00% 28.00% 
 
0.03 3 0.00% 28.00% 
     0.03 4 0.00% 28.00% 
 
0.03 4 0.00% 28.00% 
     0.04 1 0.00% 28.00% 
 
0.04 1 0.00% 28.00% 
     0.04 2 0.00% 28.00% 
 
0.04 2 0.00% 28.00% 
     0.04 3 0.00% 28.00% 
 
0.04 3 0.00% 28.00% 
     0.04 4 0.00% 28.00% 
 
0.04 4 0.00% 28.00% 
























Tree Colon Cancer Coninued
SCV 
#1 (# 16) #2 (# 16) #3 (# 16)
CP minsplit CVE TE CP minsplit CVE TE CP minsplit CVE TE
0.01 1 0.00% 28.00% 0.01 1 0.00% 28.00% 0.01 1 0.00% 28.00%
0.01 2 0.00% 28.00% 0.01 2 0.00% 28.00% 0.01 2 0.00% 28.00%
0.01 3 0.00% 28.00% 0.01 3 0.00% 28.00% 0.01 3 0.00% 28.00%
0.01 4 0.00% 28.00% 0.01 4 0.00% 28.00% 0.01 4 0.00% 28.00%
0.02 1 0.00% 28.00% 0.02 1 0.00% 28.00% 0.02 1 0.00% 28.00%
0.02 2 0.00% 28.00% 0.02 2 0.00% 28.00% 0.02 2 0.00% 28.00%
0.02 3 0.00% 28.00% 0.02 3 0.00% 28.00% 0.02 3 0.00% 28.00%
0.02 4 0.00% 28.00% 0.02 4 0.00% 28.00% 0.02 4 0.00% 28.00%
0.03 1 0.00% 28.00% 0.03 1 0.00% 28.00% 0.03 1 0.00% 28.00%
0.03 2 0.00% 28.00% 0.03 2 0.00% 28.00% 0.03 2 0.00% 28.00%
0.03 3 0.00% 28.00% 0.03 3 0.00% 28.00% 0.03 3 0.00% 28.00%
0.03 4 0.00% 28.00% 0.03 4 0.00% 28.00% 0.03 4 0.00% 28.00%
0.04 1 0.00% 28.00% 0.04 1 0.00% 28.00% 0.04 1 0.00% 28.00%
0.04 2 0.00% 28.00% 0.04 2 0.00% 28.00% 0.04 2 0.00% 28.00%
0.04 3 0.00% 28.00% 0.04 3 0.00% 28.00% 0.04 3 0.00% 28.00%
























Tree Leukemia  Cancer 
           
              LOOCV (# 98)                         
CP minsplit CVE TE 
          0.01 1 19.44% 14.37% 
          0.01 2 19.44% 14.37% 
          0.01 3 19.44% 14.37% 
          0.01 4 19.44% 14.37% 
          0.01 5 19.44% 13.24% 
          0.01 6 19.44% 13.24% 
          0.01 7 19.44% 13.24% 
          0.02 1 19.44% 14.37% 
          0.02 2 19.44% 14.37% 
          0.02 3 19.44% 14.37% 
          0.02 4 19.44% 14.37% 
          0.02 5 19.44% 13.24% 
          0.02 6 19.44% 13.24% 
          0.02 7 19.44% 13.24% 
          …  
 
…  
           0.05 1 19.44% 14.37% 
          0.05 2 19.44% 14.37% 
          
  
… 
           0.05 8 19.44% 13.75% 
          0.05 9 19.44% 13.75% 
          0.05 10 19.44% 13.75% 
          … 
 
… 
























Tree Leukemia Cancer Continued 
          
              CP minsplit CVE TE 
          0.10 1 19.44% 13.24% 
          0.10 2 19.44% 13.24% 
          0.10 3 19.44% 13.24% 
          0.10 4 19.44% 13.24% 
          0.10 5 19.44% 13.24% 
          0.10 6 19.44% 13.24% 
          0.10 7 19.44% 13.24% 
          0.10 8 19.44% 13.55% 
          0.10 9 19.44% 13.55% 
          0.10 10 19.44% 13.55% 
          0.11 1 19.44% 13.24% 
          0.11 2 19.44% 13.24% 
          0.11 3 19.44% 13.24% 
          0.11 4 19.44% 13.24% 
          
  
… 
           0.11 9 19.44% 13.55% 
          0.11 10 19.44% 13.55% 
          
              BCV                            
#1 (# 12) 
   
#2 (# 9) 
   
#3 (# 9) 
  CP minsplit CVE TE 
 
CP minsplit CVE TE 
 
CP minsplit CVE TE 
0.01 1 0.00% 14.37% 
 
0.01 1 0.00% 14.37% 
 
0.01 1 0.00% 14.37% 
0.01 2 0.00% 14.37% 
 
0.01 2 0.00% 14.37% 
 
0.01 2 0.00% 14.37% 
0.01 3 0.00% 14.37% 
 
0.01 3 0.00% 14.37% 
 
0.01 3 0.00% 14.37% 
0.01 4 0.00% 14.37% 
 
0.02 1 0.00% 14.37% 
 
0.02 1 0.00% 14.37% 
0.02 1 0.00% 14.37% 
 
0.02 2 0.00% 14.37% 
 
0.02 2 0.00% 14.37% 
0.02 2 0.00% 14.37% 
 
0.02 3 0.00% 14.37% 
 
0.02 3 0.00% 14.37% 
0.02 3 0.00% 14.37% 
 
0.03 1 0.00% 14.37% 
 
0.03 1 0.00% 14.37% 
0.02 4 0.00% 14.37% 
 
0.03 2 0.00% 14.37% 
 
0.03 2 0.00% 14.37% 
0.03 1 0.00% 14.37% 
 
0.03 3 0.00% 14.37% 
 
0.03 3 0.00% 14.37% 
0.03 2 0.00% 14.37% 
          0.03 3 0.00% 14.37% 
          0.03 4 0.00% 14.37% 
























Tree Leukemia Cancer Continued 
          
              SCV                            
#1 (# 12) 
   
#2 (# 15) 
   
#3 (# 12) 
  CP minsplit CVE TE 
 
CP minsplit CVE TE 
 
CP minsplit CVE TE 
0.01 1 0.00% 14.37% 
 
0.01 1 0.00% 14.37% 
 
0.01 1 0.00% 14.37% 
0.01 2 0.00% 14.37% 
 
0.01 2 0.00% 14.37% 
 
0.01 2 0.00% 14.37% 
0.01 3 0.00% 14.37% 
 
0.01 3 0.00% 14.37% 
 
0.01 3 0.00% 14.37% 
0.01 4 0.00% 14.37% 
 
0.01 4 0.00% 14.37% 
 
0.01 4 0.00% 14.37% 
0.02 1 0.00% 14.37% 
 
0.01 5 0.00% 13.24% 
 
0.02 1 0.00% 14.37% 
0.02 2 0.00% 14.37% 
 
0.02 1 0.00% 14.37% 
 
0.02 2 0.00% 14.37% 
0.02 3 0.00% 14.37% 
 
0.02 2 0.00% 14.37% 
 
0.02 3 0.00% 14.37% 
0.02 4 0.00% 14.37% 
 
0.02 3 0.00% 14.37% 
 
0.02 4 0.00% 14.37% 
0.03 1 0.00% 14.37% 
 
0.02 4 0.00% 14.37% 
 
0.03 1 0.00% 14.37% 
0.03 2 0.00% 14.37% 
 
0.02 5 0.00% 13.24% 
 
0.03 2 0.00% 14.37% 
0.03 3 0.00% 14.37% 
 
0.03 1 0.00% 14.37% 
 
0.03 3 0.00% 14.37% 
0.03 4 0.00% 14.37% 
 
0.03 2 0.00% 14.37% 
 
0.03 4 0.00% 14.37% 
     
0.03 3 0.00% 14.37% 
     
     
0.03 4 0.00% 14.37% 
     
     
0.03 5 0.00% 13.24% 
























Tree West Breast Cancer 
           
              LOOCV (# 120)                         
CP minsplit CVE TE 
          0.14 1 22.45% 30.96% 
          0.14 2 22.45% 30.96% 
          0.14 3 22.45% 30.96% 
          
  
… 
           0.14 9 22.45% 30.96% 
          0.14 10 22.45% 30.96% 
          
  
… 
           0.15 1 22.45% 30.96% 
          0.15 2 22.45% 30.96% 
          0.15 3 22.45% 30.96% 
          
  
… 
           0.15 9 22.45% 30.96% 
          0.15 10 22.45% 30.96% 
          
  
… 
           0.20 1 22.45% 29.83% 
          0.20 2 22.45% 29.83% 
          0.20 3 22.45% 29.83% 
          
  
… 
           0.20 9 22.45% 29.83% 
          0.20 10 22.45% 29.83% 
          
  
… 
           0.25 1 22.45% 29.19% 
          0.25 2 22.45% 29.19% 
   
 
      0.25 3 22.45% 29.19% 
          0.25 4 22.45% 29.19% 
          0.25 5 22.45% 29.19% 
          0.25 6 22.45% 29.19% 
          0.25 7 22.45% 29.19% 
          0.25 8 22.45% 29.19% 
          0.25 9 22.45% 29.19% 
          0.25 10 22.45% 29.19% 
























Tree West Breast Cancer Continued
BCV 
#1 (# 16) #2 (# 12) #3 (# 24)
CP minsplit CVE TE CP minsplit CVE TE CP minsplit CVE TE
0.01 1 0.00% 33.96% 0.01 1 0.00% 33.96% 0.01 1 0.00% 33.96%
0.01 2 0.00% 33.96% 0.01 2 0.00% 33.96% 0.01 2 0.00% 33.96%
0.01 3 0.00% 33.96% 0.01 3 0.00% 33.96% 0.01 3 0.00% 33.96%
0.01 4 0.00% 33.96% 0.02 1 0.00% 33.96% 0.01 4 0.00% 33.96%
0.02 1 0.00% 33.96% 0.02 2 0.00% 33.96% 0.01 5 0.00% 32.34%
0.02 2 0.00% 33.96% 0.02 3 0.00% 33.96% 0.01 6 0.00% 32.34%
0.02 3 0.00% 33.96% 0.03 1 0.00% 33.96% 0.02 1 0.00% 33.96%
0.02 4 0.00% 33.96% 0.03 2 0.00% 33.96% 0.02 2 0.00% 33.96%
0.03 1 0.00% 33.96% 0.03 3 0.00% 33.96% 0.02 3 0.00% 33.96%
0.03 2 0.00% 33.96% 0.04 1 0.00% 33.96% 0.02 4 0.00% 33.96%
0.03 3 0.00% 33.96% 0.04 2 0.00% 33.96% 0.02 5 0.00% 32.34%
0.03 4 0.00% 33.96% 0.04 3 0.00% 33.96% 0.02 6 0.00% 32.34%
0.04 1 0.00% 33.96% 0.03 1 0.00% 33.96%
0.04 2 0.00% 33.96% 0.03 2 0.00% 33.96%
0.04 3 0.00% 33.96% 0.03 3 0.00% 33.96%
0.04 4 0.00% 33.96% 0.03 4 0.00% 33.96%
0.03 5 0.00% 32.34%
0.03 6 0.00% 32.34%
0.04 1 0.00% 33.96%
0.04 2 0.00% 33.96%
0.04 3 0.00% 33.96%
0.04 4 0.00% 33.96%
0.04 5 0.00% 32.34%
























Tree West Breast Cancer Continued
SCV 
#1 (# 16) #2 (# 12) #3 (# 24)
CP minsplit CVE TE CP minsplit CVE TE CP minsplit CVE TE
0.01 1 0.00% 33.96% 0.01 1 0.00% 33.96% 0.01 1 0.00% 33.96%
0.01 2 0.00% 33.96% 0.01 2 0.00% 33.96% 0.01 2 0.00% 33.96%
0.01 3 0.00% 33.96% 0.01 3 0.00% 33.96% 0.01 3 0.00% 33.96%
0.01 4 0.00% 33.96% 0.02 1 0.00% 33.96% 0.01 4 0.00% 33.96%
0.02 1 0.00% 33.96% 0.02 2 0.00% 33.96% 0.01 5 0.00% 32.34%
0.02 2 0.00% 33.96% 0.02 3 0.00% 33.96% 0.01 6 0.00% 32.34%
0.02 3 0.00% 33.96% 0.03 1 0.00% 33.96% 0.02 1 0.00% 33.96%
0.02 4 0.00% 33.96% 0.03 2 0.00% 33.96% 0.02 2 0.00% 33.96%
0.03 1 0.00% 33.96% 0.03 3 0.00% 33.96% 0.02 3 0.00% 33.96%
0.03 2 0.00% 33.96% 0.04 1 0.00% 33.96% 0.02 4 0.00% 33.96%
0.03 3 0.00% 33.96% 0.04 2 0.00% 33.96% 0.02 5 0.00% 32.34%
0.03 4 0.00% 33.96% 0.04 3 0.00% 33.96% 0.02 6 0.00% 32.34%
0.04 1 0.00% 33.96% 0.03 1 0.00% 33.96%
0.04 2 0.00% 33.96% 0.03 2 0.00% 33.96%
0.04 3 0.00% 33.96% 0.03 3 0.00% 33.96%
0.04 4 0.00% 33.96% 0.03 4 0.00% 33.96%
… 0.03 5 0.00% 32.34%
0.05 5 0.00% 32.34% 0.03 6 0.00% 32.34%
0.06 6 0.00% 32.34% 0.04 1 0.00% 33.96%
0.04 2 0.00% 33.96%
0.04 3 0.00% 33.96%
0.04 4 0.00% 33.96%
0.04 5 0.00% 32.34%
























Tree Lung Cancer 
            
              LOOCV (# 14)                         
CP minsplit CVE TE 
          0.01 5 8.12% 12.45% 
          0.01 6 8.12% 12.53% 
          0.02 1 8.12% 12.64% 
          0.02 2 8.12% 12.64% 
          0.02 3 8.12% 12.66% 
          0.02 4 8.12% 12.69% 
          0.02 5 8.12% 12.45% 
          0.02 6 8.12% 12.53% 
          0.03 1 8.12% 12.32% 
          0.03 2 8.12% 12.32% 
          0.03 3 8.12% 12.32% 
          0.03 4 8.12% 12.32% 
          0.03 5 8.12% 12.42% 
          0.03 6 8.12% 12.49% 
          
    
 
         BCV                            
#1 (# 4) 
   
#2 (# 4) 
   
#3 (# 4) 
  CP minsplit CVE TE 
 
CP minsplit CVE TE 
 
CP minsplit CVE TE 
0.01 1 0.00% 12.64% 
 
0.01 1 0.00% 12.64% 
 
0.01 1 0.00% 12.64% 
0.01 2 0.00% 12.64% 
 
0.01 2 0.00% 12.64% 
 
0.01 2 0.00% 12.64% 
0.01 3 0.00% 12.66% 
 
0.01 3 0.00% 12.66% 
 
0.01 3 0.00% 12.66% 
0.01 4 0.00% 12.69% 
 
0.01 4 0.00% 12.69% 
 
0.01 4 0.00% 12.69% 
              SCV                            
#1 (# 3) 
   
#2 (# 4) 
   
#3 (# 4) 
  CP minsplit CVE TE 
 
CP minsplit CVE TE 
 
CP minsplit CVE TE 
0.01 1 0.00% 12.64% 
 
0.01 1 0.00% 12.64% 
 
0.01 1 0.00% 12.64% 
0.01 2 0.00% 12.64% 
 
0.01 2 0.00% 12.64% 
 
0.01 2 0.00% 12.64% 
0.01 3 0.00% 12.66% 
 
0.01 3 0.00% 12.66% 
 
0.01 3 0.00% 12.66% 
     
0.01 4 0.00% 12.69% 
 
0.01 4 0.00% 12.69% 

























Tree Breast Cancer 
            
              LOOCV (# 142)                         
CP minsplit CVE TE 
          0.01 5 6.19% 18.04% 
          0.01 6 6.19% 18.02% 
            
 
… 
           0.01 9 6.19% 18.00% 
          0.01 10 6.19% 18.20% 
          0.02 5 6.19% 18.04% 
          0.02 6 6.19% 18.02% 
          
  
… 
           0.02 9 6.19% 18.00% 
          0.02 10 6.19% 18.20% 
          0.03 1 6.19% 18.87% 
          0.03 2 6.19% 18.87% 
          0.03 3 6.19% 18.78% 
          
  
… 
           0.03 9 6.19% 18.00% 
          0.03 10 6.19% 18.20% 
          0.04 1 6.19% 17.89% 
          0.04 2 6.19% 17.89% 
          0.04 3 6.19% 17.89% 
          
  
… 
           0.04 9 6.19% 18.01% 
          0.04 10 6.19% 18.01% 
          0.05 1 6.19% 17.87% 
          0.05 2 6.19% 17.87% 
          0.05 3 6.19% 17.87% 
          
  
… 
           0.05 9 6.19% 18.01% 
          0.05 10 6.19% 18.01% 
          … 
 
… 
























Tree Breast Cancer Continued 
           
              0.10 1 6.19% 17.92% 
          0.10 2 6.19% 17.92% 
          0.10 3 6.19% 17.92% 
          
  
… 
           0.10 9 6.19% 17.92% 
          0.10 10 6.19% 17.92% 
          … 
 
… 
           0.15 1 6.19% 17.84% 
          0.15 2 6.19% 17.84% 
          0.15 3 6.19% 17.84% 
          0.15 4 6.19% 17.84% 
          0.15 5 6.19% 17.84% 
          0.15 6 6.19% 17.84% 
          0.15 7 6.19% 17.84% 
          0.15 8 6.19% 17.84% 
          0.15 9 6.19% 17.84% 
          0.15 10 6.19% 17.84% 
          
              BCV                            
#1 (# 8) 
   
#2 (# 12) 
   
#3 (# 6) 
  CP minsplit CVE TE 
 
CP minsplit CVE TE 
 
CP minsplit CVE TE 
0.01 1 0.00% 18.87% 
 
0.01 1 0.00% 18.87% 
 
0.01 1 0.00% 18.87% 
0.01 2 0.00% 18.87% 
 
0.01 2 0.00% 18.87% 
 
0.01 2 0.00% 18.87% 
0.01 3 0.00% 18.78% 
 
0.01 3 0.00% 18.78% 
 
0.01 3 0.00% 18.78% 
0.01 4 0.00% 18.81% 
 
0.01 4 0.00% 18.81% 
 
0.02 1 0.00% 18.87% 
0.02 1 0.00% 18.87% 
 
0.01 5 0.00% 18.04% 
 
0.02 2 0.00% 18.87% 
0.02 2 0.00% 18.87% 
 
0.01 6 0.00% 18.02% 
 
0.02 3 0.00% 18.78% 
0.02 3 0.00% 18.78% 
 
0.02 1 0.00% 18.87% 
     0.02 4 0.00% 18.81% 
 
0.02 2 0.00% 18.87% 
     
     
0.02 3 0.00% 18.78% 
     
     
0.02 4 0.00% 18.81% 
     
     
0.02 5 0.00% 18.04% 
     
     
0.02 6 0.00% 18.02% 
























Tree Breast Cancer Continued
SCV 
#1 (# 10) #2 (# 8) #3 (# 8)
CP minsplit CVE TE CP minsplit CVE TE CP minsplit CVE TE
0.01 1 0.00% 18.87% 0.01 1 0.00% 18.87% 0.01 1 0.00% 18.87%
0.01 2 0.00% 18.87% 0.01 2 0.00% 18.87% 0.01 2 0.00% 18.87%
0.01 3 0.00% 18.78% 0.01 3 0.00% 18.78% 0.01 3 0.00% 18.78%
0.01 4 0.00% 18.81% 0.01 4 0.00% 18.81% 0.01 4 0.00% 18.81%
0.01 5 0.00% 18.04% 0.02 1 0.00% 18.87% 0.02 1 0.00% 18.87%
0.02 1 0.00% 18.87% 0.02 2 0.00% 18.87% 0.02 2 0.00% 18.87%
0.02 2 0.00% 18.87% 0.02 3 0.00% 18.78% 0.02 3 0.00% 18.78%
0.02 3 0.00% 18.78% 0.02 4 0.00% 18.81% 0.02 4 0.00% 18.81%
0.02 4 0.00% 18.81%
























Tree Brain Cancer 
            
              LOOCV (# 90)                         
CP minsplit CVE TE 
          0.01 1 33.00% 50.69% 
          0.01 2 33.00% 50.69% 
          0.01 3 33.00% 50.69% 
          0.01 4 33.00% 50.69% 
          
  
… 
           0.01 9 33.00% 52.45% 
          0.01 10 33.00% 52.45% 
          0.02 1 33.00% 50.69% 
          0.02 2 33.00% 50.69% 
          
  
… 
           0.02 9 33.00% 52.45% 
          0.02 10 33.00% 52.45% 
          … 
 
… 
           0.05 1 33.00% 50.69% 
          0.05 2 33.00% 50.69% 
          
  
… 
           0.05 9 33.00% 52.45% 
          0.05 10 33.00% 52.45% 
          … 
 
… 
           0.09 1 33.00% 50.69% 
          0.09 2 33.00% 50.69% 
          
  
… 
           0.09 9 33.00% 52.45% 
          0.09 10 33.00% 52.45% 
























Tree Brain Cancer Continued 
           
              BCV                            
#1 (# 6) 
   
#2 (# 6) 
   
#3 (# 6) 
  CP minsplit CVE TE 
 
CP minsplit CVE TE 
 
CP minsplit CVE TE 
0.01 1 0.00% 50.69% 
 
0.01 1 0.00% 50.69% 
 
0.01 1 0.00% 50.69% 
0.01 2 0.00% 50.69% 
 
0.01 2 0.00% 50.69% 
 
0.01 2 0.00% 50.69% 
0.02 1 0.00% 50.69% 
 
0.02 1 0.00% 50.69% 
 
0.02 1 0.00% 50.69% 
0.02 2 0.00% 50.69% 
 
0.02 2 0.00% 50.69% 
 
0.02 2 0.00% 50.69% 
0.03 1 0.00% 50.69% 
 
0.03 1 0.00% 50.69% 
 
0.03 1 0.00% 50.69% 
0.03 2 0.00% 50.69% 
 
0.03 2 0.00% 50.69% 
 
0.03 2 0.00% 50.69% 
              
              SCV                            
#1 (# 6) 
   
#2 (# 6) 
   
#3 (# 6) 
  CP minsplit CVE TE 
 
CP minsplit CVE TE 
 
CP minsplit CVE TE 
0.01 1 0.00% 50.69% 
 
0.01 1 0.00% 50.69% 
 
0.01 1 0.00% 50.69% 
0.01 2 0.00% 50.69% 
 
0.01 2 0.00% 50.69% 
 
0.01 2 0.00% 50.69% 
0.02 1 0.00% 50.69% 
 
0.02 1 0.00% 50.69% 
 
0.02 1 0.00% 50.69% 
0.02 2 0.00% 50.69% 
 
0.02 2 0.00% 50.69% 
 
0.02 2 0.00% 50.69% 
0.03 1 0.00% 50.69% 
 
0.03 1 0.00% 50.69% 
 
0.03 1 0.00% 50.69% 
0.03 2 0.00% 50.69% 
 
0.03 2 0.00% 50.69% 
 
0.03 2 0.00% 50.69% 


















































ntree nodesize CVE TE
55 10 27.85% 33.21%
120 15 27.85% 32.65%
150 14 27.85% 32.76%
BCV 
#1 (# 4) #2 (# 1) #3 (# 1)
ntree nodesize CVE TE ntree nodesize CVE TE ntree nodesize CVE TE
75 5 27.67% 33.36% 15 5 23.92% 35.77% 320 9 26.50% 31.97%
170 1 27.67% 32.82%
200 5 27.67% 32.48%
315 4 27.67% 32.89%
SCV 
#1 (# 1) #2 (# 2) #3 (# 1)
ntree nodesize CVE TE ntree nodesize CVE TE ntree nodesize CVE TE
125 14 22.43% 32.97% 90 8 21.41% 32.90% 10 2 24.24% 36.48%


























ntree nodesize CVE TE
30 13 9.68% 16.36%
260 8 9.68% 15.38%
BCV 
#1 (# 12) #2 (# 4) #3 (# 7)
ntree nodesize CVE TE ntree nodesize CVE TE ntree nodesize CVE TE
35 10 11.28% 15.64% 30 14 9.49% 15.65% 10 8 11.03% 21.13%
35 13 11.28% 15.59% 55 12 9.49% 15.00% 25 7 11.03% 18.17%
115 8 11.28% 16.14% 145 13 9.49% 13.59% 35 14 11.03% 15.67%
125 11 11.28% 14.65% 305 12 9.49% 13.39% 55 14 11.03% 15.22%
135 15 11.28% 14.16% 120 15 11.03% 13.57%
145 11 11.28% 14.05% 130 15 11.03% 14.32%
180 15 11.28% 13.91% 385 15 11.03% 14.02%
215 3 11.28% 16.61%
265 15 11.28% 13.68%
280 14 11.28% 13.13%
280 15 11.28% 13.42%
























RF Colon Cancer Continued
SCV 
#1 (# 4) #2 (# 52) #3 (# 1)
ntree nodesize CVE TE ntree nodesize CVE TE ntree nodesize CVE TE
30 15 9.62% 15.74% 85 3 9.36% 16.37% 10 13 9.74% 20.63%
55 13 9.62% 15.01% 100 1 9.36% 16.26%
95 12 9.62% 14.58% 115 10 9.36% 15.33%
180 4 9.62% 16.24% 165 8 9.36% 15.71%
           … …
220 6 9.36% 15.80%
220 7 9.36% 15.46%
220 8 9.36% 15.16%
220 9 9.36% 14.83%
           … …
330 3 9.36% 16.18%
335 5 9.36% 15.99%
           … …
590 8 9.36% 15.13%
595 2 9.36% 16.26%
600 2 9.36% 15.53%


























ntree nodesize CVE TE
20 8 0.00% 5.47%
BCV 
#1 (# 1460) #2 (# 1) #3 (# 1855)
ntree nodesize CVE TE ntree nodesize CVE TE ntree nodesize CVE TE
15 9 1.33% 6.05% 105 15 0.00% 2.98% 15 1 1.42% 6.48%
25 5 1.33% 4.32% 25 10 1.42% 4.64%
30 10 1.33% 4.24% 30 2 1.42% 4.36%
30 14 1.33% 4.05% 30 8 1.42% 4.49
40 1 1.33% 3.83% 30 10 1.42% 4.24
50 1 1.33% 3.49% 30 12 1.42% 3.86%
              ...         …               ...         …
1000 1 1.33% 2.06% 995 15 1.42% 2.67%
1000 3 1.33% 1.83% 1000 1 1.42% 2.06%
1000 5 1.33% 2.00% 1000 3 1.42% 1.83%
1000 6 1.33% 1.94% 1000 6 1.42% 1.94%
1000 7 1.33% 1.87% 1000 7 1.42% 1.87%
1000 8 1.33% 1.77% 1000 8 1.42% 1.77%
1000 9 1.33% 1.67% 1000 9 1.42% 1.67%
1000 11 1.33% 2.08% 1000 10 1.42% 1.87%
1000 13 1.33% 2.41% 1000 11 1.42% 2.08%
1000 12 1.42% 2.41%
1000 13 1.42% 2.41%
1000 14 1.42% 2.53%
























RF Leukemia Cancer Continued 
SCV 
#1 (# 1) #2 (# 1) #3 (# 557)
ntree nodesize CVE TE ntree nodesize CVE TE ntree nodesize CVE TE
65 12 0.00% 3.00% 40 14 0.00% 3.56% 20 12 1.42% 4.93%
25 7 1.42% 4.62%
30 12 1.42% 3.86%
35 5 1.42% 4.09%
35 7 1.42% 4.01%
45 6 1.42% 3.89%
               …            …
980 9 1.42% 1.79%
985 2 1.42% 1.96%
990 3 1.42% 1.78%
990 5 1.42% 1.72%
995 2 1.42% 1.84%
995 4 1.42% 1.77%
995 5 1.42% 1.98%
995 8 1.42% 1.92%
1000 1 1.42% 2.06%
1000 3 1.42% 1.83%
1000 5 1.42% 2.00%
























RF West Breast Cancer
LOOCV (# 15)
ntree nodesize CVE TE
180 15 24.49% 42.99%
270 14 24.49% 42.80%
375 15 24.49% 43.65%
395 11 24.49% 39.38%
425 14 24.49% 41.98%
610 12 24.49% 40.17%
655 14 24.49% 41.98%
655 15 24.49% 43.18%
710 13 24.49% 40.85%
730 15 24.49% 43.00%
785 13 24.49% 40.62%
800 13 24.49% 41.12%
900 13 24.49% 42.15%
935 15 24.49% 43.29%
960 15 24.49% 42.50%
BCV 
#1 (# 5) #2 (# 1) #3 (# 1)
ntree nodesize CVE TE ntree nodesize CVE TE ntree nodesize CVE TE
80 10 22.44% 39.94% 385 13 24.00% 41.52% 100 12 22.44% 41.58%
155 12 22.44% 41.04%
185 11 22.44% 40.29%
190 11 22.44% 40.46%
500 1 22.44% 40.81%
SCV 
#1 (# 1) #2 (# 1) #3 (# 1)
ntree nodesize CVE TE ntree nodesize CVE TE ntree nodesize CVE TE


























125 15 2.54% 4.59%
BCV 
#1 (# 1) #2 (# 4) #3 (# 1)
ntree nodesize CVE TE ntree nodesize CVE TE ntree nodesize CVE TE
155 13 2.54% 4.48% 110 12 3.05% 4.55% 65 11 3.08% 4.73%
155 3 3.05% 5.21%
165 15 3.05% 4.46%
215 13 3.05% 4.50%
SCV 
#1 (# 1) #2 (# 5) #3 (# 15)
ntree nodesize CVE TE ntree nodesize CVE TE ntree nodesize CVE TE
35 10 2.01% 5.00% 85 14 2.58% 4.55% 85 9 3.08% 4.85%
105 14 2.58% 4.54% 95 12 3.08% 4.58%
110 13 2.58% 4.51% 100 15 3.08% 4.71%
120 15 2.58% 4.48% 110 15 3.08% 4.61%
180 14 2.58% 4.40% 170 13 3.08% 4.46%
185 11 3.08% 4.49%
205 10 3.08% 4.54%
265 14 3.08% 4.47%
270 11 3.08% 4.61%
315 8 3.08% 4.92%
315 12 3.08% 4.58%
400 11 3.08% 4.50%
420 12 3.08% 4.60%
435 12 3.08% 4.26%


























ntree nodesize CVE TE
45 11 8.25% 12.73%
70 13 8.25% 12.67%
85 15 8.25% 12.79%
330 10 8.25% 12.23%
BCV 
#1 (# 1) #2 (# 2) #3 (# 1)
ntree nodesize CVE TE ntree nodesize CVE TE ntree nodesize CVE TE
20 14 6.16% 13.02% 30 4 6.16% 13.62% 110 10 5.11% 12.21%
175 14 6.16% 12.71%
SCV 
#1 (# 2) #2 (# 1) #3 (# 1)
ntree nodesize CVE TE ntree nodesize CVE TE ntree nodesize CVE TE
30 10 7.27% 12.85% 45 7 7.17% 12.86% 50 14 5.06% 12.76%


























ntree nodesize CVE TE
95 5 14.29% 27.51%
BCV 
#1 (# 2) #2 (# 3) #3 (# 7)
ntree nodesize CVE TE ntree nodesize CVE TE ntree nodesize CVE TE
225 1 9.32% 25.11% 150 3 11.82% 25.17% 55 1 13.86% 26.72%
325 1 9.32% 24.12% 355 2 11.82% 24.49% 285 4 13.86% 25.72%
400 2 11.82% 24.37% 340 2 13.86% 24.20%
380 2 13.86% 23.66%
420 4 13.86% 25.11%
445 3 13.86% 23.88%
485 2 13.86% 23.80%
SCV 
#1 (# 1) #2 (# 2) #3 (# 2)
ntree nodesize CVE TE ntree nodesize CVE TE ntree nodesize CVE TE
45 3 13.19% 27.63% 150 5 14.58% 27.52% 75 5 15.28% 28.28%
420 4 14.58% 25.09% 335 2 15.28% 24.88%
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